Sepsis, Kidney and Multiple Organ Dysfunction
This book has been made possible by the generous support of
Contributions to Nephrology Vol. 144
Series Editor
Claudio Ronco
Vicenza
Proceedings of the Third International Course on Critical Care Nephrology Vicenza, June 1–4, 2004
Sepsis, Kidney and Multiple Organ Dysfunction Volume Editors
Claudio Ronco Vicenza Rinaldo Bellomo Melbourne Alessandra Brendolan Vicenza
55 figures, 7 in color, and 37 tables, 2004
Basel · Freiburg · Paris · London · New York · Bangalore · Bangkok · Singapore · Tokyo · Sydney
Contributions to Nephrology (Founded 1975 by Geoffrey M. Berlyne)
Claudio Ronco
Rinaldo Bellomo
Department of Nephrology St. Bortolo Hospital I-36100 Vicenza (Italy)
Intensive Care Unit Austin & Repatriation Medical Center Melbourne, Vic. 3084 (Australia)
Alessandra Brendolan Department of Nephrology St. Bortolo Hospital I-36100 Vicenza (Italy)
Library of Congress Cataloging-in-Publication Data A catalog record for this title is available from the Library of Congress
Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents® and Index Medicus. Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. © Copyright 2004 by S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland) www.karger.com Printed in Switzerland on acid-free paper by Reinhardt Druck, Basel ISSN 0302–5144 ISBN 3–8055–7755–9
Contents
IX Preface Ronco, C. (Vicenza); Bellomo, R. (Melbourne); Brendolan, A. (Vicenza) Epidemiology and Pathogenesis of ARF, Sepsis and MOF 1 Acute Renal Failure in the Critically Ill: Impact on Morbidity and Mortality Hoste, E.A. (Gent); Kellum, J.A. (Pittsburgh, Pa.) 12 Acute Renal Failure in the Intensive Care Unit. Risk Factors Piccinni, P.; Carraro, R.; Ricci, Z. (Vicenza) 19 Pathophysiology of Ischemic Acute Renal Failure. Inflammation, Lung-Kidney Cross-Talk, and Biomarkers Bonventre, J.V. (Boston, Mass.) 31 Pathophysiology of Sepsis and Multiple Organ Failure: Pro- versus Anti-Inflammatory Aspects Pinsky, M.R. (Pittsburgh, Pa.) 44 Tropical Acute Renal Failure Barsoum, R.S. (Cairo) The Critically Ill Patients: Pathological Mechanisms 53 Mechanisms Underlying Combined Acute Renal Failure and Acute Lung Injury in the Intensive Care Unit Chien, C.-C.; King, L.S.; Rabb, H. (Baltimore, Md.)
V
63 Cytokine Single Nucleotide Polymorphism. Role in Acute Renal Failure Liangos, O.; Balakrishnan, V.S.; Pereira, B.J.G.; Jaber, B.L. (Boston, Mass.) 76 Mechanisms of Immunodysregulation in Sepsis Cavaillon, J.-M.; Fitting, C.; Adib-Conquy, M. (Paris) Fluid, Electrolyte and Acid Base 94 Goals of Resuscitation from Circulatory Shock Pinsky, M.R. (Pittsburgh, Pa.) 105 Intravenous Fluids and Acid-Base Balance Bellomo, R.; Naka, T.; Baldwin, I. (Melbourne) 119 Glucose Control in the Critically Ill Schetz, M.; Van den Berghe, G. (Leuven) 132 Dysnatremias in the Critical Care Setting Moritz, M.L. (Pittsburgh, Pa.); Ayus, J.C. (San Antonio, Tex.) Pharmacological Issues in ARF and Sepsis 158 Rasburicase Therapy in Acute Hyperuricemic Renal Dysfunction Ronco, C. (Vicenza); Bellomo, R. (Melbourne); Inguaggiato, P. (Cuneo); Bonello, M.; Bordoni, V.; Salvatori, G.; D’Intini, V.; Ratanarat, R. (Vicenza) 166 Diuretics in Acute Renal Failure? Schetz, M. (Leuven) 182 How to Manage Vasopressors in Acute Renal Failure and Septic Shock Dan, M.; Rossi, S.; Callegarin, L.; Ronco, C. (Vicenza) Practical Aspects of CRRT 191 Management of Vascular Catheters for Acute Renal Replacement Therapy D’Intini, V.; Bonello, M.; Salvatori, G.; Ronco, C. (Vicenza) 203 Relationship between Blood Flow, Access Catheter and Circuit Failure during CRRT: A Practical Review Baldwin, I.; Bellomo, R. (Melbourne) Renal Replacement Therapy in the ICU: Consensus and Recommendations from ADQI 214 CRRT: Selection of Patients and Starting Criteria Palevsky, P.M. (Pittsburgh, Pa.)
Contents
VI
222 Fluid Composition for CRRT Leblanc, M. (Montreal) 228 Anticoagulation for Continuous Renal Replacement Therapy Davenport, A. (London) Which Treatment for ARF in ICU? 239 Peritoneal Dialysis in Acute Renal Failure of Adults: The Under-Utilized Modality Ash, S.R. (West Lafayette, Ind.) 255 Intermittent Hemodialysis for Acute Renal Failure Patients – An Update Lameire, N.; Van Biesen, W.; Vanholder, R.; Hoste, E. (Gent) 264 Continuous Renal Replacement Techniques Clark, W.R. (Lawrence, Mass./Indianapolis, Ind.); Ronco, C. (Vicenza) 278 Hybrid Renal Replacement Therapies for Critically Ill Patients Golper, T.A. (Nashville, Tenn.) 284 Pediatric Acute Renal Failure: Demographics and Treatment Goldstein, S.L. (Houston, Tex.) Technical Aspects of CRRT 291 Vascular Access for Extracorporeal Renal Replacement Therapy in the Intensive Care Unit Canaud, B.; Formet, C.; Raynal, N.; Amigues, L.; Klouche, K.; Leray-Moragues, H.; Béraud, J.-J. (Montpellier) 308 Anticoagulation in Continuous Renal Replacement Therapy Vargas Hein, O.; Kox, W.J.; Spies, C. (Berlin) 317 Replacement and Dialysate Fluids for Patients with Acute Renal Failure Treated by Continuous Veno-Venous Haemofiltration and/or Haemodiafiltration Davenport, A. (London) CRRT Information Technology 329 A Practical Tool for Determining the Adequacy of Renal Replacement Therapy in Acute Renal Failure Patients Pisitkun, T.; Tiranathanagul, K. (Bangkok); Poulin, S.; Bonello, M.; Salvatori, G.; D’Intini, V.; Ricci, Z. (Vicenza); Bellomo, R. (Melbourne); Ronco, C. (Vicenza)
Contents
VII
New Frontiers in the Management of ARF, MOF and Sepsis 350 How to Approach Sepsis Today? Vincent, J.-L. (Brussels) 362 High Volume Hemofiltration in Critically Ill Patients: Why,When and How? Tetta, C. (Bad Homburg); Bellomo, R. (Melbourne); Kellum, J. (Pittsburgh, Pa.); Ricci, Z. (Vicenza); Pohlmeier, R.; Passlick-Deetjen, J. (Bad Homburg); Ronco, C. (Vicenza) 376 Coupled Plasma Filtration Adsorption: Rationale,Technical Development and Early Clinical Experience Brendolan, A.; Ronco, C.; Ricci, Z.; Bordoni, V.; Bonello, M.; D’Intini, V. (Vicenza); Wratten, M.L. (Mirandola); Bellomo, R. (Melbourne) 387 Plasmapheresis in Sepsis Berlot, G. (Trieste); Di Capua, G. (Naples); Nosella, P.; Rocconi, S.; Thomann, C. (Trieste) 395 Author Index 396 Subject Index
Contents
VIII
Preface
Multiple epidemiological studies have established and continue to emphasize the fact that sepsis is the dominant syndrome in modern Intensive Care Units. Severe sepsis occurs in approximately 50 to 100 cases/100,000 people/ year and is the most common cause of death in intensive care patients. Severe sepsis and septic shock are now also the most common cause of kidney failure in intensive care and the most common cause of severe kidney failure requiring in general renal replacement therapy. This kind of kidney failure, however, is rarely seen in isolation. Most commonly, it occurs as part of a syndrome of multiple organ failure, where the kidney is one of several organ systems that become profoundly dysfunctional. In this setting, vasodilatory shock is frequent, mechanical ventilation is frequent and disorders of bone marrow function, acid-base balance, gastrointestinal activity and cerebral function are common. Thus, severe sepsis links kidney function, multiple organ function and patient outcome from the start to the end. The care of patients with severe sepsis and/or septic shock is complex and typically involves a multidisciplinary approach. Critical care specialists typically co-ordinate resuscitation, fluid administration, and mechanical ventilation. In conjuction with the nephrologist, they deal with issues of electrolyte and water balance, acid-base control and renal support. Increasingly, renal support focuses on complex approaches to extracorporeal therapy, which require the use of sorbents, high-volume plasma water exchange techniques and plasmafiltration or plasma exchange techniques. In conjunction with the infectious disease specialist, critical care physicians and nephrologists co-ordinate antibiotic or antifungal treatment. This requires important adjustments, which
IX
depend on renal function and the technique of renal support being applied. Accordingly, knowledge of pharmacokinetics and pharmacodynamics becomes essential. Finally, emerging evidence indicates that the resolution of the septic state and of multiorgan dysfunction might require optimization of the endocrine environment through replacement of glucocorticoids in patients with loss of adrenal functional reserve, the supplementation of vasopressin in selected patients with vasodilatory shock and, perhaps more importantly, the restoration of normoglycemia through aggressive insulin administration. The above considerations make it clear that for patients to receive optimal care, the treating physician needs a detailed working knowledge of multiple aspects of care so that appropriate multidisciplinary assistance is sought at the right time and new techniques of organ support are applied in a safe, timely and effective way. In the present book we have combined the contributions of experts in various fields to tackle some of the fundamental and complex aspects of patients care. First we have focussed on the epidemiology of acute renal failure in intensive care and on its role in determining outcome. We then present recent advances in the insight into the pathogenesis of ischemic renal failure and of sepsis and multiple organ failure. Because the immune response to infection is central in determining organ injury, the book then focuses on its role in determining renal and lung injury, on the role of immune mediators in inducing dysregulation of the immune response and on the role of genetics in determining such a response. We then move to the issue of fluid resuscitation, the goals of resuscitation, the importance of acid-base control and the issues that surround glucose control and sodium control in the ICU. Pharmacological aspects of care involving the use of common medications such as diuretics and vasopressors are analyzed and the possible role of uric acid modulation discussed. As extracorporeal therapies are being increasingly used in the care of these complex patients, we focus on important technical aspects of such therapies including vascular catheter management, control of circuit blood flow, anticoagulation, choice of replacement or dialysate fluids, the role of information technology and the selection of patients for treatment. As the choice of treatment modality remains controversial, we also discuss different approaches to renal support from intermittent dialysis to continuous therapies and hybrid techniques. Finally, we conclude with a description of advanced extracorporeal techniques of organ support and discuss their role in the management of sepsis and kidney failure in the context of an overall strategy of sepsis management. The aim of this book is to present all physicians involved in the care of critically ill patients with sepsis and kidney/multiorgan dysfunction with a practical and up-to-date summary of current knowledge and technology as well as a fundamental understanding of pathogenesis and likely future developments in this field. Our endeavour is part of a now long-standing and continuing effort
Preface
X
to improve patient outcome through laboratory and clinical research, education and consensus development. Working on the development of the specialty of Critical Care Nephrology and of the Acute Dialysis Quality Initiative (ADQI), we hope to move steadily in the direction of improved outcomes for critically patients with kidney and multiorgan dysfunction. We hope this book will serve as a useful tool for consultation, reference and informative reading for all professionals involved in the care of critically ill patients and that it will represent yet another small step toward improving the standards of care for such patients worldwide. Claudio Ronco Rinaldo Bellomo Alessandra Brendolan
Preface
XI
Epidemiology and Pathogenesis of ARF, Sepsis and MOF Ronco C, Bellomo R, Brendolan A (eds): Sepsis, Kidney and Multiple Organ Dysfunction. Contrib Nephrol. Basel, Karger, 2004, vol 144, pp 1–11
Acute Renal Failure in the Critically Ill: Impact on Morbidity and Mortality Eric A. Hostea, John A. Kellumb a
Intensive Care Unit, Ghent University Hospital, Gent, Belgium; The CRISMA Laboratory (Clinical Research, Investigation, and Systems Modeling of Acute Illness), Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pa., USA
b
The occurrence rate of acute renal failure (ARF) in critically ill patients varies in the literature between 1.1 and 31% according to the definition of ARF used and the patient population studied [1–3]. In critically ill patients more than 90% of ARF episodes are of ischemic or toxic etiology or a combination of both. However, numerous other etiologies of ARF have been identified. Examples include obstruction of the urine outflow tract, acute tubulointerstitial nephritis, acute glomerulonephritis, and atheroemboli [4–9]. The precise diagnosis of the etiology of ARF is not always obvious or easy to establish; some patients can therefore be misclassified. Furthermore, the spectrum of etiologies will be different, depending on the specific patient population studied. In turn, each etiology can be associated with a specific spectrum of comorbidities, and consequent impact on outcome. For example, the complications and prognosis of contrast media induced ARF are different from that of ischemic ARF in a patient with sepsis, or ARF caused by lupus nephritis. It is therefore not surprising that the mortality of critically ill patients with ARF as reported in recent trials varies between 28 and 82% [3, 10]. In contrast to the former dogma that patients die with and not because of ARF, there is now ample evidence that ARF is itself somehow associated with excess mortality, or in other words ARF has ‘attributable mortality’ [11]. This has been most convincingly demonstrated in patients with ARF requiring treatment with renal replacement therapy (RRT) [1, 12, 13], but also appears to be true for patients with the less severe form of contrast media-induced ARF [14]. ARF patients are amongst the sickest in the intensive care unit. Patients often develop ARF as a consequence of conditions which are themselves associated with high mortality,
e.g. sepsis, hypotension. Furthermore, ARF may result in a variety of complications that can, in turn, lead to comorbidity or organ dysfunction [12, 14], thus negatively impacting on patient outcomes in the ICU. In this review we will discuss many of the complications of ARF, and consider their potential impact on patient outcomes in the ICU. While numerous reviews have focused on the clinical effects of RRT, it is important to note that emerging evidence suggests that even when ARF does not result in RRT, there is a significant impact on mortality [15]. Thus, it is important to consider the possible mechanisms of attributable mortality with ARF even when RRT is not employed. It is this group with which we will concern ourselves.
Complications of ARF
Uremic retention products are compounds that under normal conditions are excreted by the healthy kidneys. Impaired clearance of these compounds, as in ARF, leads to higher concentrations. When these compounds interfere with organ function one speaks of ‘uremic toxins’. There are currently more than 90 uremic retention products described in the literature for patients with chronic uremia [16, 17]. Whether these compounds fulfill the definition of uremic toxin is less well established [18]. Furthermore, the role that any of these molecules plays in ARF is less certain. For example, while chronic exposure to molecules such as leptin and retinol binding protein is associated with loss of appetite and neuro-muscular symptoms, it is unknown if these toxicities occur in the acute setting where less time for accumulation has passed. Conversely, uremic toxicity might play an even larger role in acute disease. Indeed there is growing evidence that more intensive treatment of uremia, or a higher dose of RRT, improves survival [10, 19, 20]. Of course, earlier and more intensive RRT might also control blood volume, salt and acid-base variables more efficiently and this too could affect outcome. Because the literature on uremic toxicity in ARF is much less abundant than in chronic uremia, we will focus on the complications of acute renal failure, of which many are a result of uremic retention compounds and their effects on normal physiology. Volume Overload Salt and water retention result in volume overload, this can occur even early in the course of ARF. Volume overload is one of the main reasons for initiating RRT [5, 21, 22]. Patients with volume overload will develop edema, ascites, and pleural effusions. As a consequence of volume overload, cardiovascular complications, such as congestive heart failure, hypertension, and pulmonary edema
Hoste/Kellum
2
may develop. Respiratory function can be impaired by pleural effusion, and pulmonary edema. That volume overload can lead to many untoward effects has been illustrated in colorectal surgery where a restrictive fluid therapy regimen lead to a significant reduction in comorbidity [23]. Another, less common, complication of volume overload is the development of an abdominal compartment syndrome (ACS) [24]. ACS is becoming more commonly recognized as a complication of volume resuscitation and capillary leak. It has been described in patients with multiple organ failure and burns [25]. Patients with ACS have an increased intra-abdominal pressure, resulting in a pro-inflammatory response, and a decreased preload, low cardiac output, hypotension, impaired oxygenation and oliguria [26]. ACS may reduce renal perfusion and further worsen ARF or delay recovery. Formation of edema may also result in delayed wound healing [27]. Cell swelling interferes with normal cellular function, the most prominent symptoms are neurologic: impaired consciousness to coma and death [28]. In summary, volume overload can cause a whole range of complications, and this may help explain why ARF patients with oliguria have a worse survival, compared to non-oliguric ARF patients [2, 4, 7, 29–34]. Acidosis The kidneys play an important role in preservation of the acid base homeostasis; this through excretion of non-volatile acids and control of cation/anion balance. When the glomerular filtration rate (GFR) declines, there is accumulation of organic anions, e.g. hyperphosphatemia, and other unmeasured anions [35]. Furthermore, there is decreased production of bicarbonate by the decreased proximal tubular reabsorption and regeneration. Another factor that is important in the pathogenesis of metabolic acidosis is the decreased buffering capacity, secondary to hypoalbuminemia [35]. Finally, many patients will also have non-renal reasons for acidosis leading to mixed disorders in acid base balance. Examples of non-renal etiologies of acidosis are lactic acidosis, respiratory acidosis induced by permissive hypercapnia ventilation strategies or, less frequently, keto-acidosis. Mild-to-moderate acidosis is therefore a common finding in patients with ARF [35, 36]. The effects of metabolic acidosis are diverse [37, 38]. Acidosis can lead to many untoward effects, especially of the cardiovascular system, and may be associated with decreased survival [34]. Blood pressure and cardiac output can be decreased [39, 40], as well as hepatic and renal blood flow [41]. The underlying mechanisms of these effects are uncertain. Decrease of the -receptors on the cell surface of the heart can play a role [42], as well as an increase of inducible nitric oxide synthase (iNOS) which can lead to vasodilatation [43]. Furthermore, it has been demonstrated that hyperchloremic acidosis increases lung and intestinal injury and decrease gut barrier function [43–46].
ARF in the Critically Ill
3
Acidosis has also many untoward effects on metabolism. Glucose metabolism is impaired by the induction of insulin resistance [47] and inhibition of anaerobic glycolysis. Furthermore, there is induction of protein breakdown and decreased muscle protein synthesis [48–54]. Hyperchloremic acidosis has proinflammatory effects documented in vitro and in animal models. HCl infusion increases the release of NO and increases the Il-6/Il-10 ratio. In addition, HCl increased NF-B DNA binding in LPS-stimulated RAW 264.7 cells [55]. Acidosis also induces hyperkalemia by a shift of intracellular potassium to the extracellular compartment [56]. Finally, acidosis has a negative impact on metabolism of the central nervous system, resulting in impaired consciousness and eventually coma. Immunological Function, Inflammation, and Infection Patients with ARF have a high incidence of infectious complications. In one recent study, the higher the preoperative creatinine, the higher was the incidence of infections in patients who underwent open-heart surgery [57]. Bloodstream infections had an almost 3 times higher occurrence rate in critically ill patients with ARF compared to patients without ARF [58]. Finally, the occurrence rate of serious infections or sepsis in ARF patients treated with RRT ranges from 15 to 58.5% [57, 59, 60]. Thus, immunosupression seems likely in patients with ARF [58]. In patients with chronic uremia there is ample evidence that there is a decreased immune response as seen with impaired phagocytic function of white blood cells taken from these patients [61–63]. The underlying mechanisms for these effects are believed to include malnutrition, uremic toxicity, iron overload, anemia, and incompatibility of the hemodialyzers. There is less data concerning the immune response in the setting of ARF; however, the causative factors held responsible for the decreased neutrophil function are also present in patients with ARF. It seems therefore plausible that the phagocytic function of polymorphonuclear cells in ARF patients is also impaired. Finally, ARF itself, can lead to a non-infectious, pro-inflammatory response with activation of lung macrophages, secretion of pro-inflammatory cytokines, and recruitment of neurtrophils and macrophages with resultant lung injury, as has been demonstrated in animal models of ischemia-reperfusion-induced ARF [64–68]. Electrolyte Disorders Hyponatremia is a common finding in patients with ARF [36]. Usually, hyponatremia is dilutional, either hypervolemic or euvolemic. Underlying mechanisms for dilutional hyponatremia can be decreased free water clearance (hypervolemic hyponatremia), and hyperosmolar dilution, e.g. as a resultant of administration of synthetic colloids, or hyperglycemia (either hypervolemic or
Hoste/Kellum
4
euvolemic after redistribution of fluid from the intracellular to the extracellular compartment). Free water clearance can already be impaired in an early stage of ARF, before elevations of creatinine or blood urea nitrogen [69]. Hypovolemic hyponatremia can be the resultant of losses of hypertonic fluids, e.g. after excessive vomiting or diarrhea, or interstitial or ‘third space’ losses as in burns or muscle injury. Hyponatremia, especially, acute hyponatremia (duration less than 48 h), interferes with normal cell function. The hypotonic extracellular environment causes cell swelling, as the osmotic gradient causes redistribution of water from the extracellular to the intracellular compartment. Symptoms include a whole spectrum of primarily neurological symptoms from headache, lethargy to coma and even dead. The more rapid the onset of hyponatremia, the higher the likelihood of severe symptoms [70]. Like hyponatremia, hyperkalemia is a potentially life-threatening situation as it may be complicated by cardiac arrhythmias. Hyperkalemia is a common complication in patients with ARF. The kidneys play a pivotal role in potassium homeostasis; failure of the kidneys to excrete potassium may therefore result in hyperkalemia. Other common causes of hyperkalemia in ARF patients may be the increased release of potassium from the intracellular compartment, as in rhabdomyolis, tumor lysis syndrome, and hemolysis [71–74], and side effects of drugs (e.g. non-steroidal anti-inflammatory drugs and COX-2 inhibitors, trimethoprim/sulfamethoxazole, angiotensin receptor blockers, cyclosporin or tacrolimus [75–78], and heparin). Anemia Anemia is a consistent finding in ARF patients. Underlying mechanisms for anemia are decreased synthesis of red blood cells, increased destruction of red blood cells, and increased blood loss. ARF patients have inappropriate low levels of erythropoietin [79, 80]. The uremic state causes increased red blood cell fragility and destruction [81], and increased blood loss is aggravated by platelet dysfunction [82, 83]. Anemia may excacerbate cardiovascular disease. Although a hemoglobin level as low as 7 g/dl is well tolerated in a general intensive care population, and is even beneficial for the subgroups of patients who are younger, and less severely ill, higher hemoglobin levels are recommended for patients with ischemic heart disease [84, 85].
Drug Prescription
Adequate dosing of drugs is a challenge in patients with ARF, because the pharmocodynamics and pharmacokinetics of drugs may be altered at every
ARF in the Critically Ill
5
level. Plasma levels can be lower as a result of decreased availability when given orally [86], or increased volume of distribution. Alternatively, plasma drug levels may be higher as a result of reduced albumin binding, decreased metabolism and/or decreased renal excretion [87]. Additionally, plasma levels of metabolites of drugs may be increased for the same reasons, and this may also result in increased toxicity. To complicate things even more, none of the variables mentioned above remains constant during the course of an ARF episode: GFR changes and RRT affects drug concentrations. The dosing of an exhaustive list of drugs is reviewed in ‘Drug prescribing in renal failure’, a publication by the American College of Physicians [88]. We will limit ourselves to the discussion of the particular aspects of drug dosing of 3 groups of drugs, these being the most commonly prescribed to critically ill patients with ARF: vaso-active agents, antimicrobial agents, and sedatives/ analgetics. Vaso-Active Agents The dose of vasopressor agents such as norepinephrine, epinephrine and dopamine, is prescribed according to their effect on blood pressure and cardiac output. There are no dosing restrictions for patients with renal insufficiency. However, for inotropic agents from the class of phosphodiesterase inhibitors, a dose reduction is recommended for patients with renal insufficiency. Clearance of dopamine, epinephrine, and norepinephrine is minimal, and clinically insignificant when continuous veno-venous hemodiafiltration is used as mode of RRT [89]. These data can probably be extrapolated to other forms of RRT currently used for critically ill patients with ARF. Antimicrobial Agents Almost all antimicrobial agents are eliminated by the kidneys. Adjustment of dose and/or interval between 2 doses should therefore always be considered in patients with ARF in order to prevent toxicity as a result of high plasma levels. Another consideration is the increase in distribution volume that ARF patients will have as a result of edema and low albumin levels. Underdosing of antimicrobial agents and, therefore, inefficient antimicrobial treatment, is also a potential hazard in patients with ARF. In general, the loading dose of antimicrobial agents should be higher while the dosing interval longer, compared to that given to patients without ARF. Sedatives and Analgetics Most opiates and the older sedatives from the class of the benzodiazepines (e.g. diazepam and lorazepam) are excreted via the urine. Decreased renal
Hoste/Kellum
6
function will therefore lead to accumulation of the drug or its metabolites, of which some also have sedative properties (e.g. morphine-6-glucuronide, a metabolite of morphine). A dose reduction is therefore recommended for these drugs in patients with decreased kidney function. This problem exists to a much lesser extent for propofol and midazolam, drugs that have renal elimination of inactive metabolites, and remifentanyl, a recently developed opiate that is metabolized in plasma and tissues. Adequate dosing of drugs in order to become adequate drug levels is an important cornerstone of anti-infectious chemotherapy. Critically ill patients with ARF are at risk for both low and high drug levels of antimicrobial chemotherapeutic agents, and both are undesirable. High drug levels may result in drug toxicity, and low drug levels may result in inadequate eradication of the infectious process, but also increased antimicrobial resistance [90].
Conclusions
It is currently not known why, even in the absence of RRT, ARF leads to an increase in mortality in critically ill patients. However, given the number of major perturbations in physiology that result from renal dysfunction, it seems likely that the explanation is multifactorial. We do not know if correction of these abnormalities will reduce the attributable mortality of ARF or whether early RRT, or ‘renal support’ will improve outcome. We speculate that given the multiple effects of even early ARF, efforts to prevent its development or hasten its recovery will significantly improve survival in critically ill patients.
References 1
2
3 4
5
6
Chertow GM, Levy EM, Hammermeister KM, Grover F, Daley J: Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998;104: 343–348. de Mendonca A, Vincent JL, Suter PM, Moreno R, Dearden NM, Antonelli M, Takala J, Sprung C, Cantraine F: Acute renal failure in the ICU: Risk factors and outcome evaluated by the SOFA score. Intens Care Med 2000;26:915–921. Vivino G, Antonelli M, Moro M, Cottini F, Conti G, Bufi M, Cannata F, Gasparetto A: Risk factors for acute renal failure in trauma patients. Intens Care Med 1998;24:808–814. Brivet F, Kleinknecht D, Loirat P, Landais P, the French Study Group on Acute Renal Failure: Acute renal failure in intensive care units-causes, outcome, and prognostic factors on hospital mortality: A prospective, multicenter study. Crit Care Med 1996;24:192–198. Guerin C, Girard R, Selli JM, Perdrix JP, Ayzac L: Initial versus delayed acute renal failure in the intensive care unit: A multicenter prospective epidemiological study. Rhone-Alpes Area Study Group on Acute Renal Failure. Am J Respir Crit Care Med 2000;161:872–879. Groeneveld A, Tran D, van der Meulen J, Nauta J, Thijs L: Acute renal failure in the medical intensive care unit: Predisposing, complicating factors and outcome. Nephron 1991;59:602–610.
ARF in the Critically Ill
7
7 8
9 10 11 12
13
14 15
16 17
18 19 20
21
22
23
24 25
26
Liaño F, Pascual J, the Madrid Acute Renal Failure Study Group: Epidemiology of acute renal failure: A prospective, multicenter, community-based study. Kidney Int 1996;50:811–818. Liaño F, Junco E, Pascual J, Madero R, Verde E, the Madrid Acute Renal Failure Study Group: The spectrum of acute renal failure in the intensive care unit compared to that seen in other settings. Kidney Int 1998;53(suppl 66):S16–S24. Pascual J, Liaño F, the Madrid Acute Renal failure Study Group: Causes and prognosis of acute renal failure in the very old. J Am Geriatr Soc 1998;46:721–725. Schiffl H, Lang SM, Fischer R: Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002;346:305–310. Kellum JA, Angus DC: Patients are dying of acute renal failure. Crit Care Med 2002;30:2156–2157. Metnitz PG, Krenn CG, Steltzer H, Lang T, Ploder J, Lenz K, Le Gall JR, Druml W: Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002;30:2051–2058. Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM, Colardyn FA: Acute renal failure in patients with sepsis in a surgical ICU: Predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 2003;14:1022–1030. Levy EM, Viscoli CM, Horwitz RI: The effect of acute renal failure on mortality: A cohort analysis. JAMA 1996;275:1489–1494. Hoste E, Clermont G, Kersten A, Venkataraman R, Kaldas H, Angus DC, Kellum JA: Clinical evaluation of the new RIFLE criteria for acute renal failure. Crit Care 2004; abstract for the 24th International Symposium on Intensive Care and Emergency Medicine, Brussels. Vanholder R, De Smet R: Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999;10:1815–1823. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 2003; 63:1934–1943. Vanholder R, Glorieux G, De Smet R, Lameire N: New insights in uremic toxins. Kidney Int Suppl 2003;84:S6–S10. Conger JD: A controlled evaluation of prophylactic dialysis in post-traumatic acute renal failure. J Trauma 1975;15:1056–1063. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G: Effect of different doses in continuous veno-venous hemofiltration on outcomes of acute renal failure: A prospective randomized trial. Lancet 2000;356:26–30. Mehta RL, McDonald B, Gabbai FB, Pahl M, Pascual MTA, Farkas A, Kaplan RM: For the Collaborative Group for the Treatment of ARF in the ICU: A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int 2001;60:1154–1163. Cole L, Bellomo R, Silvester W, Reeves JH: A prospective, multicenter study of the epidemiology, management, and outcome of severe acute renal failure in a ‘closed’ ICU system. Am J Respir Crit Care Med 2000;162:191–196. Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K, Rasmussen MS, Lanng C, Wallin L, Iversen LH, Gramkow CS, Okholm M, Blemmer T, Svendsen PE, Rottensten HH, Thage B, Riis J, Jeppesen IS, Teilum D, Christensen AM, Graungaard B, Pott F: Effects of intravenous fluid restriction on postoperative complications: Comparison of two perioperative fluid regimens: A randomized assessor-blinded multicenter trial. Ann Surg 2003;238:641–648. Morken J, West MA: Abdominal compartment syndrome in the intensive care unit. Curr Opin Crit Care 2001;7:268–274. Balogh Z, McKinley BA, Holcomb JB, Miller CC, Cocanour CS, Kozar RA, Valdivia A, Ware DN, Moore FA: Both primary and secondary abdominal compartment syndrome can be predicted early and are harbingers of multiple organ failure. J Trauma 2003;54:848–859; discussion 859–861. Rezende-Neto JB, Moore EE, Melo de Andrade MV, Teixeira MM, Lisboa FA, Arantes RM, de Souza DG, da Cunha-Melo JR: Systemic inflammatory response secondary to abdominal compartment syndrome: Stage for multiple organ failure. J Trauma 2002;53:1121–1128.
Hoste/Kellum
8
27 28
29 30
31
32 33 34
35
36 37 38
39 40 41 42 43
44
45 46 47 48 49 50 51
Teschan PE: Acute renal failure during the Korean War. Ren Fail 1992;14:237–239. Steele A, Gowrishankar M, Abrahamson S, Mazer CD, Feldman RD, Halperin ML: Postoperative hyponatremia despite near-isotonic saline infusion: A phenomenon of desalination. Ann Intern Med 1997;126:20–25. Mehta RL, Pascual MT, Gruta CG, Zhuang S, Chertow GM: Refining predictive models in critically ill patients with acute renal failure. J Am Soc Nephrol 2002;13:1350–1357. Guerin C, Girard R, Selli J-M, Perdrix J-P, Ayzac L: For the Rhone-Alpes Area Study Group on Acute Renal Failure: Initial versus delayed acute renal failure in the intensive care unit: A multicenter prospective epidemiological study. Am J Respir Crit Care Med 2000;161:872–879. Guerin C, Girard R, Selli JM, Ayzac L: Intermittent versus continuous renal replacement therapy for acute renal failure in intensive care units: Results from a multicenter prospective epidemiological survey. Intens Care Med 2002;28:1411–1418. Rasmussen HH, Pitt EA, Ibels LS, McNeil DR: Prediction of outcome in acute renal failure by discriminant analysis of clinical variables. Arch Intern Med 1985;145:2015–2018. Bullock ML, Umen AJ, Finkelstein M, Keane WF: The assessment of risk factors in 462 patients with acute renal failure. Am J Kidney Dis 1985;5:97–103. Chertow GM, Lazarus J, Paganini E, Allgren R, Lafayette R, Sayegh M: Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis. The Auriculin Anaritide Acute Renal Failure Study Group. J Am Soc Nephrol 1998;9:692–698. Rocktaeschel J, Morimatsu H, Uchino S, Goldsmith D, Poustie S, Story D, Gutteridge G, Bellomo R: Acid-base status of critically ill patients with acute renal failure: Analysis based on Stewart-Figge methodology. Crit Care 2003;7:R60. Dolson GM: Electrolyte abnormalities before and after the onset of acute renal failure. Miner Electrolyte Metab 1991;17:133–140. Adrogue HJ, Madias NE: Management of life-threatening acid-base disorders. First of two parts. N Engl J Med 1998;338:26–34. Gunnerson KJ, Song M, Kellum JA: Influence of acid-base balance on patients with sepsis; in Vincent JL (ed): Yearbook of Intensive Care and Emergency Medicine 2004. Springer-Verlag, Berlin, 2004, pp 58–67. Weil MH, Houle DB, Brown EB Jr, Campbell GS, Heath C: Vasopressor agents: Influence of acidosis on cardiac and vascular responsiveness. Calif Med 1958;88:437–440. Kellum JA, Song M, Venkataraman R: Effects of hyperchloremic acidosis on arterial pressure and circulating inflammatory molecules in experimental sepsis. Chest 2004;125:243–248. Bersentes TJ, Simmons DH: Effects of acute acidosis on renal hemodynamics. Am J Physiol 1967; 212:633–640. Marsh JD, Margolis TI, Kim D: Mechanism of diminished contractile response to catecholamines during acidosis. Am J Physiol 1988;254:H20–H27. Pedoto A, Caruso JE, Nandi J, Oler A, Hoffmann SP, Tassiopoulos AK, McGraw DJ, Camporesi EM, Hakim TS: Acidosis stimulates nitric oxide production and lung damage in rats. Am J Respir Crit Care Med 1999;159:397–402. Salzman AL, Wang H, Wollert PS, Vandermeer TJ, Compton CC, Denenberg AG, Fink MP: Endotoxin-induced ileal mucosal hyperpermeability in pigs: Role of tissue acidosis. Am J Physiol 1994;266:G633–G646. Unno N, Hodin RA, Fink MP: Acidic conditions exacerbate interferon-gamma-induced intestinal epithelial hyperpermeability: Role of peroxynitrous acid. Crit Care Med 1999;27:1429–1436. Pedoto A, Nandi J, Oler A, Camporesi EM, Hakim TS, Levine RA: Role of nitric oxide in acidosisinduced intestinal injury in anesthetized rats. J Lab Clin Med 2001;138:270–276. DeFronzo RA, Beckles AD: Glucose intolerance following chronic metabolic acidosis in man. Am J Physiol 1979;236:E328–E334. Mitch WE, Goldberg AL: Mechanisms of muscle wasting: The role of the ubiquitin-proteasome pathway. N Engl J Med 1996;335:1897–1905. Mitch WE: Mechanisms causing loss of muscle in acute uremia. Ren Fail 1996;18:389–394. Bailey JL, Mitch WE: Metabolic acidosis as a uremic toxin. Semin Nephrol 1996;16:160–166. Mitch WE: Metabolic acidosis stimulates protein metabolism in uremia. Miner Electrolyte Metab 1996;22:62–65.
ARF in the Critically Ill
9
52 53 54
55
56 57 58
59 60
61 62
63 64
65 66
67
68 69 70 71
72 73 74 75 76
Bailey JL, England BK, Long RC, Mitch WE: Influence of acid loading, extracellular pH and uremia on intracellular pH in muscle. Miner Electrolyte Metab 1996;22:66–68. May RC, Bailey JL, Mitch WE, Masud T, England BK: Glucocorticoids and acidosis stimulate protein and amino acid catabolism in vivo. Kidney Int 1996;49:679–683. Isozaki U, Mitch WE, England BK, Price SR: Protein degradation and increased mRNAs encoding proteins of the ubiquitin-proteasome proteolytic pathway in BC3H1 myocytes require an interaction between glucocorticoids and acidification. Proc Natl Acad Sci USA 1996;93:1967–1971. Kellum JA, Song M, Li J: Lactic and hydrochloric acids induce different patterns of inflammatory response in LPS-stimulated RAW 264.7 cells. Am J Physiol Regul Integr Comp Physiol 2004; 286:R686–R692. Adrogue HJ, Madias NE: Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med 1981;71:456–467. Thakar CV, Yared JP, Worley S, Cotman K, Paganini EP: Renal dysfunction and serious infections after open-heart surgery. Kidney Int 2003;64:239–246. Hoste E, Blot S, Lameire N, Vanholder R, De Bacquer D, Colardyn F: Impact of nosocomial bloodstream infection on the outcome of critically ill patients with acute renal failure treated with renal replacement therapy. J Am Soc Nephrol 2004;15:454–462. Schiffl H, Lang SM, Konig A, Strasser T, Haider MC, Held E: Biocompatible membranes in acute renal failure: Prospective case-controlled study. Lancet 1994;344:570–572. Fiaccadori E, Lombardi M, Leonardi S, Rotelli CF, Tortorella G, Borghetti A: Prevalence and clinical outcome associated with preexisting malnutrition in acute renal failure: A prospective cohort study. J Am Soc Nephrol 1999;10:581–593. Vanholder R, Ringoir S: Infectious morbidity and defects of phagocytic function in end-stage renal disease: A review. J Am Soc Nephrol 1993;3:1541–1554. Vanholder R, De Smet R, Waterloos MA, Van Landschoot N, Vogeleere P, Hoste E, Ringoir S: Mechanisms of uremic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol. Kidney Int 1995;47:510–517. Horl WH: Neutrophil function and infections in uremia. Am J Kidney Dis 1999;33:xlv–xlviii. Kramer AA, Postler G, Salhab KF, Mendez C, Carey LC, Rabb H: Renal ischemia/reperfusion leads to macrophage-mediated increase in pulmonary vascular permeability. Kidney Int 1999;55: 2362–2367. Rabb H, Chamoun F, Hotchkiss J: Molecular mechanisms underlying combined kidney-lung dysfunction during acute renal failure. Contrib Nephrol. Basel, Karger, 2001, pp 41–52. Donnahoo KK, Meldrum DR, Shenkar R, Chung CS, Abraham E, Harken AH: Early renal ischemia, with or without reperfusion, activates NFkappaB and increases TNF-alpha bioactivity in the kidney. J Urol 2000;163:1328–1332. Donnahoo KK, Meng X, Ayala A, Cain MP, Harken AH, Meldrum DR: Early kidney TNF-alpha expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am J Physiol 1999;277:R922–R929. Donnahoo KK, Shames BD, Harken AH, Meldrum DR: Review article: The role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 1999;162:196–203. Baek SM, Makabali GG, Brown RS, Shoemaker WC: Free-water clearance patterns as predictors and therapeutic guides in acute renal failure. Surgery 1975;77:632–640. Rose BD, Post TW: Hypoosmolal states-hyponatremia; in Post TW (ed): Clinical Physiology of Acid-Base and Electrolyte Disorders, ed 5. New York, McGraw-Hill, 2001, pp 696–745. Erek E, Sever MS, Serdengecti K, Vanholder R, Akoglu E, Yavuz M, Ergin H, Tekce M, Duman N, Lameire N: An overview of morbidity and mortality in patients with acute renal failure due to crush syndrome: The Marmara earthquake experience. Nephrol Dial Transplant 2002;17:33–40. Jeha S: Tumor lysis syndrome. Semin Hematol 2001;38:4–8. Arrambide K, Toto RD: Tumor lysis syndrome. Semin Nephrol 1993;13:273–280. Gloe D: Common reactions to transfusions. Heart Lung 1991;20:506–512. Harris RC Jr: Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002;89:10D–17D. Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH: Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: Analysis of 44 cases. BMJ 2003;327:147–149.
Hoste/Kellum
10
77 78 79 80 81 82 83 84
85
86
87 88
89
90
Kahan BD: Cyclosporine nephrotoxicity: Pathogenesis, prophylaxis, therapy, and prognosis. Am J Kidney Dis 1986;8:323–331. Hsu I, Wordell CJ: Hyperkalemia and high-dose trimethoprim/sulfamethoxazole. Ann Pharmacother 1995;29:427–429. Lipkin GW, Kendall RG, Russon LJ, Turney JH, Norfolk DR, Brownjohn AM: Erythropoietin deficiency in acute renal failure. Nephrol Dial Transplant 1990;5:920–922. Lipkin GW, Kendall R, Haggett P, Turney JH, Brownjohn AM: Erythropoietin in acute renal failure. Lancet 1989;i:1029. Nagano N, Koumegawa J, Arai H, Wada M, Kusaka M: Effect of recombinant human erythropoietin on new anaemic model rats induced by gentamicin. J Pharm Pharmacol 1990;42:758–762. Eknoyan G, Wacksman SJ, Glueck HI, Will JJ: Platelet function in renal failure. N Engl J Med 1969;280:677–681. Weigert AL, Schafer AI: Uremic bleeding: Pathogenesis and therapy. Am J Med Sci 1998;316: 94–104. Hébert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J, Tweeddale M, Pagliarello G, Schweitzer I: The transfusion requirements in critical care investigators for the Canadian critical care trials group: Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001;29:227–233. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E: Group TTRiCcIftCCCT: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999;340:409–417. Craig RM, Murphy P, Gibson TP, Quintanilla A, Chao GC, Cochrane C, Patterson A, Atkinson AJ Jr: Kinetic analysis of D-xylose absorption in normal subjects and in patients with chronic renal failure. J Lab Clin Med 1983;101:496–506. Reidenberg MM: The biotransformation of drugs in renal failure. Am J Med 1977;62:482–485. Aronoff G, Berns J, Brier M, Golper T, Morrison G, Singer I, Swan SK, Bennet W: Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. Philadelphia, American College of Physicians, 1999. Bellomo R, McGrath B, Boyce N: Effect of continuous venovenous hemofiltration with dialysis on hormone and catecholamine clearance in critically ill patients with acute renal failure. Crit Care Med 1994;22:833–837. Pinder M, Bellomo R, Lipman J: Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intens Care 2002;30:134–144.
John A. Kellum, MD 608 Scaife Hall, The CRISMA Laboratory, Critical Care Medicine University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA 15261 (USA) Tel. ⫹1 412 647 6966, Fax ⫹1 412 647 3791, E-Mail
[email protected]
ARF in the Critically Ill
11
Ronco C, Bellomo R, Brendolan A (eds): Sepsis, Kidney and Multiple Organ Dysfunction. Contrib Nephrol. Basel, Karger, 2004, vol 144, pp 12–18
Acute Renal Failure in the Intensive Care Unit Risk Factors
P. Piccinni, R. Carraro, Z. Ricci Department of Anesthesiology and ICU, St.Bortolo Hospital, Vicenza, Italy
Acute renal failure (ARF) is a common clinical event affecting 2–5% of hospitalized patients and up to 10–30% of those in intensive care units (ICU), depending on the population studied and the criteria used to define [1]. The mortality rate in ARF patients remains high [2] despite hemodialysis therapy and substantial improvement of dialysis techniques. Possible explanations for this finding include the fact that ICU patients today are older and more debilitated than previously, and that the same pathophysiologic factors involved in the development of ARF are also incriminated in the failure of other organs, so that ARF is often part of the multiple organ failure (MOF) syndrome. [3] Acute renal failure can be oliguric (urinary output, ⬍400 ml per day) or nonoliguric (⬎400 ml per day). Patients with nonoliguric acute renal failure have a better prognosis than those with oliguric renal failure, probably due in large measure to the decreased severity of the insult and the fact that many have drug-associated nephrotoxicity or interstitial nephritis. The percentage of patients with acute renal failure who require dialysis ranges from 20 to 60%. Among the subgroup of patients who survive initial dialysis, less than 25% require long-term dialysis, demonstrating the potential reversibility of the syndrome [3]. Brivet et al. [4], in a prospective, multicenter study, found seven predictive factors for severe ARF patients requiring ICU stay related to the acute clinical setting in which ARF occurred and three characteristics of ARF influenced the outcome of patients: (a) hospitalization before ICU admission or a delayed occurrence of ARF during ICU stay; (b) sepsis, and (c) oliguria. Levy et al. [5] on an objective to determine if the high mortality in ARF is explained by underlying illnesses in cohort analytic study, found that the
mortality in subjects without renal failure was 7%, compared with 34% in the corresponding index subjects with renal failure. In ICU some 75% of ARF is a consequence of surgery, often associated with sepsis. A small focus of fecal contamination in the abdomen in a patient with acute renal failure or multiple organ failure will prove fatal and, similarly, a segment of dead bowel also negates recovery. ARF remains an infrequent but major complication of surgery necessitating cardiopulmonary bypass (CPB): the likelihood of developing ARF after cardiac surgery depends on factors associated with poor cardiac performance (particularly when separating from CPB) and with the level of baseline renal insufficiency [6]. The outcome of patients with ARF complicating cardiac surgery was particularly poor in those with associated cardiovascular failure [7]. Risk factors for ARF in severe trauma increased by age, ISS ⬎17, the presence of hemoperitoneum, shock, hypotension, rhabdomyolysis with CPK ⬎10,000 IU/l, presence of acute lung injury requiring mechanical ventilation, and Glasgow Coma Score ⬍10 [8]. A renal injury by exotoxins (e.g. antibiotics, anesthetic agents, contrast media, diuretics) and endotoxins (e.g. myoglobin) may also be involved. In patients with prerenal azotemia renal injury is more likely to be caused by drugs that can alter intrarenal hemodynamics, such as NSAIDs, or reach high concentrations in renal tissue, such as aminoglycosides. Patients with preexisting renal insufficiency are predisposed to acute renal failure due to radiocontrast agents, aminoglycosides, atheroembolism and cardiovascular surgery. Patients with both renal insufficiency and diabetes mellitus are at particularly high risk for toxic reactions to radiocontrast agents. Patients with hyperbilirubinemia also appear to be predisposed to acute renal failure. Elderly patients are susceptible to many forms of acute renal failure because the aging kidney loses functional reserve and its ability to withstand acute insults is compromised [9]. Synergy between renal hypoperfusion and toxic insults from an increased renal concentration of toxins at a time when sodium reabsorption and urinary concentration are enhanced and the oxygen supply is reduced are shown in figure 1 [10]. Severe infection include a combination of factors such inadequate perfusion with consequent inadequate delivery of oxygen, the sepsis-endotoxin-cytokine mediator system and superimposed disseminated intravascular coagulation (malignant intravascular inflammation). In this condition, the hemodynamic of this kidneys is impaired even without systemic hypotension: this is nevertheless a common feature of SIRS even in presence of high cardiac output (hyperdynamic hypotension) and it is due to decrease of, resistances or decrease of critical closing pressure in the arterial circuit [11, 12].
ARF in the Intensive Care Unit
13
Medullary oxygen insufficiency
Precipitation of Tamm–Horsfall protein
↑ Delivery of Na to macula densa
NSAIDs
Release of prostanoids, adenosine, nitric oxide
↑ Medullary blood flow
Volume depletion Cortical vasoconstriction
↓ IGF-I
BJP
Tubular obstruction and damage
↓ mTAL transport Renal failure
Medullary oxygen sufficiency
Fig. 1. Probable mechanisms leading from medullary hypoxia to renal failure. From Brezis and Rosen [10], modified.
Recently, an original study is published on behalf of the SOFA group of the European Society of Intensive Care Medicine on objective to describe risk factors for the development of ARF in ICU, and the association of ARF with MOF and outcome using the sequential organ failure assessment (SOFA) score. Forty participating centers in 16 countries enrolled 1,411 patients and conclude that the most important risk factors for development of ARF present on admission were acute circulatory or respiratory failure; age more than 65 years, presence of infection, past history of chronic heart failure (CHF) lymphoma or leukemia, or cirrhosis. The presence of infection during the ICU stay increased the risk of death by all other factors, especially circulatory failure [13]. In other words, there are conditions favoring deterioration of factors that render the kidney susceptible to acute injury, like: high O2 consumption; counter current multiplier; high blood flow; unique glomerular structure; renal blood flow autoregulation. Systemic hypotension induces loss of autoregulatory flow and repetitive periods of low perfusion pressure may induce repetitive ischemia in a region of the kidney already prone to hypoxia such as the medulla of the thick ascending limb of Henle’s loop (mTAL), see fig. 2. Heterogeneity of intrarenal blood flow contributes to the pathophysiology of ischemic acute renal failure. An imbalance between the vasodilator nitric
Piccinni/Carraro/Ricci
14
Blood flow, 4.2ml/min/g
Macula densa
Cortical labyrinths
PO2, ~50 mm Hg
Medullary rays Outer Blood flow, medulla 1.9 ml/min/g
PO2, ~10–20 mm Hg
Inner medulla
Medullary thick ascending limbs
Cortex Renal vein
Renal artery
Fig. 2. Anatomical and physiologic features of the renal cortex and medulla. From Brezis and Rosen [10], modified.
oxide and the vasoconstrictor endothelin may also impair medullary blood flow and contribute to tubular-cell damage. In the outer medulla, where tubules have high oxygen requirements, ischemia causes swelling of tubular and endothelial cells as well as adherence of neutrophils to capillaries and venules. These changes lead to vascular congestion and decreased blood flow, tipping the tenuous balance between oxygenation and energy demand. This ‘medullary anginal syndrome’ is a possible cause of apoptosis for part of parenchyma which had not undergone previous necrosis, i.e. the infinite story in biology of programmed cell death [14]. Apoptosis is an evolutionarily conserved and highly regulated program of cell death, which plays an important role in both normal physiologic processes and, when accelerated, in disease states as well. Many reports on apoptosis have focused on the role of the executioner cysteine-aspartate proteases termed ‘caspases’ that are triggered in response to proapoptotic signals and that result in disassembly of the cell. Recent studies demonstrated the coexistence of multiple parallel apoptotic pathways; in mammalian cells, at least four distinct pathways exist. Knowledge of caspase regulation may allow manipulation of apoptosis. A key caspase involved in the apoptotic pathway is caspase. Inhibition of caspase-3 has been linked to prevention of apoptotic death in vitro, although certain stimuli can induce apoptosis by a caspase-3-independent pathway. A second area of apoptosis research focused on the antiapoptotic protein, BCL [15–17].
ARF in the Intensive Care Unit
15
Pathophysiology of Ischemic Acute Renal Failure
The pathophysiology of ischemic acute renal failure, because of prerenal azotemia, can be considered a preischemic state and prerenal azotemia and ischemia are common causes of acute renal failure. As in any cell, anoxia in kidney cells results in the depletion of energy stores, collapse of electrolyte gradients, disruption of the actin cytoskeleton, activation of phospholipases, and changes in gene expression. Renal hypoxia induces the loss of epithelial polarity along the proximal tubules and the selective induction of growthresponse genes with rapid DNA fragmentation (suggestive of apoptosis) along the medullary thick limbs. Ischemic injury to renal vessels increases renovascular reactivity and predisposes patients to secondary ischemic insults from hypotension during the recovery from acute renal failure. Ischemia induces the expression of histocompatibility antigens on renal tubular cells and of intercellular adhesion molecules on endothelial cells, which leads to the local aggregation of neutrophils and platelets. After ischemia, intrarenal congestion is prominent in the outer medulla because of regional hypoxia and because the vasa recta are easily compressed by surrounding tubular edema [18, 19].
Acute Morphologic Lesions in Tubules
Anoxic damage along the tubules is governed by the intrinsic vulnerability of the various nephron segments and by the tissue gradients of oxygenation. Glomeruli and collecting ducts are relatively resistant to a lack of oxygen. By contrast, both proximal and distal tubules (especially medullary thick limbs) are intrinsically susceptible to hypoxia [20]. Nevertheless, the distribution of tubular damage in vivo appears to be determined largely by intrarenal oxygen gradients. Some of the cellular events associated with cell death and the restoration of tubule integrity are shown in figure 3 [21]. Ultimately, the mainstay is the maintenance of systemic arterial pressure at a value compatible with renal perfusion pressure: other factors can be concomitant but don’t play such a primary role. From the above comes that the risk factors for ARF in ICU are all these conditions reducing an effective circulating volume and lead to a further decrease in mean arterial pressure and thus also renal perfusion pressure such as: hypotension, hypoxia, the presence of sepsis and/or SIRS, fluid restriction and depletion, nephrotoxicity, positive pressure ventilation, and raised intraabdominal pressure.
Piccinni/Carraro/Ricci
16
Fig. 3. Tubular-cell injury and repair in ischemic acute renal failure. From Thadhani et al. [21], modified.
All this speculation confirms the idea that ARF is a ‘broad church’ with heterogeneity of causes and clinical presentation making extremely difficult the comparison of different study populations at different times ARF in ICU patients. These factors should be taken into account also when testing new approaches for the prevention and treatment of ARF and other organ dysfunctions in the critically ill [22] because the factors implicated in the development of ARF and its associated poor prognosis are not well defined in the literature and studies aimed at identifying risk factors could assist in our understanding of this disease process.
ARF in the Intensive Care Unit
17
References 1 2 3 4 5 6 7 8 9 10 11
12
13 14
15 16 17
18 19
20 21 22
Groeneveld AB, Tran DD, Van der Meulen J: Nauta JJ, Thijs LG: Acute renal failure in the medical intensive care unit: Predisposing, complicating factors and outcome. Nephron 1991;59:602–610. Vilkes B, Mailloux L: Acute renal failure: Pathogenesis and prevention. Am J Med 1986;80:1129. Pinsky MR, Matuschak GM: Multiple system organ failure: A unifying hypotesis. J Crit Care 1990;5:108–114. Brivet F, Kleinknecht D, Loirat P, Landais P: Acute renal failure in intensive care units – causes, outcome and prognostic factors: A prospective multicentre study. Crit Care Med 1996;24:192–198. Levy E, Viscioli C, Horowitz R: The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996;275:1489–1494. Conlon PJ, Stafford-Smith M, White WD: Acute renal failure following cardiac surgery. Nephrol Dial Transplant 1999;14:1158–1162. Ostermann ME, Taube D, Morgan CJ, Evans TW: Acute renal failure following cardiopulmonary bypass: A changing picture. Intens Care Med 2000;26:565–571. Vivino G, Antonelli M, Moro ML, Cottini F, Conti G, Bufi M, Cannata F, Gasparetto A: Risk factors for acute renal failure in trauma patients. Intens Care Med 1998;24:808–814. Endre ZH: Post cardiac surgery acute renal failure in the 1990s. Aust NZ J Med 1997;25:278–279. Brezis M, Rosen S: Hypoxia of the renal medulla: Its implications for disease. N Engl J Med 1995;332:647–655. American College of Chest Physisians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864–874. Bone RC: Immunologic dissonance: A continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996;125:6780–6787. de Mendonça A, Vincent JL, Suter PM, Moreno R, Dearden NM, Antonelli M: Acute renal failure in the ICU: Risk factors and outcome evaluated by the SOFA score. Intens Care Med 2000;26:915–921. Abbis IA, Camerons JS: Epidemiology of acute renal failure in the intensive care unit; in Ronco C, Bellomo R (eds): Critical Care Nephrology. Amsterdam, Kluwer Academic Publishers, 1998, pp 133–141. Brady H, Singer G: Acute renal failure. Lancet 1995;346:1533–1540. Toda N, Takahashi T, et al: Tin chloride pretreatment prevents renal injury in rats with ischemic acute renal failure. Crit Care Med 2002;30:1512–1522. Tetta C, Mariano F, Buades J, Ronco C, Wratten ML, Camussi G: Relevance of platelet-activating factor in inflammation and sepsis: Mechanisms and kinetics of removal in extracorporeal treatments. Am J Kidney Dis 1997;5(suppl 4):S57–S65. Majno G, Joris I: Apoptosis, oncosis, and necrosis: An overview of cell death. Am J Pathol 1995; 146:3–15. Black SC, Huang JQ, Rezaiefar P, et al: Colocalization of the cysteine protease caspase-3 with apoptotic myocytes after in vivo myocardial ischemia and reperfusion in the rat. J Mol Cell Cardiol 1998;30:733–742. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997;3:614. Thadhani R, Pascual M, Bonventre J: Acute renal failure. N Engl J Med 1996;334:1448–1460. Vincent JL: Dear SIRS, I’m sorry to say that I don’t like you. Crit Care Med 1997;371–374.
Pasquale Piccinni Department of Anesthesiology and ICU, St. Bortolo Hospital Via Rodolfi 37, IT–36100 Vicenza (Italy) Tel. ⫹39 444 993862 – 3400, Fax ⫹39 444 927567 E-Mail
[email protected]
Piccinni/Carraro/Ricci
18
Ronco C, Bellomo R, Brendolan A (eds): Sepsis, Kidney and Multiple Organ Dysfunction. Contrib Nephrol. Basel, Karger, 2004, vol 144, pp 19–30
Pathophysiology of Ischemic Acute Renal Failure Inflammation, Lung-Kidney Cross-Talk, and Biomarkers
Joseph V. Bonventre Renal Division, Brigham and Women’s Hospital and Department of Medicine, Harvard Medical School, and the Harvard-Massachusetts Institute of Technology, Division of Health Sciences and Technology, Boston, Mass., USA
Ischemic acute renal failure (ARF) is a syndrome that results from a mismatch between oxygen and nutrient delivery to the nephrons and energy demand of the nephrons. At times there is a clearly defined transient drop in total or regional blood flow to the kidney which results from compromise of the systemic circulation; at other times, for example in the setting of sepsis, the reduction in perfusion may not be associated with systemic signs of hypotension or circulatory compromise. ARF is frequently associated with multiple organ failure and sepsis. Despite advances in preventative strategies and support measures, this syndrome continues to be associated with significant morbidity and mortality. In animal models, experimental renal ischemia results in rapid loss of cytoskeletal integrity and cell polarity. There is shedding of the proximal tubule brush border, mislocalization of adhesion molecules and other membrane proteins such as the NaKATPase, as well as apoptosis and necrosis [37]. With severe injury, viable and non-viable cells are desquamated leaving regions where the basement membrane remains as the only barrier between the filtrate and the peritubular interstitium. This allows for backleak of the filtrate, especially under circumstances where the pressure in the tubule is increased due to intratubular obstruction resulting from cellular debris in the lumen interacting with proteins such as fibronectin which enter the lumen [41]. In contrast to the heart or brain, the kidney can completely recover from an ischemic or toxic insult that results in cell death. Surviving cells that remain adherent undergo repair with the potential to recover normal renal function. When the kidney recovers from acute injury it relies on a sequence of events
that include epithelial cell spreading and possibly migration to cover the exposed areas of the basement membrane, cell dedifferentiation and proliferation to restore cell number, followed by differentiation which results in restoration of the functional integrity of the nephron [2]. In this review I will focus briefly on three aspects of the pathogenesis of acute renal failure: (1) the role of inflammation; (2) pulmonary-renal cross-talk, and (3) biomarkers of injury.
Inflammation
The pathogenesis of ischemic acute renal failure has been attributed to abnormal regulation of local blood flow following the initial ischemic episode. Persistent generalized preglomerular vasoconstriction may be a contributing factor; however, we believe that a more important pathophysiological component of ischemic ARF is a reduction in local blood flow to the outer medulla. Despite the extensive literature suggesting that enhanced vasoconstriction, mediated by various endogenous vasoactive agents, contributes to the pathophysiology of acute renal failure, no vasodilator has proved useful in preventing or treating ARF associated with tubular necrosis in man. In animals protective effects of agents designed to block vasoconstrictors such as endothelin may be related to the effects of these agents on neutrophil adhesion or other aspects of leukocyteendothelial interactions [34]. Vasodilators, such as nitric oxide, also can have effects to decrease inflammation. NO inhibits TNF-induced adhesion of neutrophils to endothelial cells, stimulated by TNF-, which would also be protective [23]. It has been known for quite some time now that there is less flow to the medullary than the cortical region in the postischemic kidney [39]. In addition, as endothelial cells are injured with resulting cell swelling and increased expression of cell adhesion molecules, so also are leukocytes activated. Enhanced leukocyte-endothelial interactions can result in cell-cell adhesion, which can physically impede blood flow [5]. Furthermore, these interactions will additionally activate both leukocytes and endothelial cells and contribute to the generation of local factors that promote vasoconstriction especially in the presence of other vasoactive mediators, resulting in compromised local blood flow and impaired tubule cell metabolism [35]. These leukocyte-endothelial interactions likely impact the outer medulla to a greater extent than the cortex. The concept that endothelial cells are a target of post-ischemic renal injury was suggested as early as 1972 by Leaf and colleagues when they described endothelial swelling and narrowing of the blood vessel lumen as important features of post-ischemic injury [12]. There is marked congestion of the outer medulla after ischemia [28]. Recently, evidence for endothelial dysfunction in the cortex has also been presented in studies that demonstrated
Bonventre
20
retrograde blood flow through peritubular capillaries upon reperfusion following ischemia [7]. With reperfusion, a partial transient compromise of the patency of the peritubular capillaries was also observed. When human umbilical vein endothelial cells or human embryonic kidney cells, stably expressing endothelial nitric oxide synthase, were administered either intravenously or into the renal artery following ischemia, these cells implanted into the kidney and resulted in partial functional protection against injury [7]. In addition, following prolonged ischemia (60 min) in the rat, peritubular capillaries suffer permanent damage [1]. The number of microvessels in the inner stripe of the outer medulla declines, with the reduction in number associated with increased tubulointerstitial fibrosis and altered concentrating ability. With ischemia-reperfusion, endothelial cells upregulate integrins, selectins, and members of the immunoglobulin superfamily, including intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule (VCAM). Administration of anti-ICAM-1 antibodies prior to renal ischemia-reperfusion protects the kidney from injury [20]. Kidneys of ICAM-1 knockout mice also are protected [21]. There are many mechanisms by which leukocytes potentiate renal injury. Leukocytes are activated by inflammatory mediators, including cytokines, chemokines, eicosanoids, and reactive oxygen species (ROS), which upregulate adhesion molecules that engage counter-receptors on the activated epithelium. Leukocytes are recruited and activated by chemokines, which are upregulated by the proinflammatory cytokines interleukin-1 (IL-1) and tumor necrosis factor- (TNF-). TNF-, IL-1, and IFN-, produce a number of injurious changes in proximal tubular epithelial cells. These cytokines also disrupt cell-matrix adhesion dependent on 1 integrin, inducing cell shedding into the lumen. Leukocyte subgroups are likely to contribute in different ways to ischemiareperfusion injury. Myeloperoxidase activity is elevated soon after ischemic insult and may originate from macrophages and/or neutrophils [28]. If neutrophil accumulation is prevented, however, tissue injury is ameliorated [21]. It is possible that neutrophil depletion models, however, may not adequately differentiate involvement of neutrophils from T lymphocytes and macrophages. Later phases of ARF are characterized by infiltration of macrophages and T lymphocytes which predominate over neutrophils. Knock-out mice lacking CD4/CD8, a cell adhesion receptor on T lymphocytes, are protected from ischemia-reperfusion injury [32], suggesting a causal role for T lymphocytes in mediating injury. In addition, blockade of T cell CD28-B7 costimulation protects against ischemic injury in rats and significantly inhibits T cell and macrophage infiltration and activation in situ [10]. The role of the T cell, however, has been recently questioned. Mice deficient in recombination-activating
Pathophysiology of Ischemic Acute Renal Failure
21
gene (RAG)-1 lack T and B cells and do not produce immunoglobulins or T cell receptor proteins. In the absence of these cells and their receptors, RAG-1 deficient mice are not protected from ARF induced by ischemia. Tubular necrosis and neutrophil infiltration are present to a degree comparable to that seen in wild type mice [30]. Complement may also potentiate leukocyte-endothelial interactions. In a number of different tissues exposed to ischemia-reperfusion, complementdependent upregulation of endothelial cell adhesion molecules, with resulting neutrophil accumulation in the vasculature, has been implicated as a mechanism for complement-mediated injury [15]. Some investigators, however, suggest that the primary effect of complement in kidney ischemia-reperfusion is on the epithelial cell due to a direct effect of the membrane attack complex of complement [40]. ROS that are generated during reperfusion and as a result of the inflammatory response play a major role in cell injury. ROS are generated by activated infiltrating leukocytes and by epithelial cells. ROS are directly toxic to tubular epithelial cells, with ROS generating systems mimicking the effects of ischemic injury [24]. In some cases, scavengers (superoxide dismutase, glutathione, vitamin E) and inhibitors of ROS (deferoxamine) have been found to protect against renal injury [26]. The presence of ROS can result in the peroxidation of lipids in cell membranes, protein denaturation and DNA strand breaks. Lipid peroxidation by ROS enhances membrane permeability and impairs function of membrane enzymes and ion pumps. ROS-induced strand breaks in DNA leads to activation of DNA repair mechanisms, including the nuclear enzyme poly(ADP-ribose) synthetase (PARS). PARS transfers ADP-ribose from nicotinamide adenine diphosphate (NAD) to nuclear proteins. Following ischemiareperfusion, PARS is activated, NAD is depleted and generation of cellular ATP is inhibited, worsening the injury. This amplification of injury, also called the PARS suicide, may be the major mechanism by which ROS is directly toxic to cells. Inhibiting PARS protects renal cells against ROS-induced injury, in particular, resulting from ischemia-reperfusion [8]. ROS also upregulate chemokine expression. Transgenic mice overexpressing the anti-oxidants, intracellular and extracellular glutathione peroxidases, are protected against ischemic injury [19]. These animals have less induction of the chemokines, interleukin8 (IL-8) and monocyte chemotactic protein-1 (MCP-1), less neutrophil infiltration and less functional injury compared to the wild type controls, suggesting that the effects of ROS are mediated by chemokines. Exposure of leukocytes to circulating cytokines reduces their deformability and enhances their tendency to be sequestered [36]. Sequestered leukocytes can then potentiate injury by further generating more ROS and eicosanoids, enhancing inflammation and vascular tone.
Bonventre
22
Tubule Contribution to Inflammatory Injury
Both the S3 segment of the proximal tubule and the medullary thick ascending limb (MTAL) are located in the outer stripe of the outer medulla. This region of the kidney is marginally oxygenated under normal conditions and after an ischemic insult, oxygenation is further compromised because the return in blood flow is delayed. Both segments of the nephron contribute to the inflammatory response in ARF [4]. The tubule epithelial cells are known to generate proinflammatory and chemotactic cytokines such as TNF-, MCP-1, IL-8, interleukin-6 (IL-6), interleukin-1 (IL-1), and TGF-, MCP-1, IL-8, RANTES and ENA-78 [6]. Proximal tubular epithelial cells may respond to T lymphocyte activity through activation of receptors for T cell ligands [22]. When CD40 is ligated in response to interaction with CD154, there is MCP-1 and IL-8 production, TRAF6 recruitment, and MAPK activation in the proximal epithelial cell [22]. CD40 also induces RANTES production by human renal tubular epithelia, an effect which is amplified by production of IL-4 and IL-13 by Th2 cells, a subpopulation of T cells [11]. B7–1 and B7–2 can be induced on proximal tubule epithelial cells in vivo and in vitro. After B7–1 and B7–2 induction, proximal tubule epithelial cells costimulate CD28 on T lymphocytes resulting in cytokine production [25].
Protection against Injury by Ischemic Preconditioning
An area of increasing interest is the possibility of rendering an organ resistant to subsequent injury by a prior insult or preconditioning maneuver. Ischemic preconditioning of the kidney confers protection against a subsequent ischemic attack [3]. Identification of the mechanisms responsible for renal ischemic preconditioning will likely facilitate our understanding of the pathophysiology of ischemic injury and guide the development of novel therapeutics aimed at mimicking the protective mechanism(s). Several candidates that could potentially serve as mediators of preconditioning have been identified. These include activation of NOS [27] and phosphatidylinositol-3-kinase Akt/PKB pathways, reduction in the relative activation of JNK as compared to ERK1/2 [28, 29], and induction of heat shock proteins, heme oxygenase, and endoplasmic reticulum stress proteins [16]. A recent review discusses many of these candidate mediators of preconditioning in more detail [3]. Of these potential mediators, the NOS pathway is particularly important to mention. Recently, this laboratory demonstrated that iNOS is responsible for a component of the long-term protection afforded the kidney by ischemic preconditioning [27]. Thirty minutes of prior ischemia results in a prolonged increase
Pathophysiology of Ischemic Acute Renal Failure
23
in the expression of iNOS and eNOS as well as heat shock protein (HSP)-25. In addition, there is increased interstitial expression of alpha smooth muscle actin, an indicator of long-term renal interstitial changes. Gene deletion of iNOS, but not eNOS, increased kidney susceptibility to ischemia, as did treatment with pharmacological inhibitors of NO synthesis, including N-nitro-L-arginine (L-NNA) and L-N6-(1-iminoethyl)lysine (L-NIL), the latter a specific inhibitor of iNOS. When the initial period of ischemia was reduced (15 min), there was less protection of the kidney from subsequent ischemia on day 8. Under these conditions, there was no sustained increase in iNOS or eNOS expression, and protection was not abolished by L-NIL treatment, suggesting that the residual protection was not related to iNOS. In addition, renal function was not impaired and expression of interstitial alpha-smooth muscle actin did not change. The data indicate that iNOS plays an important role in kidney protection afforded by prolonged ischemic preconditioning and that persistent long-term changes in the renal interstitium may be critical in affording this protection by sustaining iNOS synthesis. In addition, this study is the first to demonstrate in any organ system that partial protection persists up to 12 weeks after an initial ischemic event. The iNOS-independent protection associated with preconditioning may be related, at least in part, to an upregulation of HSP-25. Mitogen-activated protein (MAP) kinases are also likely to be involved in affording protection following ischemic preconditioning [28]. MAP kinases are ubiquitously expressed serine/threonine kinases which, in mammalian cells, play central roles in determining if the response to multiple signaling inputs will be proliferation, differentiation or apoptosis. In mammalian cells, three MAP kinase cascades have been identified. The best studied of these include the extracellular signal-regulated kinase (ERK) cascade, involved in cell proliferation and differentiation in a variety of cell types. The ERK pathway is activated by growth factors and many other agonists, including vasoactive peptides. Jun N-terminal kinase (JNK), also known as stress-activated protein kinase (SAPK), and p38 are components of the two other MAP kinase cascades. JNK and p38 are activated by inflammatory cytokines (TNF and IL-1) and with cellular stress, including genotoxic stress and osmolar stress. They are only minimally activated by growth factors. JNK has been implicated in proximal tubular cell injury and is increased following ATP depletion in vitro and ischemia-reperfusion injury in vivo [31]. Interestingly, ERK is activated predominantly in distal cells (MTAL) [33], perhaps explaining in part the differential susceptibility to injury of the proximal and distal nephron segments. When the kidney is preconditioned to injury by ischemia, after the second ischemic exposure activation of JNK and p38 is markedly reduced, as is activation of their upstream MAPK kinases (MKK7, MKK4 and MKK3/6). By contrast, activation of ERK1/2 and its upstream MAPKK activator, MKK3/4, is unaltered by preconditioning. Thus, the relative ratio of
Bonventre
24
60
L-NAME
*
50
*
40 30 †
20
†
10 0 VT 7
VT 20
VT 20NS
Albuminuria (mg/24h)
24-Hour total protein/creat (mg/g creat)
No treatment
70
16 14 12 10 8 6 4 2 0
*
VT 7
VT 20
VT 20NS
Fig. 1. Effects of mechanical ventilation and N-nitro-L-arginine methyl ester (LNAME) on urine protein excretion. Twenty-four-hour urine total protein normalized to total creatinine excretion (a) and albumin (b) are depicted. Ventilation was at 85 breaths/min for 2 h at 7 (VT 7) or 20 ml/kg without (VT 20) or with (VT 20 NS) normal saline (10 ml/kg) administration. Large tidal volume ventilation (VT 20), with or without normal saline administration, caused significant proteinuria compared with the VT 7 group (n 6 in each group). Proteinuria and albuminuria were mitigated by treating the animals with L-NAME *p 0.05 vs. VT 7; †p 0.05 vs. no treatment at VT 7. Modified with permission from Choi et al. [9].
ERK1/2 activation to JNK or p38 activation is enhanced in the preconditioned postischemic kidney.
Lung-Kidney Cross-Talk
Many of our patients with ARF have multiple organ failure and many are on positive pressure mechanical ventilation. We have recently found that ventilation of the lung has distal effects on the kidney even if the kidney has not been manipulated in the rat [9]. Rats were ventilated with room air at 85 breaths/min for 2 h with either VT 7 or 20 ml/kg. Positive pressure ventilation resulted in increased microvascular leak in the lung that is dependent on nitric oxide synthase (NOS) expression. Kidney microvascular leak, which was assessed by measuring 24-hour urine protein and tissue Evans blue dye, was found to be markedly increased. There was significant microvascular leak in both lung and kidney with large VT (20 ml/kg) ventilation. Injection of 0.9% NaCl corrected the hypotension and the decreased cardiac output related to large VT, but it did not attenuate microvascular leak in lung and kidney. There was an increase in total proteinuria and albuminuria resulting from the ventilation (fig. 1). Serum vascular endothelial growth factor was significantly elevated in large VT groups. Endothelial NOS but not inducible NOS expression significantly increased in the lung and kidney tissue with large VT ventilation. The NOS inhibitor, N-nitro-L-arginine methyl
Pathophysiology of Ischemic Acute Renal Failure
25
ester (L-NAME), attenuated the microvascular leak in lung and kidney and the proteinuria seen with hyperventilation. Endothelial NOS may mediate the systemic microvascular leak in this model of ventilation-induced lung injury. These findings may have important implications for the pathophysiology of ischemic ARF since enhanced microvascular permeability in the renal parenchyma of the outer medulla could be expected to contribute to outer medullary congestion and impaired blood flow through the microcapillary bed supplying the tubule structures in that region of the kidney.
Biomarkers
A major shortcoming in our ability to conduct clinical studies to test putative therapeutic agents in ARF, and hence test pathophysiological concepts reflected by the therapeutic approach, is the lack of a biomarker that will herald the disease early enough so that intervention can be introduced at a time when there is a reasonable chance to alter the natural history of the disease. Therapeutic intervention is in general delayed in ARF. There is no equivalent of ‘troponin’ or creatinine phosphokinase (CPK) which can be used as early markers for ischemic injury in the heart. Biomarkers for ischemic injury could be monitored in the blood or urine. While several urinary proteins have been evaluated as potential non-invasive markers of renal injury [38] none of these markers have been used successfully to screen for early renal injury or to identify the site of injury within the kidney. The availability of sensitive and specific urine markers of ARF would lead to improvements in diagnosis, better enable monitoring of therapy, as well as establishment of prognosis and risk assessment. In addition, identification of urinary proteins expressed during ARF may lead to the identification of novel targets for therapy, or of markers that could be used to evaluate the effectiveness of therapeutic interventions. Hampel et al. [13] published urinary protein profiles in 25 patients following administration of radiocontrast material. Using surface-enhanced laser desorption/ionization (SELDI) protein chip array-time of flight mass spectrometry, they demonstrated perturbations in the patterns of urinary protein expression following cardiac catheterization. The temporal course of protein expression differed between patients with normal renal function and patients with impaired renal function at baseline. Since the patient population was small and the follow-up time was short, no correlation was found between changes in urinary protein expression patterns and the development of ARF. Furthermore, specific proteins were not identified. Nevertheless, it is quite likely that some of the proteins found could serve as markers of impending contrast-induced acute renal failure. While these results must be extended and confirmed by larger studies, they suggest that uroscopy
Bonventre
26
with mass spectrometry may lead to the identification of markers of ARF with important diagnostic and/or predictive implications. Our laboratory has a long-standing interest in identifying clinically useful markers of acute renal failure. We cloned from rats, mice and humans a novel adhesion molecule, kidney injury molecule 1 (KIM-1 names the human form and Kim-1 names the rodent form), which may serve as a marker of ischemic tubular injury [17]. In addition to its upregulation in the postischemic kidney, Kidney injury molecule-1 is upregulated in various models of toxic renal injury in the rat [18]. In addition, it is expressed on the proximal tubule epithelial cells in human kidney biopsy sections from patients with acute tubular necrosis [14]. Importantly, there is no staining for KIM-1 in normal human kidney, suggesting that KIM-1 is a marker of injured renal tissue. We recently investigated the utility of KIM-1 as a marker of acute tubular damage in humans. We found that soluble KIM-1 was detected at higher levels in the urine of patients with acute tubular necrosis (ATN) compared to patients with other forms of acute renal failure or chronic renal disease [14]. These findings suggest that a soluble form of KIM-1 may be a clinically useful marker for proximal renal tubular injury. We also found that levels of KIM-1 increase and return to baseline following aortic cross-clamping in a patient with no overt clinical evidence of ARF. This suggests that KIM-1 may be useful as a marker of ATN early in the course of ARF, before other markers of ARF become evident. We are working to further characterize the function of KIM-1 and to characterize its utility as a biomarker for ATN.
Conclusions
Ischemic renal injury is a dynamic process that often exists in the context of multiple organ failure and involves hemodynamic alterations, inflammation and direct injury to the tubular epithelium followed by a repair process that restores epithelial differentiation and function. Inflammation is a significant component of this disease, playing a considerable role in its pathophysiology. Although significant progress has been made in defining the major components of this process, the complex cross-talk between endothelial cells, inflammatory cells and the injured epithelium, with each generating and often responding to cytokines and chemokines, is not well understood. In addition, we have not adequately integrated the contributions of other organs in this pathophysiology. A better understanding of the pathophysiology underlying this disease with better ways to limit the inflammatory component and/or promote the repair process, will depend upon the identification of biomarkers that can help us identify the disease early at a time when intervention can alter its
Pathophysiology of Ischemic Acute Renal Failure
27
natural history. Progress is being made on multiple fronts but we continue to be humbled by ARF whose mortality rate has not significantly changed over four decades.
Acknowledgments This work was supported by the National Institutes of Health (grants DK 39773, DK 38452, NS 10828, DK54741, DK 46267).
References 1
2 3 4 5 6 7
8
9
10 11
12 13
14 15 16
Basile DP, Donohoe D, Roethe K, Osborn JL: Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol 2001;281: F887–F899. Bonventre JV: Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 2003;14(suppl 1):S55–S61. Bonventre JV: Kidney ischemic preconditioning. Curr Opin Nephrol Hypertens 2002;11:43–48. Bonventre JV, Brezis M, Siegel N, Rosen S, Portilla D, Venkatachalam M: Acute renal failure. I. Relative importance of proximal vs. distal tubular injury. Am J Physiol 1998;275:F623–F632. Bonventre JV, Weinberg JM: Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003;14:2199–2210. Bonventre JV, Zuk A: Ischemic acute renal failure: An inflammatory disease? Kidney Int 2004; in press. Brodsky SV, Yamamoto T, Tada T, Kim B, Chen J, Kajiya F, Goligorsky MS: Endothelial dysfunction in ischemic acute renal failure: Rescue by transplanted endothelial cells. Am J Physiol 2002;282:F1140–F1149. Chatterjee PK, Zacharowski K, Cuzzocrea S, Otto M, Thiemermann C: Inhibitors of poly (ADPribose) synthetase reduce renal ischemia-reperfusion injury in the anesthetized rat in vivo. FASEB J 2000;14:641–651. Choi WI, Quinn DA, Park KM, Moufarrej RK, Jafari B, Syrkina O, Bonventre JV, Hales CA: Systemic microvascular leak in an in vivo rat model of ventilator-induced lung injury. Am J Respir Crit Care Med 2003;167:1627–1632. De Greef KE, Ysebaert DK, Dauwe S, Persy V, Vercauteren SR, Mey D, De Broe ME: Anti-B7–1 blocks mononuclear cell adherence in vasa recta after ischemia. Kidney Int 2001;60:1415–1427. Deckers JG, De Haij S, van der Woude FJ, van der Kooij SW, Daha MR, van Kooten C: IL-4 and IL-13 augment cytokine- and CD40-induced RANTES production by human renal tubular epithelial cells in vitro. J Am Soc Nephrol 1998;9:1187–1193. Flores J, DiBona DR, Beck CH, Leaf A: The role of cell swelling in ischemic renal damage and the protective effect of hypertonic solutions. J Clin Invest 1972;51:118–126. Hampel DJ, Sansome C, Sha M, Brodsky S, Lawson WE, Goligorsky MS: Toward proteomics in uroscopy: Urinary protein profiles after radiocontrast medium administration. J Am Soc Nephrol 2001;12:1026–1035. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV: Kidney injury molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int 2002;62:237–244. Homeister JW: Lucchesi BR: Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu Rev Pharmacol Toxicol 1994;34:17–40. Hung CC, Takaharu I, Stevens JL, Bonventre JV: Protection of renal epithelial cells against oxidative injury by endoplasmic reticulum stress preconditioning is mediated by ERK1/2 activation. J Biol Chem 2003;278:29317–29326.
Bonventre
28
17
18
19
20 21
22 23 24
25
26 27
28
29
30
31
32
33
34 35 36
Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, Sanicola M: Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998;273:4135–4142. Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV: Kidney injury molecule-1: A tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 2004; 286:F552–F563. Ishibashi N, Weisbrot-Lefkowitz M, Reuhl K, Inouye M, Mirochnitchenko O: Modulation of chemokine expression during ischemia/reperfusion in transgenic mice overproducing human glutathione peroxidases. J Immunol 1999;163:5666–5677. Kelly KJ, Williams WW, Colvin RB, Bonventre JV: Antibody to intercellular adhesion molecule-1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 1994;91:812–816. Kelly KJ, Williams WW, Colvin RB, Meehan SM, Springer TA, Gutierrez-Ramos JC, Bonventre JV: Intercellular adhesion molecule-1 deficient mice are protected against renal ischemia. J Clin Invest 1996;97:1056–1063. Li H, Nord EP: CD40 ligation stimulates MCP-1 and IL-8 production, TRAF6 recruitment, and MAPK activation in proximal tubule cells. Am J Physiol 2002;282:F1020–F1033. Linas S, Whittenburg D, Repine JE: Nitric oxide prevents neutrophil-mediated acute renal failure. Am J Physiol 1997;272:F48–F54. Malis CD, Weber PC, Leaf A, Bonventre JV: Incorporation of marine lipids into mitochondrial membranes increases susceptibility to damage by calcium and reactive oxygen species: Evidence for enhanced activation of phospholipase A2 in mitochondria enriched with n-3 fatty acids. Proc Natl Acad Sci USA 1990;87:8845–8849. Niemann-Masanek U, Mueller A, Yard BA, Waldherr R, van der Woude FJ: B7–1 (CD80) and B7–2 (CD 86) expression in human tubular epithelial cells in vivo and in vitro. Nephron 2002;92:542–556. Paller MS: Renal work, glutathione and susceptibility to free radical-mediated postischemic injury. Kidney Int 1988;33:843–849. Park KM, Byun JY, Kramers C, Kim JI, Huang PL, Bonventre JV: Inducible nitric oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney. J Biol Chem 2003;278:27256–27266. Park KM, Chen A, Bonventre JV: Prevention of kidney ischemia/reperfusion-induced functional injury and JNK, p38, and MAPK kinase activation by remote ischemic pretreatment. J Biol Chem 2001;276:11870–11876. Park KM, Kramers C, Vayssier-Taussat M, Chen A, Bonventre JV: Prevention of kidney ischemia/reperfusion-induced functional injury, MAPK and MAPK kinase activation, and inflammation by remote transient ureteral obstruction. J Biol Chem 2002;277:2040–2049. Park P, Haas M, Cunningham PN, Bao L, Alexander JJ, Quigg RJ: Injury in renal ischemiareperfusion is independent from immunoglobulins and T lymphocytes. Am J Physiol 2002; 282:F352–F357. Pombo CM, Bonventre JV, Avruch J, Woodgett JR, Kyriakis JM, Force T: The stress activated protein kinases are major c-jun amino-terminal kinases activated by ischemia and reperfusion. J Biol Chem 1994;269:26545–26551. Rabb H, Daniels F, O’Donnell M, Haq M, Saba SR, Keane W, Tang WW: Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am J Physiol 2000;279: F525–F531. Safirstein RL, Bonventre JV: Molecular response to ischemic and nephrotoxic acute renal failure; in Schlündorff D, Bonventre JV (eds): Molecular Nephrology. New York, Marcel Dekker, 1995, pp 839–854. Sanz MJ, Johnston B, Issekutz A, Kubes P: Endothelin causes P-selectin-dependent leukocyte rolling and adhesion within rat mesenteric microvessels. Am J Physiol 1999;277:H1823–H1830. Sheridan AM, Bonventre JV: Cell biology and molecular mechanisms of injury in ischemic acute renal failure [In Process Citation]. Curr Opin Nephrol Hypertens 2000;9:427–434. Suwa T, Hogg JC, Klut ME, Hards J, van Eeden SF: Interleukin-6 changes deformability of neutrophils and induces their sequestration in the lung. Am J Respir Crit Care Med 2001;163: 970–976.
Pathophysiology of Ischemic Acute Renal Failure
29
37 38 39 40 41
Thadhani R, Pascual M, Bonventre JV: Acute renal failure. N Engl J Med 1996;334:1448–1460. Tolkoff-Rubin NE, Rubin RH, Bonventre JV: Noninvasive renal diagnostic studies. Clin Lab Med 1988;8:507–526. Vetterlein F, Pethö A, Schmidt G: Distribution of capillary blood flow in rat kidney during postischemic renal failure. Am J Physiol 1986;251:H510–H519. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH: Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000;105:1363–1371. Zuk A, Bonventre JV, Matlin KS: Expression of fibronectin splice variants in the postischemic rat kidney. Am J Physiol 2001;280:F1037–F1053.
Joseph V. Bonventre, MD, PhD Brigham and Women’s Hospital, Renal Division MRB-4, 75 Shattuck Street, Boston, MA 02115 (USA) Tel. +1 617 429 2146, E-Mail
[email protected]
Bonventre
30
Ronco C, Bellomo R, Brendolan A (eds): Sepsis, Kidney and Multiple Organ Dysfunction. Contrib Nephrol. Basel, Karger, 2004, vol 144, pp 31–43
Pathophysiology of Sepsis and Multiple Organ Failure: Pro- versus Anti-Inflammatory Aspects Michael R. Pinsky Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pa., USA
Many of the common severe illnesses, including sepsis and septic shock, severe trauma, burns or other overwhelming stresses, are characterized by the widespread activation of host innate immunity response. The hallmark of this activation is the release of potent inflammatory mediators into the circulation [1]. This response is often referred to as the systemic inflammatory response syndrome (SIRS) [2] to accentuate the non-specific inflammatory nature of the process as assessed by measures of circulating active small molecules capable of inducing a generalized inflammatory response on remote organ systems. Furthermore, if sustained, this system-wide inflammatory process may result in loss of the normal vasoregulatory adaptations to stress and metabolic demand. This peripheral vascular paralysis often precedes the development of multiple organ system dysfunction and death in critical illness. Historical perspectives, recent clinical trials of immunomodulating agents and cellular and molecular data have created an exciting and productive story that only recently lead to the first positive outcome trial of pharmacotherapy for severe sepsis.
Initial Cellular Events of Innate Immunity: Outside-In Signaling
Inflammatory processes require immune cell response, recruitment into the local area and further activation if the inflammatory response is to be sustained. This response involves initial cellular recognition of the stimulant via innate immune systems. This initial recognition process involves a complex interaction of host-derived co-factors, such as lipopolysaccharide-binding protein,
compliment activation and coating of foreign biological material (bacteria) and release of pro-coagulant materials. Many of these activation complexes nonspecifically bind to the host universal inflammation receptor CD14 whose transmembrane domain, the Toll-like receptor (TLR), activates an intracellular tyrosine kinase system that eventually activates the oxidant sensitive proinflammatory promoter, nuclear factor-B (NF-B). Presently, 10 specific TLR proteins have been identified; however, TLR-2 and TLR-4 appear to be primarily involved in the innate immunity aspects of circulating monocytes, polymorphonuclear leukocytes (PMN) and dendrocytes and TLR-4 appears to be trans-membrane moiety that it associates with in order to initiate outside-in cell signaling [31]. Simultaneously, expression of novel cell surface receptors and gene induction and new protein synthesis occur. Following this immune competent cells and responsive parenchymal cells make novel protein species needed to induce a localized inflammatory response. The release of immune active mediators stimulates primary target cell (immune cell) responses via similar mechanisms to those described by the primary activation sequence, except now more complex cell surface receptors, co-stimulating factors and parallel mediator systems interactions co-exist. These include activation of the contact system (compliment), fibrinolytic system (thrombin and activate protein C) and paired cytokine stimuli (TNF- and IL-1, or IL-8 and MIP-1). Secondary parenchymal cell response via these soluble mediators and formed cell interactions then occur via cell-cell, or paracrine activation. The low molecular weight protein mediators that initiate, sustain and modulated the inflammatory interactions are called cytokines. With the exception of pre-pro-IL-1, cytokines have to be synthesized de novo in response to a specific external stimulus. Thus, the inflammatory response is a determined process requiring energy and protein synthesis to occur, post-translational protein processing to mature the mediators, and secretion to get them into the microenvironment needed for cell-cell signaling. Based on our understanding of their actions, cytokines are presumably present to modulate cellular response and metabolism on a local or paracrine level. However, once these cytokines gain access to the blood stream in numbers capable of inducing a systemic immune cell response, then a generalized inflammatory response develops. It is still not clear to what extent this systemic response is adaptive or maladaptive to the host. On the one hand, fever and the induction of release of acute-phase proteins by the liver and heat shock proteins into the cells of the body improve survival in bacterial infections, and malaise may be a very adaptive symptom in limiting the host activity and excess consumption of limited energy resources. However, on several levels the generalized inflammatory response may not confer survival advantage for the host.
Pinsky
32
Clearly, on a local level, a violent inflammatory response is highly effective at containing, killing and removing foreign biological material (alive or dead) and the lack of a vigorous local inflammatory response may impair survival. This was best exemplified by the recent documentation that patients with a mild TNF- response, as characterized by a specific genotype of a mild TNF- responder, had a greater likelihood of dying from meningococcal meningitis than patients who had the vigorous TNF- responds genotype. Still, persistent activation, rather than massive pulse activation appears to be detrimental for survival. Pinsky et al. [3] measured the circulating levels of TNF-, IL-1, and IL-2 and the immunomodulating cytokines IL-6 and interferon-. Although levels of IL-1, IL-2 and interferon- did not correlate with any aspect of the generalized inflammatory response, severity of illness nor mortality, sustained elevations of the pro-inflammatory cytokine TNF- and the immunomodulating cytokine IL-6 did. Thus, rather than the maximal serum levels of any specific cytokines, those patients who will subsequently develop multiple organ dysfunction and may eventually die display a persistent elevation of TNF- and IL-6 in their blood [3–5]. This observation of a sustained plasma elevation of TNF- and IL-6 in severe sepsis and its association with a poor outcome initially led to the erroneous assumption that SIRS reflected an isolated excess pro-inflammatory state. However, the increased expression of pro-inflammatory cytokines is only part of this evolving immunologic picture. First Goldie et al. and then others demonstrated that both pro-inflammatory cytokines (TNF-, IL-1, IL-6, and IL-8) and anti-inflammatory species (IL-1 receptor antagonist (IL-1ra), IL-10, and the soluble TNF- receptors I and II (sTNFr-I and sTNFr-II), respectively) co-exist in the circulation, and the anti-inflammatory specifics are markedly increased in patients with established SIRS [6, 7]. Thus, SIRS or sepsis may be more accurately described as a malignant form of intravascular inflammation, rather than merely the over expression of simply pro- or anti-inflammatory substances. This paradoxical expression in the blood of pro- and anti-inflammatory molecular species creates a cacophony of unregulated immunologic noise within the internal milieu that if sustained impairs host adaptability to stress. Since cytokines appear to be an important component of the SIRS we shall first consider cytokine actions.
Intracellular Inflammatory Events
The inflammatory response requires an inflammatory stimulus to initiate it. Initiating inflammatory mediators include bacterial and yeast cell walls, such as endotoxin (lipopolysaccharides or LPS), exotoxins and other products. Vascular
Pathophysiology of Sepsis
33
Key intracellular events in innate immunity CD11b upregulation and activation
TNF- p50 p65 I-B
LPS TNF- TNF- IL-1 IF- C5a
Oxidative stress
iNOS and COX2 mRNA
NF-B
CD14
Serine TLR-4 kinase and MAP kinase
Hsp70
TNF- mRNA
I-B
HSF Hsp70
Mitochondrial oxidative stress
Hsp70 mRNA
Cytochrome C
Fig. 1. A schematic representation of some of the intracellular processes of pro- and anti-intracellular processes operative in sepsis. External signaling, either from mediator binding to cell surface receptors of CD11b activation induces a series of redundant and parallel intracellular kinase reactions through Toll-like receptors (TLR). Part of this initial activation is the up-regulation the cell surface expression of CD11b/CD18. Inflammation primarily induces an intracellular oxidative stress that can be measured by changes in mitochondrial membrane potential. Oxidative stress activates nuclear factor B (NF-B) by phosphorylation cleavage of its inhibitory sub-unit I-B as well as stressing the mitochondria. IB is degraded by phosphorylation and ubiquinization and the free remaining active p50-p65 dimer translocates into the nucleus where it binds to promoter sites initiating and/or augmenting mRNA synthesis of specific genes that code for the synthesis of pro-inflammatory mediators (TNF-, IL-1, IL-8, iNOS, COX2, etc.). Intracellular oxidative stress also activates heat shock factor (HSF) that, like NF-kB, migrates into the nucleus and binds to its own promoter regions that augment the synthesis of mRNA coding for heat shock protein (Hsp). One such Hsp is I-kB and others of the 70s class (Hsp70). Hsp70 down-regulates NF-B activation by both limiting subsequent mitochondrial oxidation and by limiting NF-B phosphorylation. Also, Hsp70 by limiting mitochondrial oxidative stress minimizes cytochrome release thus decreasing apoptotic stress.
collagen, damaged endothelial surfaces, the denatured proteins caused by thermal injury and oxidative stress all stimulate the innate inflammatory response (fig. 1). These inflammatory mediators bind to cell surface receptors inducing a transmembrane signal transduction and intracellular response via activation of several specific gene promoter proteins. Numerous unrelated exogenous stimulants, such as endo- and exotoxins and endogenous stimulants, activated compliment (C5a), Hageman’s factor (XIIa), and products of generalized cell injury can
Pinsky
34
induce immune competent cells (usually modeled as monocytes) to synthesize TNF- and IL-1. Presently, numerous cell surface receptors have been identified [reviewed in reference 31]. One cell-surface receptor with an amazing broad range of affinities to a variety of different types of pro-inflammatory substances is CD14. Many foreign substances, such as endotoxin require initial fusing with lipopolysaccharide binding protein before they can bind to CD14. Thus, hostderived factors (usually proteins) are probably necessary for the host recognition of foreign materials as foreign and initiate the inflammatory response. However, no such intermediate binding appears necessary for stimulation of the inflammatory response via the intrinsic mediators. CD14 then combines with TLR4 to induce a trans-membrane activation of a series of serine kinases that release potent pro-inflammatory promoter proteins which markedly enhance translation of numerous genes encoding proteins essential for the host inflammatory response. The major oxidative stress proinflammatory promoter protein is nuclear factor kappa B (NF-B), so named because it was originally described as the kappa light chain promoter protein for B lymphocytes. NF-B is an intracellular species that is resident in the cytosol as a p50p65 heterodimer attached to an inhibitory sub-unit called IB. The IB subunit binds to the p65 subunit masking is nuclear binding site. Activation of the heterodimer follows cleavage of IB by serine kinase-induced IB phosphorylation. Serine kinase, in turn requires an intracellular oxidative stress to trigger its activation via the TLR4 activation. Importantly, oxidative stress is an early event in inflammation. The phosphorylated IB is rapidly digested. The active p50-p65 heterodimer migrates into the nucleus, binds to various promoter sites on the genome stimulating mRNA synthesis of genes coding for many if not most of the pro-inflammatory cytokines. A partial list of NF-B inducible proteins is shown in table 1, and includes all the known potent proinflammatory mediators, such as TNF- and IL-1, as well as the pro-inflammatory enzymes inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2). NF-B is an excellent target for modulating the intracellular inflammatory response. In fact, several intracellular mechanisms exist that modulate NF-B activity. Studies of endotoxin tolerance allow for examination of these processes. Exposure to small amounts of endotoxin induces an endotoxin-tolerant state in both cell culture and animal models about 8 hours later. In this state, subsequent exposure to a previously lethal dose of endotoxin often does not induce the fatal pro-inflammatory state. The endotoxin-tolerate state lasts in decreasing strength for about 24–36 h, depending on the species and the initial dose of endotoxin. Interestingly, following the induction of an endotoxin-tolerant state, the initial steps of pro-inflammatory signal transduction up to cleavage of IB can occur. However, the liberated NF-B appears to be dysfunctional. The reasons for this dysfunction are multiple and not fully defined.
Pathophysiology of Sepsis
35
Table 1. Some of the known target genes regulated by NF-B Cytokines
Adhesion molecular Immunoreceptors
Acute phase proteins Others
TNF- TNF- IL-2 IL-6 IL-8 interferon- G-CSF GM-CSF endothelial-leukocyte adhesion molecule-1 vascular cell adhesion molecule-1 immunoglobulin -light chain T cell receptor A and B major histocompatibility class 1 and 2 tissue factor-1 complement factor B complement factor C4 COX-2 lipoxgenase 1
Under baseline conditions the body appears to have a distinctly antiinflammatory flavor. Thus, the initial pro-inflammatory processes operate on a system that at rest exists as a generalized anti-inflammatory one. For example, the endothelium is anti-thrombotic reducing platelet adhesion. Even the immune effector cells carry their preformed pro-inflammatory promoter proteins in a dysfunctional form. This resting anti-inflammatory state actually becomes more pronounced during generalized sepsis. Experimentally, it has been shown that inflammation induces its own counter-regulatory anti-inflammatory response that in the setting of sustain inflammatory stimuli causes a generalized anergic state, referred to as ‘inflammatory stimuli-induced anergy’ or ‘endotoxin tolerance’ [8]. Presumably, inflammatory stimuli-induced anergy minimizes the inflammatory response, preventing a chain-reaction, system-wide activation of the inflammatory processes. However, it also limits the host’s subsequent ability to mount an appropriate inflammatory defense to infection. Anti-inflammatory cytokines, such as IL-4, IL-10 and somewhat by IL-1 (but not TNF-), IL-6 or IL-8, and transforming growth factor- (TGF-) can induce this anergic response. NF-B Activation Biology
NF-B activation requires cleavage of the IB subunit off the p65 subuit. IB kinase causes the phosphorylation and subsequent degradation of IB
Pinsky
36
allowing the translocation of NF-B dimers into the nucleus. IB binds to the responsive element of the p65 subunit and has a greater affinity for the p65 subunit that does the corresponding response element on the genome. Thus, IB excess can pull active p50-p65 dimers off their promoter sites in the nucleus or prevent their release from the cytosol all together. NF-B dimers exist in several forms. However, the two most common forms are the heterodimer p50-p65, which is comprised of the p65 subunit with its active DNA consensus domain binding site and a smaller subunit p50 subunit devoid the active binding site. Importantly, the p65 subunit with its DNA consensus domain-binding site allows gene activation once bound to such promoter regions on chromosomes. The p50 monomer has no such activity [9]. The other common NF-B form is the p50-p50 homodimer, which does not bind IB or the genome. Endotoxin-tolerance induced NF-B dysfunction reflects excess synthesis of the inhibitor of NF-B, IB- [10] presumably due to the absence of induction of IB kinase. When endotoxin tolerant cells are challenged with a second dose of LPS, cytosolic levels of IB are not reduced, as they are with the initial challenge, and IB remains in cytoplasm where it sequesters free NF-B dimers [11]. Furthermore, the IB- promoter can be up-regulated by NF-B, thus providing a negative feedback loop for further NF-B activation [12]. Another adaptive mechanism involves the balance of NF-B p50-p65 to p50p50 species. The ratio of p65-p50 to p50-p50 determines transcription rates of genes coding for the NF-B inflammatory proteins. Ratios of NF-B p50-p65 heterodimer to p50-p50 homodimer of 1.8 0.6 or greater are associated with NF-B activation inducing mRNA synthesis of these genes, while a ratio of 0.8 0.1 or less confers lack of mRNA transcription following cleavage of IB [9]. Other post-translational controls on mRNA and protein trafficking also occur but at present have not been identified as being as important as these initial steps. Down-regulation of NF-B-related intercellular processes is an important aspect of the overall intracellular inflammatory response. However, these mechanisms do not explain why both pro- and anti-inflammatory activation is often sustained in critical illness. Anti-inflammatory pathways are activated by the same stimuli that active pro-inflammatory pathways. The cell does have several anti-inflammatory processes. However, the heat shock protein system is the most prevalent, in terms of mass of protein and scope of its oversight.
Heat Shock Proteins and the Stress Response
The heat shock protein system is a complex, widespread and overarching basic cellular defense mechanism against numerous stresses, such as fever,
Pathophysiology of Sepsis
37
trauma, and inflammation [13]. It is the oldest philogenetic cellar defense mechanism identified. The heat shock proteins constitute a significant proportion of the intracellular protein pool. At baseline in the un-stimulated cell they reflect 2% of the resting cellular protein component, whereas in the stressed cell they can comprise up to 20% of the cellular protein pool. Heat shock proteins have several important and varied functions. Their singular distinguishing characteristic is that their expression is up regulated in response to intracellular stress. Although originally described as a specific response to heat shock, it was subsequently demonstrated that many stresses, most notably oxidative stress (H2O2, peroxynitrate, ionized radiation) and even some pharmacologic agents could induce the up-regulation of the heat shock response. The exact mechanism by which heat induces the activation of the heat shock response is unknown. However, the initial intracellular signaling mechanisms are the release of heat shock factor (HSF) from its cytosolic pool complexed with three molecules of heat shock protein 70 (HSP-70). Presumably, oxidative stress induced protein unfolding (denaturation) stimulates HSP-70 to bind to these unfolded proteins and refold them, releasing its co-traveler HSF at the same time. HSF, which like NF-B, is a protein resident in the cytosol that is activated by the intracellular oxidative stress to make a promoter protein to bind to specific genes to stimulate synthesis of heat shock proteins. Heat shock proteins are classified by the molecular size. This classification is not arbitrary because their functions tend to also follow class size. They are cellular chaperones that prevent nascent proteins from being degraded by cytosolic enzymes. They also aid in the subsequent quaternary folding of nascent proteins prior to export. As a repair process, they aid in the tertiary and quaternary refolding of intracellular protein structure after heat or ionizing radiationinduced unfolding (denaturation). Heat shock proteins confer a survival advantage to their host. Thermal pretreatment is associated with attenuated lung damage in a rat model of acute lung injury induced by intratracheal instillation of phospholipase A2 [14]. Thermal pretreatment reduces mortality rate and sepsis-induced acute lung injury produced by cecal ligation and perforation [15]. The subsequent increased expression of a broad variety of heat shock proteins confers a non-specific protection from not only subsequent oxidative stress but also minimizes the cellular response to proinflammatory stimuli. Survival, in cold blooded animals given an infectious inoculum, is linearly related to body temperature. Finally, if specific heat shock proteins are depleted, then multiple intracellular signaling processes can be affected. Both HSF and NF-B are induced to become active by similar stimuli. It is not known if all the processes that stimulate HSF activation are the same as those that stimulate NF-B activation, but during sepsis and other forms of intracellular oxidative stress HSF and NF-B are activated in a parallel fashion.
Pinsky
38
Mitochondria as Both a Marker and Target of Intracellular Inflammation
The production of reactive oxygen species and an associated oxidative stress on the mitochondria is an initial step in the intracellular activation of the inflammatory pathway. It links mediator binding to the cell surface, ischemiareperfusion and traumatic injury with inflammatory gene activation [16]. Mitochondria are the primary energy sources of the cell. They produce ATP by driving electrons down a chemi-osmotic gradient via a transmembrane charge induced by the Krebs’s cycle inside their inner membranes. Loss of internal membrane polarization is a cardinal sign of mitochondrial energy failure and results in leakage of cytochrome C from the mitochondria into the cytosol. Importantly, cytochrome C activates the intrinsic caspase system to initiate apoptosis or programmed cell death. Thus, preventing mitochondrial depolarization would be an important cytoprotective mechanism. The HSP-70 family of heat shock proteins prevents mitochondrial oxidative stress and blunts the inflammatory response. HSP-70 also minimizes nitric oxide, oxygen free radical and stretozotocin cytotoxicity [17]. For these and other reasons, HSP-70 is an inducible protective agent in myocardium against ischemia, reperfusion injury and nitric oxide toxicity [18]. Nitric oxide-induced HSP synthesis blunts the inflammatory response to endotoxin and TNF- in vitro. Evidence that HSP-70 may be active in human sepsis comes from the observation that higher HSP-70 expression is seen in peripheral mononuclear cells in septic patients. Although not conclusive, these data strongly suggest that heat shock proteins, and HSP-70 in particular, may be important in modulating the intracellular inflammatory signal acting at the level of NK-B. Importantly, Wong et al. [19] identified a potential heat shock responsive element in the I-B promoter that can be activated by HSF after heat shock. And the heat shock response can also modulate NF-B inactivation by this increased I-B expression. Thus, the primary inhibitor of NF-B activation, I-B is itself a heat shock protein. The interaction between the heat shock protein system and the pro-inflammatory pathway, however, has yet to be defined.
Is Sepsis Characterized by Excessive Pro- and Anti-Inflammatory Activity? Assessment by Inside-Out Signaling
Both pro- and anti-inflammatory processes are active during acute injury states. This is observable as intracellular activation of both NF-B and HSF and extracellular expression of both pro- and anti-inflammatory mediators in the bloodstream. Thus, the immune effector cells and parenchyma receive mixed
Pathophysiology of Sepsis
39
messages during acute injury. However, the phenotypic response of pro- or antiinflammatory posturing that they make is often difficult to predict. The normal cellular inflammatory response is essential to survival. It localizes and eliminates foreign material, including microorganisms. Similarly, some degree of systemic inflammatory response is adaptive. Fever reduces microorganism growth, malaise causes the host to rest, and induces both the intracellular heat shock response and the extracellular acute-phase protein release. Both of which minimize oxidative injury. However, inflammation is also destructive. Local abscess formation causes local necrosis, and generalized inflammation can induce both increased necrosis and apoptosis leading to multiple systems organ failure [30]. However, sepsis also carries a strong anti-inflammatory response, with expression of anergy and increased susceptibility to nosocomial infection. All acute severe processes result in the expression in the systemic circulation of cytokines. However, it is difficult to assess the degree of inflammatory stimulation by measuring serum cytokine levels. Serum cytokine levels can change within minutes and may be very different in adjacent tissue compartments [20]. Although an excellent marker of disease severity and a good positive predictor of the subsequent development of remote organ system dysfunction, measuring blood levels of cytokines, such as IL-6 [22], do not aid in defining the pro- to anti-inflammatory balance on in predicting response to therapy. We shifted our attention to the examination of the functional status of circulating immune effector cells. Since polymorphonuclear leukocyte (PMN) activation and localization represent the initial cellular host defense against infection, their tight control is essential to prevent widespread non-specific injury. Subsequently, monocytes localize at the site of inflammation. Their activity appears to become the predominant process in both host defense and repair, especially during the second and third day onward in the course of acute illness. Thus, inhibition of monocyte immune responsiveness is a powerful mechanism to downregulate the inflammatory response. Anergy is a cardinal characteristic of severe illness and reflects macrophage inhibition of antigen processing. Importantly, antigen processing reflects a primary aspect of this cellular response. In this regard, the cell surface receptor family, HLA-DR, is responsible for antigen presentation to antigen-processing cells. Immature monocytes cannot process antigen and have lower cell surface HLA-DR levels. Volk et al. [21] demonstrated that monocytes require HLA-DR levels 20% for normal cell meditated immunity. Lower levels of HLA-DR expression confirm immune suppression. Consistent with the overall theme of increased antiinflammatory responses in severe sepsis, these workers and others have found a profound decrease in HLA-DR expression on circulating monocytes from patients with sepsis.
Pinsky
40
Rosenbloom et al. [22] examined the relation between circulating cytokine levels and the expression of the strong 2-integrin surface cell adhesion molecules on circulating immune effector cells. The activation state of circulating immunocytes can be indirectly assessed by measuring the intensity of display on their 2-integrin surface cell adhesion molecules. They showed that all circulating immune effector cells, including PMNs, lymphocytes and monocytes are activated in critical illness. Furthermore, the level of circulating immune effector cell activation is proportional to mean circulating IL-6 levels [22]. Importantly, the degree of organ dysfunction but not the level of shock severity correlated with CD11b expression. Since the level of activation of circulating PMN, as measured by total PMN count and its display of immature forms, is used clinically as an indicator of the host response to systemic inflammation, assessment of PMN responsiveness should also be a good measure of the proand anti-inflammatory balance in severe sepsis. Prior studies have shown that PMNs can be both overactive [23] and dysfunctional [24], and that their CD11b display can be either decreased [25] or increased [26] in critically ill patients. In essence, measuring immune responsiveness of circulating immune effector cells can be used as a functional bioassay. One can also expose native PMN to pro-inflammatory stimuli in vitro and assay their subsequent expression of CD11b. Many proinflammatory stimuli, such as TNF-, IL-8 and phorbol ester can be used to induce this response. The de novo display of CD11b on circulating PMNs and its subsequent change in expression of both total CD11b and its avid form, CBRM1/5 epitope, in response to in vitro stimulation to TNF- or IL-8 characterize the in vivo state of PMN activation and responsiveness. Circulating PMNs of septic humans have a similar phenotype characterized by high CD11b and low L-selectin expression [27]. This is the phenotype of acute activation of the inflammatory response. Thus, severe sepsis is associated with an increased de novo activation of circulating immune effector cells. Paradoxically, however, those same PMNs with a sustained inflammatory state are also impaired in their ability to upregulate CD11b further or to change surface CD11b to the avid state [28] in response to an ex vivo challenge by exposure to biologically significant levels of TNF-. Furthermore, circulating PMN from subjects with severe sepsis have impaired phagocytosis, reduced oxygen burst capacity and diminished in vitro adhesiveness [29]. This desensitization to exogenous TNF- or IL-8 was not due to a loss of TNF receptors because the cell surface TNF- receptor density is not reduced on the cells of septic patients. Importantly, the hyporesponsiveness is extended across all circulating PMN and monocytes in critically ill patients [27]. The NF-B activity and in vitro responsiveness to LPS of peripheral blood monocytes from septic subjects displays a similar pattern to that seen with
Pathophysiology of Sepsis
41
endotoxin tolerance [30]. The cause of the reduced nuclear translocation of NF-B is apparently not due to a negative feedback interaction because cytosolic IB are not increased in sepsis. Rather one sees an increase in the proportion of the inactive p50-p50 species relative to the active p65-p50 species, suggesting that alteration of NF-B synthesis per se is the primary regulatory function seen in the immune suppression of sepsis. In one study [30], survivors had higher levels of NF-B than non-survivors, again suggesting that although downregulation of inflammation is a normal aspect of sepsis, and excessive inhibition of the process is associated with a poor prognosis.
Acknowledgement This work was supported in part by the federal government (GM61992–03, NHLBI K-24 HL67181–01A2, and NRSA 2-T32 HL07820–06).
References 1 2 3 4 5 6
7
8 9
10 11 12
13 14
Schlag G, Redl H: Mediators of injury and inflammation. World J Surg 1996;20:406–410. Bone RC: Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation. Crit Care Med 1996;24:163–172. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E: Serum cytokine levels in human septic shock: Relation to multiple-system organ failure and mortality. Chest 1993;103:565–575. Thijs LG, Hack CE: Time course of cytokine levels in sepsis. Intensive Care Med 1995;21 (suppl 2):S258–S263. Blackwell TS, Christman JW: Sepsis and cytokines: Current status. Br J Anaesth 1996;77:110–117. Goldie AS, Fearon KC, Ross JA, Barclay GR, Jackson RE, Grant IS, Ramsay G, Blyth AS, Howie JC: Natural cytokine antagonists and endogenous anti-endotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 1995;274:172–217. Vanderpoll T, Malefyt RD, Coyle SM, Lowry SF: Anti-inflammatory cytokine responses during clinical sepsis and experimental endotoxemia – Sequential measurements of plasma soluble interleukin (IL)-1 receptor type Ii, IL-10, and IL-13. J Infect Dis 1997;175:118–122. Cavaillon JM: The nonspecific nature of endotoxin tolerance. Trends Microbiol 1995;3:320–324. Ziegler-Heitbrock HWL, Wedel A, Schraut W, Strobel M, Wendelgass P, Sterndorf T, Bauerle PA, Haas JG, Riethmuller G: Tolerance to lipopolysaccharide involves mobilization of nuclear factor B with predominance of p50 homodimers. J Biol Chem 1994;269:17001–17004. Larue KEA, McCall CE: A liable transcriptional repressor modulates endotoxin tolerance. J Exp Med 1994;180:2269–2275. Kohler NG, Joly A: The involvement of an LPS inducible IB kinase in endotoxin tolerance. Biochem Biophys Res Commun 1997;232:602–607. De Martin R, Vanhove B, Cheng Q, Hofer E, Csizmadia V, Winckler H, Bach FH: Cytokineinducible expression in endothelial cells of an IB-like gene is regulated by NFB. EMBO J 1993;12:2773–2779. Jäättelä M, Wising D: Heat shock proteins protect cells from monocyte cytotoxicity: Possible mechanism of self-protection. J Exp Med 1993;177:231–236. Villar J, Edelson JD, Post M, Mullen BM, Slutsky AS: Induction of the heat stress proteins is associated with decreased mortality in an animal model of acute lung injury. Am Rev Respir Dis 1993; 147:177–181.
Pinsky
42
15
16
17
18
19 20
21
22
23
24
25 26 27
28 29 30
31
Villar J, Ribiero SP, Mullen BM, Kuliszewski M, Post M, Slutsky AS: Induction of the heat shock response reduces mortality rate and organ damage in a sepsis-induced acute lung injury model. Crit Care Med 1994;22:914–921. Polla BS, Jacquier-Sarlin MR, Kantengwa S, Mariethoz E, Hennet T, Russo-Marie F, Cossarizza A: TNF- alters mitochondrial membrane potential in L929 but not in TNF-resistance L929.12 cells: Relationship with the expression of stress proteins, annexin 1 and superoxide dismutase activity. Free Rad Res 1996;25:125–131. Bellmann K, Wenz A, Radons J, Burkart V, Kleemann R, Kolb H: Heat shock induces resistance in rat pancreatic islet cells against nitric oxide, oxygen radicals and streptozototocin toxicity in vitro. J Clin Invest 1995;95:2840–2845. Malyshev IY, Malugin AV, Golubeva LY, Zenina TA, Manukhina EB, Mikoyan VD, Vanin AF: Nitric oxide donor induces HSP70 accumulation in the heart and in cultured cells. FEBS Lett 1996;391:21–23. Wong HR, Ryan M, Wispé JR: Stress response decreases N-FB nuclear translocation and increases I-B expression in A549 cells. J Clin Invest 1997;99:2423–2428. Boutten A, Dehoux MS, Seta N, Ostinelli J, Venembre P, Crestani B, Dombret MC, Durand G, Aubier M: Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1996;153:336–342. Docke WD, Syrbe U, Meinecke A, Platzer C, Makki A, Asadullah K, Klug C, Zuckermann H, Reinke P, Brunner H, von Baehr R, Volk HD: Improvement of monocyte function: A new therapeutic approach; in Reinhart K, Eyrich K, Sprung C (eds): Sepsis: Current Perspectives in Pathophysiology and Therapy. Berlin, Springer, 1994, pp 473–500. Rosenbloom AJ, Pinsky MR, Bryant JL, Shin A, Tran T, Whiteside T: Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS: Correlation with serum interleukin-6 levels and organ dysfunction. JAMA 1995;274:58–65. Trautinger F, Hammerle AF, Poschl G, Micksche M: Respiratory burst capability of polymorphonuclear neutrophils and TNF-alpha serum levels in relationship to the development of septic syndrome in critically ill patients. J Leukocyte Biol 1991;49:449–454. McCall CE, Grosso-Wilmoth LM, LaRue K, Guzman RN, Cousart SL: Tolerance to endotoxininduced expression of the interleukin-1 beta gene in blood neutrophils of humans with the sepsis syndrome. J Clin Invest 1993;91:853–861. Nakae H, Endo S, Inada K, Takakuwa T, Kasai T: Changes in adhesion molecule levels in sepsis. Res Comm Mol Pathol Pharmacol 1996;91:329–338. Lin RY, Astiz ME, Saxon JC, Rackow EC: Altered leukocyte immunophenotypes in septic shock. Studies of HLA-DR, CD11b, CD14, and IL-2R expression. Chest 1993;104:847–853. Rosenbloom AJ, Pinsky, MR, Napolitano C, Nguyen T-S, Levann D, Pencosky N, Dorrance A, Ray BK, Whiteside T: Suppression of cytokine mediated 2-integrin activation on circulating neutrophils in critically ill patients. J Leukocyte Biol 1999;66:83–89. Diamond MS, Springer TA: A Subpopulation of Mac-1 (CD11b/CD18) Molecules Mediates Neutrophil Adhesion to ICAM-1 and Fibrinogen. J Cell Biol 1993;120:545–556. Terregino CA, Lubkin C, Thom SR: Impaired neutrophil adherence as an early marker of systemic inflammatory response syndrome and severe sepsis. Ann Emerg Med 1997;29:400–403. Adib-Conquy M, Adrie C, Moine P, Ashnoune K, Fitting C, Pinsky MR, Dhainaut J-F, Cavaillon J-M: NF-AB expression in mononuclear cells of septic patients resembles that observed in LPS-tolerance. Am J Respir Crit Care Med 2000;162:1877–1883. Lien E, Ingalls RR: Toll-like receptors. Crit Care Med 2002;30:S1–S11.
Michael R. Pinsky, MD 606 Scaife Hall, 3550 Terrace Street Pittsburgh, PA 15261 (USA) Tel. 1 412 647 5387, Fax 1 412 647 8060 E-Mail
[email protected]
Pathophysiology of Sepsis
43
Ronco C, Bellomo R, Brendolan A (eds): Sepsis, Kidney and Multiple Organ Dysfunction. Contrib Nephrol. Basel, Karger, 2004, vol 144, pp 44–52
Tropical Acute Renal Failure Rashad S. Barsoum Cairo Kidney Center, Cairo, Egypt
Acute renal failure (ARF) is one of the most challenging medical problems in the tropics. Typical weather conditions and compromised public health standards impose a highly polluted bio-ecological environment, which leads to a high prevalence of both primary and secondary infection. Late or misdiagnosis and inadequate management are often responsible for important complications, including ARF. Another key factor is the lack of professional primary medical care in remote areas in the tropics. Millions of people are treated by Witch Doctors, Sangomas and quacks, who often use traditional medications with obscure composition and side effects. These agents have been frequently blamed in the pathogenesis of toxic ARF, in addition to other organ damage. Secondary and tertiary care are also compromised by the lack of expertise, equipment and funds. All these factors make of ARF an issue of major importance and grave prognosis in tropical countries.
Epidemiology
There are no reliable statistics about the incidence of ARF in the tropics. Based on regional sporadic publications, it is possible to estimate the average annual incidence around 150 cases per million population [1]. This is certainly an underestimate, reflecting only those referred to large hospitals staffed with enthusiastic physicians who are keen to report. Nevertheless, these cases constitute the major source of our information on tropical ARF. As shown in table 1, medical causes of ARF are far more common in the tropics, as opposed to the predominance of surgical causes in the developed world.
Table 1. Principal causes of ARF in the Tropics compared to that in the developed world
Surgical and post-traumatic1 Obstetric2 Infections Exogenous toxins
South (%)
North (%)
10–15 15–25 45–50 15–20
65–70 1–3 5–10 10–30
1Mostly
urologic and abdominopelvic in the tropics, cardiopulmonary in the North [1, 2]. 2Septic abortion, pregnancy toxemia [2–4].
Medical Causes of Tropical ARF
Infection and chemical intoxication are the two major causes of medical ARF in the tropics. Their relative incidence varies in different countries, depending on the local bioecology and social behavior. Figure 1 shows some examples which illustrate this discrepancy.
Infection
Primary tropical infections can lead to acute renal injury in four ways: (a) Direct invasion of the renal parenchyma by microbial agents; (b) Induction of an immune response that leads to glomerular or tubulointerstitial inflammation; (c) Induction of hemodynamic disturbances that lead to tubular necrosis, and (d) Iatrogenic renal injury associated with treatment or prophylaxis against tropical infections. Direct Parenchymal Invasion Many bacterial agents may cause acute hematogenous ‘pyelonephritis’. The lesions are mostly interstitial. They may be diffuse or focal, the latter taking the form of micro-abscesses as with septicemic melioidosis, or typical solitary abscesses as with typhoid. Diffuse interstitial inflammation may be encountered in leptospirosis, diphtheria, scrub typhus, tuberculosis and leprosy [1]. It is unusual for these forms of renal invasion to cause ARF, although a transient oliguria and marginal retention of non-protein nitrogen is not uncommon. However, ARF may occur if the infection is associated with significant
Tropical Acute Renal Failure
45
80 70
South Africa
Ghana
India
Thailand
Singapore
Egypt
USA
UK
Percent of cases
60 50 40 30 20 10 0 Medical
Obstetric
Surgical
Fig. 1. Main causes of ARF in selected tropical countries, compared to that in the USA and the UK.
hemodynamic effects as with septicemia, intravascular hemolysis, rhabdomyolysis or disseminated intravascular coagulation (DIC). Viral interstitial nephropathies are more likely to cause ARF by direct invasion. Typical examples include Dengue fever and Hantan viral disease, both of which can cause an acute hemorrhagic syndrome with reversible ARF. Direct glomerular invasion by viral particles has been suggested to explain the glomerular lesions with HIV [5], HCV [6] and other infections. Of the tropical parasitic infections Kala-azar may cause febrile ARF, particularly in immunocompromized patients [7]. Leishmanial amastigotes tend to reside inside the interstitial monocytes and evade their phagocytic function; yet the monocytes continue to release cytokines that mediate an acute interstitial nephritis. Immune-Mediated Renal Lesions Immune complex-mediated acute post-infectious glomerulonephritis, occasionally associated with transient mild to moderate renal insufficiency, has been described with streptococcal infections of the skin in African kids as opposed to the pharynx in the developed world. Other tropical infections that may cause acute nephritis include typhoid, paratyphoid and leptospirosis. Crescentic glomerulonephritis is more often associated with acute or rapidly progressive renal failure. This has been described with HIV, HAV, HCV, Mycoplasma pneumoniae lung infection, post-streptococcal glomerulonephritis, staphylococcal and other bacterial infections of the endocardium
Barsoum
46
and visceral abscess. It may occur with secondary syphilis and lepromatous leprosy [8]. Many of these conditions may be associated with type II or III mixed cryoglobulinemia. Crescentic glomerulonephritis may also be pauci-immune. Patients with severe streptococcal or falciparum malarial infection have evidence of systemic or renal limited pANCA-positive vasculitis, in which case necrotizing glomerular lesions are characteristic [9]. Similar lesions are occasionally seen in hepatitis B viral infection [10], where ANCAs are not detected. A distinct type of immune-mediated ARF is the postdysenteric hemolytic uremic syndrome, which is notoriously common in children in North India and Bangladesh [11]. This syndrome is identical with the D⫹ HUS seen with certain Escherichia coli infections in the West. Hemodynamically Mediated ARF Pyrexial illness in the warm and humid tropical climate leads to excessive fluid loss with perspiration and sweating. Many infections are associated with vomiting and/or diarrhea, which add to the dehydration. Shrinkage of blood volume becomes particularly dangerous in kids. Although renal failure in these cases is usually pre-renal, the presence of infective toxemia (e.g. in cholera) and renal interstitial lesions often add up leading to more serious consequences. Hyperpyrexia may nonspecifically lead to rhabdomyolysis, which augments the renal injury even in the absence of significant circulatory impediment. Certain infections may cause an outrageous release of catecholamines (e.g. tetanus), thereby amplifying the consequences of renal ischemia [12]. The acute systemic effects of disseminated bacterial infection may lead to peripheral blood pooling and capillary leakage with subsequent reduction in blood volume, renal ischemia and acute tubular necrosis. Several mediators have been incriminated in this scenario including nitric oxide, TNF-␣, dilatory prostaglandins, kinins and free oxygen radicles. Tubular injury may be induced by intrinsic pigments as hemoglobin and bilirubin, as well as microbial toxins or medications. ARF is further propagated by tubular obstruction by detached viable tubular cells, necrotic cell debris and pigment casts. Sludging of red cells and platelets is often encountered in the renal microcirculation, due to the associated hemoconcentration. This factor is considerably augmented in falciparum malaria, owing to increased stickiness of the red cells and platelets. Increased mechanical fragility of the parasitized red cells leads to intravascular hemolysis, which adds up to the pathogenesis of ARF in malaria [9]. Many other infections may lead to intravascular hemolysis in patients with G6PD deficiency, as viral hepatitis, typhoid and typhus. The same and
Tropical Acute Renal Failure
47
other infections may also lead to DIC, which further compromises the renal circulation [1]. Iatrogenic Renal Injury Renal injury in acute tropical infections may be attributed to treatment rather than to the primary disease. Typical examples are different antibiotics, notoriously amphotericin B, aminoglycosides, cephalosporines and vancomycin. Nephrotoxicity is considerably augmented when these agents are used in combination, and when diuretics or non-steroidal anti-inflammatory agents are added. Another interesting example of iatrogenic ARF is the vasculitic ARF occurring with interferon treatment for HCV infection [13]. This complication is often encountered with the first few injections, and is characterized by severe systemic effects including pyrexia, hypotension, leukopoenia and thrombocytopenia. The renal lesion is dominated by interstitial edema, cellular infiltration and variable degrees of tubular atrophy. Most patients respond to steroid treatment, which has lead to the inclusion of these agents in several interferon-based protocols in viral hepatitis. ARF may also occur as a result of vaccination. Anaphylactic and serumsickness types of immune response leading to ARF have been described with many vaccines. A recent alarming report from Brazil incriminates vaccination for transmitting yellow fever, resulting in fatal hemorrhagic ARF [14].
Intoxication
ARF may be attributed to exposure to a long list of occupational or environmental toxins, which are beyond the scope of this review. Of specific epidemiological and clinical interest in the tropics is the renal injury resulting from accidental exposure or therapeutic use of certain poisons of animal or plant origin as traditional medicines. Toxins of Animal Origin The prototype of these poisons is the bite of snakes, usually Viperidae or Elapidae occurring mainly in West Africa, the Indian subcontinent, South-East Asia, New Guinea and Latin America. ARF occurs in 5–80% of cases [15] being attributed to the induction of massive release of monokines, complement activation, hemolysis and intravascular coagulation. Snake venom may also lead to a widespread vasculitis which involves the glomerular capillaries. Specific antibody response may lead to immune complex formation and secondary glomerular injury.
Barsoum
48
Less common are scorpion or jellyfish stings as well as spider or centipede bites, often encountered in southern America, North Africa and the Middle East. These may lead to ARF in 6–10% of cases by inducing hemodynamic sequelae similar to those of snakebites. Scorpion stings are associated with massive catecholamines release, which significantly contributes to renal ischemia. Insect stings may also lead to ARF particularly in sub-Saharan Africa. Oral ingestion of raw carp bile is a fairly common habit in South East Asia, Taiwan, China and Korea. The stuff is traditionally believed to improve visual acuity, stop cough, decrease body temperature and lower blood pressure. Ingestion of large quantities may lead to gastrointestinal toxicity that may be associated with ARF in up to 54%, hematuria in 77% and jaundice in 62% of patients [16]. The mechanism of ARF seems to be multifactorial, involving renal ischemia, tubular toxicity and bile pigment nephropathy. Toxins of Plant Origin Mushroom poisoning is the best known of this group. Accidental ingestion of certain wild mushrooms (Amanita or Galerina species) leads to gastrointestinal and hepatic toxicity. ARF occurs 10–14 h after exposure. The latter is usually severe, with up to 50% mortality. People in Indonesia, Malaysia and southern Thailand frequently use Djenkol beans as digestives. Toxicity follows ingestion of the raw bean in large amounts. ARF occurs in about 50% of patients [17]. Hair dyes have been incriminated in the pathogenesis of ARF in Turkey, Northern Africa and the Sudan. Accidental toxicity from Henna, a traditional cosmetic material used in the Middle East, has been described in the Turkey, being attributed to absorption through the skin. Suicidal ingestion of a similar cosmetic compound, paraphenylenediamine (PPD) was reported to induce a systemic inflammatory response, with respiratory distress and ARF in Morocco [18]. Combination of PPD and Henna seems to be even more toxic, with a reported mortality of 40% in the Sudan [19]. Other poisons of plant origin, frequently used as traditional medicines for the relief of cough, colics, impotence and many other common conditions may lead to ARF [20]. These include Callilepis laureola, Semecarpus anacardium, Securidaca longipedunculata, Euphorbia matabelensis and Crotalaria laburnifolia. The renal damage associated with these poisons is attributed to direct nephrotoxicity as well as to the non-specific effects of gastrointestinal and hepatic toxicity. Intoxication with Industrial Chemicals Accidental exposure to many industrial chemicals may induce ARF. Such accidents are particularly common in tropical countries owing to the poor control
Tropical Acute Renal Failure
49
over the manufacture process, storage and waste disposal. Major accidents have been reported with copper sulphate in India and Bangladesh, naphthalene in Nigeria and many others.
Special Clinical Considerations in Tropical ARF
The clinical profile of ARF in the tropics is modified by a number of factors. Most significant is the overlap between the manifestations of ARF and those of severe systemic infection or intoxication. In many cases, there is severe toxemia, shock, dehydration, DIC, hepatocellular or pulmonary injury, central nervous system involvement, etc. These may impose difficulties in the selection of certain treatment modalities as hemodialysis in the presence of shock or a bleeding tendency. The complexity of pathogenetic factors involved such as hemolysis, rhabdomyolysis and DIC often leads to aggravation of the uremic syndrome. Most patients reaching the hospital are already severely anemic, thrombocytopenic, severely acidotic and critically hyperkalemic. Coma, convulsions, pericarditis, ascending paralysis, urea frost and similar clinical signs that are now seldom seen in the West, are an everyday experience in tropical ARF. Sky high serum creatinine concentrations and incredible serum potassium levels of 9 or 10 mEq/l associated with all the classical ECG signs may be seen when there is significant rhabdomyolysis. All that usually occurs in a patient with background chronic disease of variable severity. Many natives in the tropics would be living with multiple chronic parasitic infestations and significant protein-calorie malnutrition. The added catabolic effects of the new infection or intoxication, and subsequently that of the uremic state result in a considerable negative nitrogen balance that has a major impact on outcome. Finally, there is the effect of delayed referral. Lack of adequate information in the primary care units, patients’ reluctance to leave their own territories to be treated in central hospitals, inefficient and unsafe transfer vehicles may lead to a very high mortality from ARF that has been estimated in a consensus meeting to approach 80%. This is in sharp contrast to the reported mortality from referral hospitals that ranges between 20 and 30% [21].
Management of Tropical ARF
As with conventional ARF, the most effective intervention is prevention. Awareness of the potential renal complications of injury, surgery, obstetric
Barsoum
50
complication, infections and medications is the most cost-effective single measure. Unfortunately, very little attention is paid by different medical specialities to this important issue. Timely intervention at the onset of ARF is usually rewarded by excellent results. Adequate attention to a primary infection, prompt control of hyperpyrexia, correction of shock, adequate hydration, avoidance of nephrotoxic drugs or drug combinations are simple but most effective. There is no evidence that induction of diuresis by osmotic or loop diuretics would change the outcome, nor does the use of dopamine, calcium channel blockers or ACE inhibitors. Adequate care of nutrition is of vital importance. Patients who are unable to eat or drink must be supported by enough fluids, electrolytes, calories and amino acids parenterally. This may be difficult with severe oliguria, when the total permissible fluid intake is restricted. An undoubted blessing, in this respect, is that patients treated in the tropical climate may lose a lot of fluid in sweat and insensible routes, which provides more room for intravenous fluid administration. Taking the multifactorial nature of ARF into consideration, dialysis is often needed as soon as the patient has reached the hospital. Fortunately, facilities for peritoneal dialysis, acute hemodialysis and even continuous renal replacement therapy are now available in most tropical countries, though critically restricted to teaching or army hospitals. In addition to logistic difficulties in transfer and acceptance of patients in these hospitals, there may be technical problems is implementing dialysis and other extracorporeal therapies due to vascular access problems, bleeding tendencies, circulatory instability etc. It is hoped that the use of peritoneal dialysis finds its way to smaller territorial hospitals where prompt renal replacement therapy can be implemented when needed. The challenge facing the medical profession will continue for many decades. Patients will continue to die of ARF until the value of proper education of the primary care physician is appreciated and implemented. Unfortunately, this simple fact is lost within the jungle of politics, inappropriate diversion of funds, and inequity of health care.
References 1 2 3 4
Barsoum R, Sitprija V: Tropical nephrology; in Schrier RW, Gottaschalk CW (eds): Diseases of the Kidney, ed 4. Boston, Little, Brown, 1996, pp 2221–2286. Kleinknecht D: Epidemiology of acute renal failure; in Cantarovich F, Rangoonwala B, Verho M (eds): Progress in Acute Renal Failure. New Jersey, Marion Roussel, 1998, pp 11–22. Firmat J, Zucchini A, Martin R, Aguirre C: A study of 500 cases of acute renal failure (1978–1991). Ren Fail 1994;16:91–99. Randeree IG, Czarnocki A, Moodley J, Seedat YK, Naiker IP: Acute renal failure in pregnancy in South Africa. Ren Fail 1995;17:147–153.
Tropical Acute Renal Failure
51
5 6
7 8
9 10 11 12 13 14 15 16 17 18 19 20 21
Cohen AH: HIV-associated nephropathy: Current concepts. Nephrol Dial Transplant 1998;13: 540–542. Horikoshi S, Okada T, Shirato I, et al: Diffuse proliferative glomerulonephritis with hepatitis C virus-like particles in paramesangial dense deposits in a patient with chronic hepatitis C virus hepatitis. Nephron 1993;64:462–464. Caravaca F, Munoz A, et al: Acute renal failure in visceral leishmaniasis. Am J Nephrol 1991;11: 350–352. Barsoum R: The Kidney in tropical infections; in El-Nahas AM, Harris K, Anderson S (eds): Mechanisms and Clinical Management of Chronic Renal Failure, ed 2. Oxford, Oxford University Press, 2000, pp 371–400. Barsoum RS: Malarial acute renal failure. J Am Soc Nephrol 2000;11:2147–2154. Lai KN, Lai FM, Chan KW, et al: The clinicopathologic features of hepatitis B virus-associated glomerulonephritis. Q J Med 1987;63:323–333. Srivastava RN, Moudgil A, Bagga A, Vasudev AS: Hemolytic uremic syndrome in children in northern India. Pediatr Nephrol 1991;5:248–288. Daher EF, Abdulkader RC, Motti E, et al: Prospective study of tetanus-induced acute renal dysfunction: Role of adrenergic overactivity. Am J Trop Med Hyg 1997;57:610–614. Dimitrov Y, Heibel F, Marcellin L, et al: Acute renal failure and nephrotic syndrome with alpha interferon therapy. Nephrol Dial Transplant 1997;12:200–203. Vasconcelos PF, Luna EJ, Galler R, et al: Serious adverse events associated with yellow fever 17DD vaccine in Brazil: A report of two cases. Lancet 2001;358:91–97. Warrell DA: Venomous bites and stings in the tropical world. Med J Aust 1993;159:773–779. Park SK, Kim DG, Kang SK, et al: Toxic acute renal failure and hepatitis after ingestion of raw carp bile. Nephron 1990;56:188–193. Eiam-ong S, Sitprija V, Saetang P, et al: Djenkol bean nephrotoxicity in Southern Thailand. Proc First Asia Pacific Congress on Animal, Plant and Microbial Toxins, Singapore, 1989, p 628. Bourquia A, Jabrane AJ, Ramdani B, Zaid D: Systemic toxicity of paraphenylenediamine. 4 cases. Presse Med 1988;17:1798–1800. Devecioglu C, Katar S, Dogru O, Tas MA: Henna-induced hemolytic anemia and acute renal failure. Turk J Pediatr 2001;43:65–66. Kadiri S, Arije A, Salako BL: Traditional herbal preparations and acute renal failure in south west Nigeria. Trop Doct 1999;29:244–246. Barsoum RS: Dialysis in developing countries; in Jacobs C, Kjellstrand CM, Koch KM, Winchester JF (eds): Replacement of Renal Function by Dialysis, ed 4. Dordtrecht, Kluwer, 1996, pp 1433–1445.
Professor Rashad S. Barsoum The Cairo Kidney Center, 3, Hussein El-Memar Street, Antik-khana PO Box 91, Bab-El-Louk, 11513, Cairo (Egypt) Tel. ⫹20 2 5761673, Fax ⫹20 2 5769749, E-Mail
[email protected]
Barsoum
52
The Critically Ill Patients: Pathological Mechanisms Ronco C, Bellomo R, Brendolan A (eds): Sepsis, Kidney and Multiple Organ Dysfunction. Contrib Nephrol. Basel, Karger, 2004, vol 144, pp 53–62
Mechanisms Underlying Combined Acute Renal Failure and Acute Lung Injury in the Intensive Care Unit Chu-Chun Chien, Landon S. King, Hamid Rabb Department of Medicine, Johns Hopkins University, Baltimore, Md., USA
Acute renal failure (ARF) is associated with high morbidity and mortality in intensive care unit patients [1]. It is increasingly recognized that ARF is an independent risk factor for death, and that ARF is a systemic disease. With the availability of dialysis, much of the mortality associated with ARF occurs due to extrarenal complications such as circulatory collapse, cardiopulmonary failure, and gastrointestinal bleeding [2, 3]. Lung dysfunction is particularly common, and astute clinicians have long observed that there is a predisposition to combined lung and kidney dysfunction in the critically ill patient. When ARF and acute lung injury (ALI) are combined, the mortality rate exceeds 80% [4]. We will briefly review the mechanisms underlying combined ARF and ALI (fig. 1). Classic renal-pulmonary syndromes such as Goodpasture’s disease, Wegeners and other autoimmune diseases, though important considerations in the differential diagnosis of a patient with combined ARF and ALI [5, 6], will not be discussed in this chapter. In addition, the pulmonary consequences of dialysis will not be discussed [7, 8].
Pulmonary Effects of Acute Renal Failure
ARF leads to fluid retention, which in turn contributes to venous congestion and impaired pulmonary gas exchange [9]. Acidosis stimulates compensatory hyperventilation and increases the work of breathing, potentially accelerating respiratory muscle fatigue [10]. However, the impact of renal failure on lung function extends beyond simply fluid overload and its sequelae.
Consequences Inflammation and increased vascular permeability Pulmonary edema Abnormalities in ENaC, AQP5, Na-K-ATPase
Mediators Macrophages Cytokines? Uremic toxins?
Acute lung injury Mediators Hemodynamics Cytokines? Leukocytes?
Acute renal failure
Consequences Increased vascular perm Proteinuria Abnormalities in ENaC, AQP2, Na-K-ATPase Inflammation Epithelial injury and apoptosis
Fig. 1. Interaction between injured kidney and lung. ARF leads to an increase in pulmonary vascular permeability and inflammation during ARF, which is in part, macrophagemediated. Lung epithelial sodium channel, aquaporin-5 and Na-K-ATPase are downregulated during ARF, which may be mediated by cytokines or uremic toxins. Conversely, mechanical ventilation leads to a decrease in renal epithelial sodium channel, aquaporin-2 and Na-KATPase. Potential mediators of these changes include hemodynamic factors, cytokines and leukocytes. Modified from Rabb H, Chamoun F, Hotchkiss J: Molecular mechanisms underlying combined kidney-lung dysfunction during acute renal failure; in Ronco C, Bellomo R, La Grecca G (eds): Blood Purification in Intensive Care. Basel, Karger, 2001.
The uremic milieu likely contributes to the development or exacerbation of lung injury and dysfunction [11], and this can be improved with renal transplantation [12, 13]. A marked decrease in lung diffusion capacity in uremic patients had been noted for decades [14–16], and this abnormality correlated well with the severity of renal impairment. However, many have argued that the ‘uremic lung’ was merely a consequence of volume overload, and that aggressive fluid removal with dialysis resolves the pulmonary changes. The important clinical association between combined ARF and ALI, as well as controversy in this area has led to studies to directly test causal links between ARF and ALI (table 1). Increased pulmonary vascular permeability is the hallmark of noncardiogenic pulmonary edema. It was hypothesized that ARF would directly lead to an increase in pulmonary vascular permeability, and hence predispose to adult respiratory distress syndrome (ARDS). Rats undergoing renal ischemia/reperfusion injury (IRI) demonstrated a significant increase in pulmonary vascular permeability to albumin compared to sham-operated animals at 24 h that peaked 48 h after reperfusion [17]. Lungs from rats subjected to renal IRI had a marked increase in red blood cells in the interstitium with accompanying edema, as well as alveolar hemorrhage and sludging of red blood cells in the microvasculature.
Chien/King/Rabb
54
Table 1. Effects of experimental ARF on lung Renal injury model
Animal species
Lung changes
Reference No.
30 min IRI or bilateral nephrectomy
rat
downregulated pulmonary ENaC, Na-K-ATPase, AQP5
11
30 min IRI
rat
increased pulmonary vascular permeability, interstitial edema and alveolar inflammation, partially macrophage-mediated
17
40 min IRI
mouse
increased wet to dry weight ratio and upregulation of signaling process ␣-MSH inhibited many effects
19
30 min IRI
mouse
increased expression of adhesion molecules and neutrophil infiltration
20
IRI ⫽ Ischemia-reperfusion injury; ENaC ⫽ epithelial sodium channel; AQP5 ⫽ aquaporin-5; ␣-MSH ⫽ ␣-melanocyte-stimulating hormone.
Although the literature suggested that neutrophils participate in the pathogenesis of ARDS, neutrophil depletion did not alter the effect of ARF on lung function. Macrophages were targeted with CNI-1493, an agent that inhibits macrophage function by blocking both cytokine-inducible arginine uptake and the p38 mitogen-activated protein (MAP) kinase signal transduction pathway. Rats in ARF receiving CNI-1493 displayed significant protection, with a reduction in the increase in pulmonary vascular permeability following IRI. The CN11493 treated animals demonstrated interstitial edema, but alveolar hemorrhage was absent. No effect on serum creatinine was observed. In another study, bilateral ischemic renal injury or bilateral nephrectomy, but not unilateral ischemia-reperfusion, led to down-regulation of Na-KATPase and aquaporin-5 (AQP5) levels in the lung [11]. Decreased pulmonary abundance of the epithelial sodium channel (ENaC) was also observed in this setting, and was associated with renal injury. The clinical relevance of decreased membrane transporters in the distal lung is supported by the observation of augmented pulmonary edema with amiloride or ouabain administration in a pulmonary IRI model [18]. Recent data indicate that lung injury occurs rapidly following renal ischemia. Mice with ischemic ARF had evidence of marked pulmonary edema and neutrophil accumulation at 4 and 8 h after ischemia, associated with an
Acute Renal Failure and Lung Injury in the Critically Ill Patient
55
upregulation of proinflammatory signaling molecules in the lung. Treatment with ␣-melanocyte-stimulating hormone (␣-MSH) attenuated both the ARF and associated lung changes in this model [19]. The increase in pulmonary neutrophils during ARF is likely modulated in part by upregulation of leukocyte adhesion molecules [20]. The factors that link ARF and ALI are unknown. Circulating cytokines have been implicated in the pathogenesis of lung injury following distant organ IRI [21–23]. Macrophage-derived proinflammatory cytokines including tumor necrosis factor-␣ (TNF-␣) [24–26], interleukin-1 (IL-1) [27, 28], interleukin-6 (IL-6) [29] have been implicated. The type II alveolar epithelial cells might be the target of these macrophage-derived inflammatory mediators [30]. Remote effects of reperfusion injury have also been attributed to complement activation [31–33], and arachidonate derivatives such as thromboxane [34, 35] and leukotriene B4 [36, 37]. In view of recent data implicating T cells in ARF [38, 39], the T cell is an attractive circulating candidate to mediate the ARF-ALI association. In an effort to reduce the systemic inflammatory responses that can contribute to the high mortality associated with ARF, continuous renal replacement therapy is being explored as a therapeutic intervention beyond the conventional use for renal replacement [40, 41]. Innovative approaches with plasmapheresis are also promising for ARF [42].
Renal Effects of Mechanical Ventilation
Patients requiring mechanical ventilation often have renal dysfunction that may be a consequence of the underlying illness. However, it is increasingly recognized that mechanical ventilation itself can damage the kidney. Several clinical reports and experimental studies have shown that mechanical ventilation has significant influence on renal function. Positive-pressure ventilation alters venous return, cardiac preload, pulmonary vascular resistance, and cardiac afterload. A decrease in several parameters of renal function, including glomerular filtration rate (GFR), renal blood flow (RBF), and free-water clearance were noted using positive pressure ventilation [43]. The interaction between mechanical ventilation and renal function has been extensively examined in the setting of positive end expiratory pressure (PEEP). In an anesthetized canine model, institution of 10 cm of PEEP markedly decreased urine flow rate, urinary sodium excretion, and creatinine clearance [44]. Prompt deterioration in renal function following the initiation of PEEP [45], continuous positive airway pressure (CPAP) [46] and continuous positive-pressure ventilation (CPPV) [47] has been observed repeatedly in various animal models. Both animal and human studies indicate that positive
Chien/King/Rabb
56
intrathoracic pressure might negatively affect renal function by decreasing venous return and compromising cardiac output [48]. This effect may be worsened by concurrent volume depletion [49], consistent with the observation that intravascular volume expansion may decrease the injury; however, the effects of positive intrathoracic pressure on RBF have not been consistent. A comparison of intermittent mechanical ventilation (IMV) and continuous mechanical ventilation (CMV) in anesthetized canines with normal lung function indicated that IMV may have lesser negative influence on renal function [50], potentially a consequence of decreased mean intra-thoracic pressure that limits the retention of water and salt that occurs during prolonged mechanical ventilation [50, 51]. Positive pressure ventilation may change the expression of several mediators central to renal function. Mechanical ventilation reduces production of renal dopamine, potentially an independent factor mediating renal injury. Examination of the effects of IMV in awake humans with healthy lungs revealed a decrease in urine output and an increase in antidiuretic hormone (ADH) following institution of mechanical ventilation, without a change in free-water clearance [52]. PEEP has also been shown to increase antidiuretic hormone and aldosterone levels in some [53], but not all [54], animal studies, and may contribute to the decreasing urine output observed after institution of this modality. In some studies this effect can be ameliorated by adequate fluid resuscitation [55–57]. The rapid restoration of diuresis and natriuresis suggests the change of antidiuretic hormone in this setting may be a consequence of a decreased atrial transmural filling pressure caused by a positive intrathoracic pressure [58]. This topic has been comprehensively reviewed recently [59]. Ischemia remains the major cause of ARF in hospitalized patients, and recent studies suggest that renal injury is also regulated by circulating cytokines such as TNF-␣ [60–62] and growth factors such as hepatocyte growth factor (HGF) [63, 64] produced by extrarenal organs. Mechanical ventilation, especially with prior lung injury, produces similar changes in inflammatory molecules in kidney, such as TNF-␣, IL-6 [29, 65], and vascular endothelial growth factor (VEGF) [29, 65] (table 2). In a mouse model of 4 h of mechanical ventilation, marked decreases in renal ENaC, aquaporin-2 (AQP2) and Na-KATPase were found – similar to what occurs after direct ischemic injury to kidneys. Recent experiments have demonstrated that mechanical ventilation without change in blood pressure or central venous pressure caused flattening of epithelial cells in the canine kidney [66]. In a rabbit model of injurious mechanical ventilation, renal tubular apoptosis as well as biochemical markers of renal dysfunction were found, supporting a causal association between mechanical ventilation and the development of remote renal injury [67]. High tidal volume
Acute Renal Failure and Lung Injury in the Critically Ill Patient
57
Table 2. Effects of experimental acute lung injury on kidney Lung injury model
Animal species
Renal changes
Reference No.
4 h ventilation ⫾ HCl
mouse
ventilation alone increases VEGF acid aspiration plus high VT ventilation increases IL-6, VEGFR-2
29
5 h ventilation
mouse
increased neutrophil infiltration increased Il-1, ICAM-1, and IL-6 decreased AQP2, ENaC increased AQP1 in high VT ventilation
65
6 h ventilation ⫾ LPS and HCl
dog
neutrophil margination in the peritubular capillaries tubular cell sloughing
66
4 and 8 h ventilation ⫾ HCl
rabbit
increased epithelial apoptosis index
67
1 h ventilation
rat
high VT group with more glomerular collapse and perivascular edema
68
2 h ventilation
rat
high VT group with renal vascular leak and proteinuria L-NAME attenuated this effect
69
HCl ⫽ Hydroxyl chloride; VEGF ⫽ vascular epithelial growth factor; IL-6 ⫽ interleukin-6; VEGFR-2 ⫽ vascular epithelial growth factor receptor 2; IL-1 ⫽ interleukin-1; ICAM-1 ⫽ intracellular adhesion molecule 1; AQP2 ⫽ aquaporin-2; ENaC ⫽ epithelial sodium channel; AQP1 ⫽ aquaporin-1; LPS ⫽ lipopolysaccharide; VT ⫽ tidal volume; L-NAME ⫽ N-nitroL-arginine methyl ester.
ventilation in rats produced a higher percentage of collapse of Bowman’s space [68] and proteinuria resulted from renal microvascular leak [69].
Conclusion
The persistent high mortality associated with ARF requires nephrologists to broaden mechanistic studies beyond the pathophysiology of isolated ARF and metabolites of dialysis approach, to the more complex arena of inter-organ failure. Advances in our understanding of inflammation and lung mechanics may provide a basis for investigation of these critically ill patients with ARF that will
Chien/King/Rabb
58
lead to new treatment strategies. It is likely that an important developmental link between lung and kidney also contributes to this problem. Integrative physiologic approaches on the bench and prospective cross-specialty clinical trials will be required to make the necessary inroads in this lethal syndrome.
Acknowledgements CC was supported by a training grant from Chang-Gung Memorial Hospital, Taipei, Taiwan. HR was supported by NIDDK R01 DK54770 and ROTRF 696313559. LK was supported by NHLBI R01 HL70217 and American Heart Association Grant Aid. Both HR and LK are supported by NHLBI SCCOR grant HL073944.
References 1 2
3 4 5 6
7 8 9 10 11 12 13 14 15 16 17
Vivino G, Antonelli M, Moro ML, Cottini F, Conti G, Bufi M, Cannata F, Gasparetto A: Risk factors for acute renal failure in trauma patients. Intens Care Med 1998;24:808–814. Chertow GM, Lazarus JM, Paganini EP, Allgren RL, Lafayette RA, Sayegh MH: Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis. The Auriculin Anaritide Acute Renal Failure Study Group. J Am Soc Nephrol 1998;9:692–698. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J: Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998;104:343–348. Mehta RL, Pascual MT, Gruta CG, Zhuang S, Chertow GM: Refining predictive models in critically ill patients with acute renal failure. J Am Soc Nephrol 2002;13:1350–1357. Falk RJ, Jennette JC: ANCA small-vessel vasculitis. J Am Soc Nephrol 1997;8:314–322. von Vigier RO, Trummler SA, Laux-End R, Sauvain MJ, Truttmann AC, Bianchetti MG: Pulmonary renal syndrome in childhood: A report of twenty-one cases and a review of the literature. Pediatr Pulmonol 2000;29:382–388. Grassi V, Malerba M, Boni E, Tantucci C, Sorbini CA: Uremic lung. Contrib Nephrol. Basel, Karger, 1994, vol 106, pp 36–42. Prezant DJ: Effect of uremia and its treatment on pulmonary function. Lung 1990;168:1–14. Mehta RL, Clark WC, Schetz M: Techniques for assessing and achieving fluid balance in acute renal failure. Curr Opin Crit Care 2002;8:535–543. Tarasuik A, Heimer D, Bark H: Effect of chronic renal failure on skeletal and diaphragmatic muscle contraction. Am Rev Respir Dis 1992;146:1383–1388. Rabb H, Wang Z, Nemoto T, Hotchkiss J, Yokota N, Soleimani M: Acute renal failure leads to dysregulation of lung salt and water channels. Kidney Int 2003;63:600–606. Kalender B, Erk M, Pekpak MA, Apaydin S, Ataman R, Serdengecti K, Sariyar M, Erek E: The effect of renal transplantation on pulmonary function. Nephron 2002;90:72–77. Chan CH, Lai CK, Li PK, Leung CB, Ho AS, Lai KN: Effect of renal transplantation on pulmonary function in patients with end-stage renal failure. Am J Nephrol 1996;16:144–148. Lee HY, Stretton TB, Barnes AM: The lungs in renal failure. Thorax 1975;30:46–53. Herrero JA, Alvarez-Sala JL, Coronel F, Moratilla C, Gamez C, Sanchez-Alarcos JM, Barrientos A: Pulmonary diffusing capacity in chronic dialysis patients. Respir Med 2002;96:487–492. Moinard J, Guenard H: Membrane diffusion of the lungs in patients with chronic renal failure. Eur Respir J 1993;6:225–230. Kramer AA, Postler G, Salhab KF, Mendez C, Carey LC, Rabb H: Renal ischemia/reperfusion leads to macrophage-mediated increase in pulmonary vascular permeability. Kidney Int 1999;55: 2362–2367.
Acute Renal Failure and Lung Injury in the Critically Ill Patient
59
18
19 20 21
22 23 24 25 26
27 28 29
30 31 32 33
34
35 36 37 38 39
40 41
Khimenko PL, Barnard JW, Moore TM, Wilson PS, Ballard ST, Taylor AE: Vascular permeability and epithelial transport effects on lung edema formation in ischemia and reperfusion. J Appl Physiol 1994;77:1116–1121. Deng J, Hu X, Yuen PS, Star RA: ␣-Melanocyte-stimulating hormone inhibits lung injury after renal ischemia-reperfusion. Am J Respir Crit Care Med 2004 Jan 7 [Epub ahead of print]. Boydstun I, Lam VD, Hawkins EP, Welty SE: Adhesion molecule induction in lung following renal ischemia reperfusion injury. J Am Soc Nephrol 1997;8:584A. Welborn MB III, Moldawer LL, Seeger JM, Minter RM, Huber TS: Role of endogenous interleukin-10 in local and distant organ injury after visceral ischemia-reperfusion. Shock 2003;20: 35–40. Koike K, Moore EE, Moore FA, Franciose RJ, Fontes B, Kim FJ: CD11b blockade prevents lung injury despite neutrophil priming after gut ischemia/reperfusion. J Trauma 1995;39:23–27. Moore FA: The role of the gastrointestinal tract in postinjury multiple organ failure. Am J Surg 1999;178:449–453. Rabinovici R, Zhang D, Su Y, Luo X, Zhao Q, Yang JH: MOB-1 and TNF-alpha interact to induce microvascular lung injury. Shock 2002;18:261–264. McCarter MD, Mack VE, Daly JM, Naama HA, Calvano SE: Trauma-induced alterations in macrophage function. Surgery 1998;123:96–101. Beierle EA, Vauthey JN, Moldawer LL, Copeland EM: Hepatic tumor necrosis factor-alpha production and distant organ dysfunction in a murine model of obstructive jaundice. Am J Surg 1996; 171:202–206. Shimabukuro DW, Sawa T, Gropper MA: Injury and repair in lung and airways. Crit Care Med 2003;31:S524–S531. Welk B, Malloy JL, Joseph M, Yao LJ, Veldhuizen AW: Surfactant treatment for ventilation-induced lung injury in rats: Effects on lung compliance and cytokines. Exp Lung Res 2001;27:505–520. Gurkan OU, O’Donnell C, Brower R, Ruckdeschel E, Becker PM: Differential effects of mechanical ventilatory strategy on lung injury and systemic organ inflammation in mice. Am J Physiol 2003;285:L710–L718. Crestani B, Aubier M: Inflammatory role of alveolar epithelial cells. Kidney Int Suppl 1998;65: S88-S93. Guo RF, Lentsch AB, Sarma JV, Sun L, Riedemann NC, McClintock SD, McGuire SR, Van Rooijen N, Ward PA: Activator protein-1 activation in acute lung injury. Am J Pathol 2002;161:275–282. Wada K, Montalto MC, Stahl GL: Inhibition of complement C5 reduces local and remote organ injury after intestinal ischemia/reperfusion in the rat. Gastroenterology 2001;120:126–133. Kuhnle GE, Kiefmann R, Sckell A, Kuebler WM, Groh J, Goetz AE: Leukocyte sequestration in pulmonary microvessels and lung injury following systemic complement activation in rabbits. J Vasc Res 1999;36:289–298. Kukkonen S, Heikkila L, Verkkala K, Mattila S, Toivonen H: Thromboxane receptor blockade does not attenuate pulmonary pressure response in porcine single lung transplantation. J Heart Lung Transplant 1996;15:409–414. Turnage RH, Kadesky KM, Bartula L, Myers SI: Pulmonary thromboxane release following intestinal reperfusion. J Surg Res 1995;58:552–557. Fantini GA, Conte MS: Pulmonary failure following lower torso ischemia: Clinical evidence for a remote effect of reperfusion injury. Am Surg 1995;61:316–319. Klausner JM, Paterson IS, Kobzik L, Valeri CR, Shepro D, Hechtman HB: Leukotrienes but not complement mediate limb ischemia-induced lung injury. Ann Surg 1989;209:462–470. Rabb H, Daniels F, O’Donnell M, Haq M, Saba SR, Keane W, Tang WW: Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am J Physiol 2000;279:F525–F531. Burne MJ, Daniels F, El Ghandour A, Mauiyyedi S, Colvin RB, O’Donnell MP, Rabb H: Identification of the CD4(⫹) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 2001;108:1283–1290. Scheel P, Eustace J, Rabb H: Continuous dialysis as systemic therapy in the critically ill patient? Crit Care Med 2003;31:988–989. Ronco C, Bellomo R, Ricci Z: Continuous renal replacement therapy in critically ill patients. Nephrol Dial Transplant 2001;16(suppl 5):67–72.
Chien/King/Rabb
60
42 43 44 45 46
47 48
49
50 51 52 53
54
55 56
57
58
59 60
61
62 63 64
Stegmayr BG, Banga R, Berggren L, Norda R, Rydvall A, Vikerfors T: Plasma exchange as rescue therapy in multiple organ failure including acute renal failure. Crit Care Med 2003;31:1730–1736. Murdaugh HV Jr, Sieker HO, Manfredi F: Effect of altered intrathoracic pressure on renal hemodynamics, electrolyte excretion and water clearance. J Clin Invest 1959;38:834–842. Hall SV, Johnson EE, Hedley-Whyte J: Renal hemodynamics and function with continuous positive-pressure ventilation in dogs. Anesthesiology 1974;41:452–461. Steinhoff HH, Samodelov LF, Trampisch HJ, Falke KJ: Cardiac afferents and the renal response to positive pressure ventilation in the dog. Intens Care Med 1986;12:147–152. Marquez JM, Douglas ME, Downs JB, Wu WH, Mantini EL, Kuck EJ, Calderwood HW: Renal function and cardiovascular responses during positive airway pressure. Anesthesiology 1979;50: 393–398. Fewell JE, Bond GC: Renal denervation eliminates the renal response to continuous positivepressure ventilation. Proc Soc Exp Biol Med 1979;161:574–578. Mitaka C, Nagura T, Sakanishi N, Tsunoda Y, Amaha K: Two-dimensional echocardiographic evaluation of inferior vena cava, right ventricle, and left ventricle during positive-pressure ventilation with varying levels of positive end-expiratory pressure. Crit Care Med 1989;17:205–210. Shinozaki M, Muteki T, Kaku N, Tsuda H: Hemodynamic relationship between renal venous pressure and blood flow regulation during positive end-expiratory pressure. Crit Care Med 1988;16: 144–147. Steinhoff HH, Kohlhoff RJ, Falke KJ: Facilitation of renal function by intermittent mandatory ventilation. Intens Care Med 1984;10:59–65. Baratz RA, Ingraham RC: Renal hemodynamics and antidiuretic hormone release associated with volume regulation. Am J Physiol 1960;198:565–570. Khambatta HJ, Baratz RA: IPPB, plasma ADH, and urine flow in conscious man. J Appl Physiol 1972;33:362–364. Kaczmarczyk G, Jorres D, Rossaint R, Krebs M, Unger V, Falke K: Extracellular volume expansion inhibits antidiuretic hormone increase during positive end-expiratory pressure in conscious dogs. Clin Sci (Lond) 1993;85:643–649. Teba L, Dedhia HV, Schiebel FG, Blehschmidt NG, Lindner WJ: Positive-pressure ventilation with positive end-expiratory pressure and atrial natriuretic peptide release. Crit Care Med 1990; 18:831–835. Costa KN, Carvalho WB, Kopelman BI, DiDo R: Dosage of atrial natriuretic peptide in pediatric patients submitted to mechanical ventilation. Rev Assoc Med Bras 2000;46:320–324. Rossaint R, Jorres D, Nienhaus M, Oduah K, Falke K, Kaczmarczyk G: Positive end-expiratory pressure reduces renal excretion without hormonal activation after volume expansion in dogs. Anesthesiology 1992;77:700–708. Ramamoorthy C, Rooney MW, Dries DJ, Mathru M: Aggressive hydration during continuous positive-pressure ventilation restores atrial transmural pressure, plasma atrial natriuretic peptide concentrations, and renal function. Crit Care Med 1992;20:1014–1019. Andrivet P, Adnot S, Sanker S, Chabrier PE, Macquin-Mavier I, Braquet P, Brun-Buisson C: Hormonal interactions and renal function during mechanical ventilation and ANF infusion in humans. J Appl Physiol 1991;70:287–292. Pannu N, Mehta RL: Mechanical ventilation and renal function: An area for concern? Am J Kidney Dis 2002;39:616–624. Donnahoo KK, Meng X, Ao L, Ayala A, Shames BD, Cain MP, Harken AH, Meldrum DR: Differential cellular immunolocalization of renal tumour necrosis factor-alpha production during ischaemia versus endotoxaemia. Immunology 2001;102:53–58. Donnahoo KK, Meng X, Ayala A, Cain MP, Harken AH, Meldrum DR: Early kidney TNF-alpha expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am J Physiol 1999;277:R922–R929. Meldrum KK, Meldrum DR, Meng X, Ao L, Harken AH: TNF-alpha-dependent bilateral renal injury is induced by unilateral renal ischemia-reperfusion. Am J Physiol 2002;282:H540–H546. Liu Y: Hepatocyte growth factor and the kidney. Curr Opin Nephrol Hypertens 2002;11:23–30. Matsumoto K, Mizuno S, Nakamura T: Hepatocyte growth factor in renal regeneration, renal disease and potential therapeutics. Curr Opin Nephrol Hypertens 2000;9:395–402.
Acute Renal Failure and Lung Injury in the Critically Ill Patient
61
65
66
67
68
69
Tremblay LN, Miatto D, Hamid Q, Govindarajan A, Slutsky AS: Injurious ventilation induces widespread pulmonary epithelial expression of tumor necrosis factor-alpha and interleukin-6 messenger RNA. Crit Care Med 2002;30:1693–1700. Chien CC, Haas M, Jakobe A, McVerry B, Simon BA, Rabb H: Mechanical ventilation associated lung injury in canines causes renal histologic changes consistent with early acute tubular necrosis. J Am Soc Nephrol 2003;14:354A. King L, Doddo OJ, Becker P, Haas M, Chien CC, Burne-Taney MJ, Rabb H: Mechanical ventilation in mice leads to renal inflammation and dysregulation of transporters. J Am Soc Nephrol 2003;14:564A. Valenza F, Sibilla S, Porro GA, Brambilla A, Tredici S, Nicolini G, Miloso M, Tredici G, Gattinoni L: An improved in vivo rat model for the study of mechanical ventilatory support effects on organs distal to the lung. Crit Care Med 2000;28:3697–3704. Choi WI, Quinn DA, Park KM, Moufarrej RK, Jafari B, Syrkina O, Bonventre JV, Hales CA: Systemic microvascular leak in an in vivo rat model of ventilator-induced lung injury. Am J Respir Crit Care Med 2003;167:1627–1632.
H. Rabb, MD Johns Hopkins University Hospital Ross 970, 720 Rutland Ave, Baltimore, MD 21205 (USA) Tel. ⫹1 410 502 1555, Fax ⫹1 410 614 5129, E-Mail
[email protected]
Chien/King/Rabb
62
Ronco C, Bellomo R, Brendolan A (eds): Sepsis, Kidney and Multiple Organ Dysfunction. Contrib Nephrol. Basel, Karger, 2004, vol 144, pp 63–75
Cytokine Single Nucleotide Polymorphism Role in Acute Renal Failure
Orfeas Liangos, Vaidyanathapuram S. Balakrishnan, Brian J. G. Pereira, Bertrand L. Jaber Dialysis Research Laboratory, Division of Nephrology, Tufts-New England Medical Center, Boston, Mass., USA
Acute renal failure (ARF) is a serious complication and carries high mortality rate [1, 2], which has not improved despite advances in intensive care and dialytic support. The lack of improvement in patient outcomes calls for novel preventive and therapeutic approaches.
Mediators of the Systemic Inflammatory Response Syndrome in ARF
Sepsis or the broader syndrome, the systemic inflammatory response syndrome (SIRS), represents an overwhelming, host response to a variety of triggers such as gram-negative bacterial endotoxin [3]. During the initial phase of sepsis, pro-inflammatory cytokines are released, including tumor necrosis factor- (TNF-) and interleukin-1 (IL-1), which in turn stimulate the release of other biologically active molecules, resulting in vascular endothelial damage and organ dysfunction. This initial phase is followed by a compensatory anti-inflammatory response (CARS) in which anti-inflammatory cytokines are produced, which offset pro-inflammatory responses [4]. Interleukin-10 is the most potent anti-inflammatory cytokine, and its release inhibits production of TNF- and IL-1 [5–7]. Acute renal failure often develops during sepsis, and pro-inflammatory cytokines released in response to endotoxin, organ ischemia-reperfusion, complement activation, and through other cytokines and immune modulators have been
Sepsis
Ischemia-reperfusion
Endotoxin release
Complement activation
Genetic influence
TNF-
IL-10
Genetic influence
Oxygen free radicals Nitric oxide
Arachidonic acid metabolites Cellular activation
Proteases Plateletactivating factor
Endothelins ↑ Urinary markers (NAG, KIM-1… )
Kidney injury
↑ Circulating markers (serum creatinine)
Fig. 1. Schematic representation of the inflammatory response to sepsis and resulting kidney injury. NAG N-acetyl--D-glucosaminidase; KIM kidney injury molecule 1. Modified from Jaber et al. [63], with permission.
shown to play a role in the development of endotoxin-mediated ARF [8, 9] (fig. 1). Leukocyte activation with expression of adhesion molecules, and the production of oxygen-free radicals, arachidonic acid metabolites, platelet-activating factor, nitric oxide, endothelins, and heat-shock proteins follows [10] whereby creating a pro-inflammatory cascade that contributes to injury of the glomerular and peritubular vasculature [11]. TNF-receptor-1 deficient mice are resistant to endotoxin-induced ARF, arguing for a critical role for TNF- [9]. In addition, bacterial products can activate neutrophils in situ and IL-8-mediated chemotaxis further recruits neutrophils to sites of inflammation [12]. Morphological studies of acute tubular necrosis in humans have shown neutrophils in the vasa recta and the interstitium and support a role for inflammation in the pathogenesis of ARF [13]. Ischemic and Nephrotoxic Injury in ARF
Increasing evidence supports an important role for inflammatory mechanisms in both ischemic [11, 14] and nephrotoxic [15, 16] renal injury. Animal models of ischemic ARF have demonstrated an activation of renal myeloperoxidase (MPO) and increased gene expression of intercellular adhesion molecule-1
Liangos/Balakrishnan/Pereira/Jaber
64
(ICAM-1) and IL-6 [17]. A mouse model of cisplatin nephrotoxicity shows increased TNF- and IL-1 mRNA expression and increased urinary TNF- [16]. Inhibitors of TNF- such as pentoxifylline and anti-TNF- monoclonal antibodies have been shown to ameliorate the pro-inflammatory response. Similarly, TNF--deficient mice are resistant to cisplatin nephrotoxicity, arguing for a central role for TNF- [16]. On the other hand, exogenous administration of IL-10 inhibits TNF- and ICAM-1 mRNA expression in mouse kidneys following ischemic and nephrotoxic injury [15], and antibodies to ICAM-1 protect the kidney against ischemic injury [18].
Cytokines and ARF in Humans
Increased plasma and urinary cytokine levels have been shown to correlate with urinary levels of N-acetyl--D-glucosaminidase (NAG), a bio-marker of renal proximal tubular dysfunction following surgery with cardiopulmonary bypass (CPB) [19]. However, it is unclear as to whether urinary cytokines are filtered by the glomerulus or produced in situ. More studies, perhaps involving the recently described soluble form of human kidney injury molecule-1 (KIM-1), a highly specific bio-marker for renal proximal tubular injury [11] may shed light on a potential pathogenetic link between urinary cytokines and early tubular injury. In regards to plasma cytokine levels, IL-6 and IL-10 have been shown to differentiate surviving from non-surviving patients with ARF [20]. In addition, elevated serum levels of soluble TNF receptors among patients with septic shock were shown to predict ARF and mortality [21]. The above data support the role of cytokines as important mediators of kidney parenchymal injury, but the role of genetic factors affecting cytokine production in the inflammatory response cascade and their implications for ARF following ischemic or nephrotoxic injury have remained largely unexplored.
Human Gene Polymorphism and Biological Diversity
Among humans, there is a remarkable homogeneity of genetic information, with two unrelated individuals sharing greater than 99.9 percent of their DNA sequences [22]. Variations observed in the remaining 0.1% of the human genome have become the subject of intense investigation [23]. This variability, known as gene polymorphism, is the basis of biological diversity and some genotypic variations have been shown to correlate with specific phenotypes
Cytokine Gene Polymorphism in Acute Renal Failure
65
Start of transcription
Exons (coding sequences) • Silent • Alteration in gene expression • Alteration in gene function (structure, binding or trafficking of protein product
5'
3'
Initiator codon Termination Untranslated Promoter codon region region • Alteration in • Alteration in Introns (intervening sequences) mRNA half-life transcriptional activity • Defect in RNA processing • Alteration in • Defect in mRNA processing ribosomal mRNA Direction of transcription translation
Fig. 2. Sketch of the structure of a human gene with potential sites of polymorphism.
relevant to human disease [24]. It is not clear, however, whether many of these genetic variants are causal for the diseases in question or simply located in proximity to other, yet unknown pathogenic genetic factors, an occurrence known as linkage disequilibrium. Polymorphism of human genes occurs at one or more of the following sites (fig. 2): (1) the promoter or 5-flanking region affecting transcriptional activity [25]; (2) the exon(s) or the gene coding sequences affecting gene expression or function through changes in structure, binding or trafficking of the gene product; (3) the intron(s) or the gene intervening sequences where changes may lead to defects in RNA and mRNA processing, and (4) the 3-untranslated (3-UTR) region further downstream which may affect gene expression through altered RNA half-life or influencing ribosomal translation of mRNA. On a molecular level, gene polymorphism can be categorized into: (1) single nucleotide polymorphism (SNP); (2) variable number of tandem repeats (VNTR) or minisatellite polymorphism, and (3) microsatellite polymorphism [25], of which the single nucleotide polymorphism is the most common and consists of single nucleotide substitution. SNP in the promoter region may change transcriptional activity and thereby be of functional relevance.
Identification of Genes Relevant to Human Disease
There are two approaches to identifying genes relevant to human disease: Linkage analyses and association studies. Linkage analyses identify co-inheritance of a specific phenotype with a region of the genome in families. These analyses
Liangos/Balakrishnan/Pereira/Jaber
66
are successful in identifying novel genes for ‘monogenic’ diseases, and environmental factors play a minimal role in disease expression. One such example is polycystic kidney disease. Association studies identify susceptibility genes for common ‘polygenic’ diseases. This is known as the ‘candidate gene’ approach and relies on biological plausibility to identify highly likely candidate genes. In this analytical approach, environmental factors play a critical role in disease expression. Examples would include the study of genes encoding for cytokines in sepsis. Association Studies in Acute Infectious and Inflammatory Disorders
In recent years, the study of cytokine gene polymorphism has become the subject of intense interest, as these genetic markers may be potential determinants of susceptibility to disease incidence, severity of illness and clinical outcomes. For inflammatory conditions, polymorphisms of the TNF and IL-10 genes are of particular interest, particularly those associated with altered gene expression. Associations between these polymorphisms and acute inflammatory states are summarized (table 1). Tumor Necrosis Factor Locus
The TNF- gene is located on the short arm of chromosome 6. Polymorphism within the promoter region of the TNF- gene at positions 238 (G to A) and 308 (G to A) have been described. The 308 A-allele, also known as the TNF-2 allele, has been associated with high promoter activity [26, 27] and enhanced TNF- production [28]. The gene coding for TNF-, also known as lymphotoxin- (LT-), lies next to the TNF- gene. Single nucleotide polymorphism at position 1069 (G to A) in the first intron of the TNF- gene has been characterized [29]. The ‘A’ variant is the TNF-2 allele whereas the less frequent ‘G’ variant is known as the TNF-1 allele. TNF-2 homozygous individuals produce significantly higher amounts of TNF- and IL-1 [30, 31]. There is strong linkage disequilibrium between the TNF-308 (G to A) and TNF- also called NcoI polymorphisms, whereby heterozygosity for both TNF polymorphisms is associated with higher TNF- production [32]. This finding highlights the importance of linkage disequilibrium in studies examining the association between polymorphism of a single candidate gene and severity of disease. Polymorphism of the TNF- gene has been studied extensively and has been associated with adverse clinical outcomes among patients with sepsis
Cytokine Gene Polymorphism in Acute Renal Failure
67
Table 1. Association between polymorphism of TNF, IL-10 genes and sepsis or acute renal failure (modified from Jaber et al. [63] with permission) Polymorphic allele TNF-a 308 A-allele (TNF-2) 308 A-allele (TNF-2) 308 A-allele (TNF-2) 308 A-allele (TNF-2) 238 A-allele TNF-b (LT-a) 250 AA genotype 1069 (NcO1) allele-2/2 1069 (NcO1) allele-2/2 1069 (NcO1) allele-2/2 IL-10 1082 GA genotype 1082 G-allele 592 A-allele
Acute illness
Reference
sepsis/septic shock meningococcal disease neonatal acute renal failure increased mortality in dialysis-requiring acute renal failure increased risk of death in community-acquired pneumonia
[33, 34, 36] [64] [39] [40]
increased risk of septic shock in community-acquired pneumonia septic shock following acute biliary pancreatitis increased mortality in severe sepsis susceptibility to severe post-traumatic sepsis meningococcal disease severity of illness in community-acquired pneumonia mortality in sepsis
[35]
[35, 37]
[65] [66] [36]
[42, 67] [43]
[44]
[33, 34] as well as patients with community-acquired pneumonia [35]. Other studies have linked TNF-2 homozygous status with higher mortality of and increased susceptibility to severe sepsis [36]. The TNF- 250 AA-genotype has been associated with a greater risk of septic shock in community-acquired pneumonia [37]. Both the TNF- 250 G and the TNF- 308 G-alleles have also been associated with prolonged mechanical ventilation following coronary artery bypass graft (CABG) surgery [38]. The 308 A-allele (TNF2) has also been associated with an increased incidence of ARF among neonates [39] and with higher TNF- production and a higher risk of death among adult patients with dialysis-requiring ARF (fig. 3) [40]. These data support the hypothesis that TNF- gene polymorphisms linked to increased production of pro-inflammatory cytokines may have important
Liangos/Balakrishnan/Pereira/Jaber
68
1.0
0.8 Cumulative survival
Low TNF-, high IL-10 Low TNF-, low IL-10 0.6 High TNF-, high IL-10 0.4
0.2
High TNF-, low IL-10
0.0 0
20
10
30
Time (days)
Fig. 3. Cumulative survival in a cohort of patients with dialysis requiring ARF stratified by the combination of TNF- and IL-10 gene-polymorphism and adjusted for APACHE II score. Modified from Jaber et al. with permission [40].
implications in the severity of ARF, and, consequently, the requirement for dialysis and hospital mortality.
The Interleukin-10 Gene
The IL-10 gene is located on the long arm of chromosome 1. The IL-10 promoter region is polymorphic with a single-base-pair substitution at position 1082 (G to A) [41]. In vitro studies have identified three phenotypic secretion levels based on allelic substitutions: GG, GA and AA genotype, for high, intermediate and low producer status, respectively [27, 41]. Additional polymorphisms at positions 819 (C to T) and 592 (C to A) have been described. Polymorphisms at these two sites are in linkage disequilibrium. Interleukin-10 1082 polymorphic alleles have been associated with susceptibility to meningococcal disease and adverse clinical outcomes [42], and severity of illness in community-acquired pneumonia [43]. In dialysis-requiring ARF, carriers of the IL-10 1082 G-allele had higher IL-10 production and lower risk of death after adjustment for severity of illness scores, especially when combined to the TNF- low producer genotype (308 A-allele carrier) (fig. 3) [40]. The IL-10 592 A-allele has been associated with higher mortality in sepsis [44].
Cytokine Gene Polymorphism in Acute Renal Failure
69
Limitations of Gene Polymorphism-Association Studies
Polymorphism-association studies are typically designed in a case-control format. They frequently have a small sample size, and should be interpreted with caution. This is particularly true for diseases that are common and polygenic in nature and where a single candidate gene hypothesis lacks biological plausibility. Small, single center studies may also be limited in their external validity regarding ethnicity and geographical boundaries [45]. Survival bias is another concern in case control studies evaluating genetic markers as predictors of mortality. Proper matching for age and follow up time or using prospective cohort study designs can overcome these limitations [46].
The Future in ARF
Future developments in ARF will focus on development and establishment of early bio-markers of kidney injury such as NAG and KIM-1. There is also a need to develop non-invasive tools that help detect ARF-induced inflammation. The ultra-small super-paramagnetic iron oxide (USPIO) enhanced MRI is one such example. This technology can detect inflammation caused by experimental cerebral ischemia, arthritis, nephrotoxic nephritis, and renal transplant rejection [47]. The USPIO particles are internalized by leukocytes, and once internalized, MRI signal intensity decreases on T2-weighted images. This extremely promising tool awaits further studies in humans. Novel risk assessment and stratification tools to help allocate resources are also likely to be the focus of future research efforts, and cytokine genotype profiles are a good example for such use. Finally, targeted therapies, including the use of cytokine modulating strategies are another example of future interventions in ARF. Indeed, due to their importance in inflammatory diseases, the modification of cytokine responses through therapeutic intervention remains a focus of intense investigation. A summary of modulation of two particular cytokines, TNF- and IL-10, is briefly reviewed.
Down-Regulation of TNF-␣
Glucocorticoids, pentoxifylline and thalidomide inhibit TNF- synthesis at distinct points of its biosynthetic pathway. Glucocorticoids interfere with NF-B which in turn decreases expression of TNF- activity [48], and reduces posttranscription protein translation [49]. The xanthine derivative pentoxifylline, reduces TNF- mRNA expression in monocytes [50], which is partly mediated
Liangos/Balakrishnan/Pereira/Jaber
70
by generation of cyclic adenosine monophosphate (cAMP) which inhibits NF-B-mediated transcription [51]. Rolipram, a specific inhibitor of monocyte predominant phosphodiesterose inhibitor type-4, is a 500-fold more potent inhibitor of TNF- synthesis in human monocytes, compared with pentoxifylline [52]. Thalidomide also selectively inhibits biosynthesis of TNF- [53]. Interleukin-10 reduces expression of TNF- [54], and its administration to healthy volunteers inhibits endotoxin-induced rise in body temperature and release of TNF- [55]. Both monoclonal antibodies to TNF- (Inflixmab, Adalilumab) as well as soluble TNF receptors (sTNFR) (Etanercept) can bind and neutralize this cytokine. Finally, somatostatin is also capable of down-regulating cell-surface TNF receptor expression in human macrophages, which become less responsive to TNF- [56]. These therapeutic approaches of immune modulation in inflammatory diseases could play a role in ameliorating the inflammatory component in the pathophysiology of ARF.
Upregulation of IL-10
Cyclic AMP stimulates IL-10 gene transcription via activation of cAMP response element binding proteins [57]. The phosphodiesterase inhibitors theophylline and rolipram induce IL-10 expression [58, 59]. The xanthine derivatives pentoxifylline and caffeine, however, decrease IL-10 whereas dexamethasone increases its release [60]. Calcineurin inhibitors also increase IL-10 mRNA expression and synthesis [61]. Finally, glucocorticoids have been shown to modulate the inflammatory response syndrome in favor of IL-10, resulting in a decrease in TNF-, interleukin-6 (IL-6) and interleukin-8 (IL-8) levels and an increase in IL-10 levels [62].
Summary and Conclusions
Although the pathogenesis of ARF is heterogeneous and results from a combination of different environmental influences and host responses, there is overwhelming data to suggest a common pathway that involves pro- and antiinflammatory molecules, which in turn, determines the extent of tissue injury. The number of recognized cytokine gene polymorphisms is growing daily. The development of cytokine gene mapping may help identify patients in whom an excessive systemic inflammatory response may follow a therapeutic intervention (e.g. CABG, contrast administration), and who may be at increased risk for developing acute organ dysfunction. Through these advances, tools may be developed to better understand, prevent and treat ARF.
Cytokine Gene Polymorphism in Acute Renal Failure
71
Low
High
e.g. TNF- -308, IL-10 -1082 SNP…
Spectrum of genetic predisposition
Risk of acute renal failure
Spectrum of environmental predisposition
e.g. radiocontrast, sepsis, surgery… High
Low
Fig. 4. Acute renal failure risk stratification: A model for genetic and environmental interaction.
Genetic epidemiology studies may help characterize the importance of genetic markers in the development of ARF. This would require large prospective cohort studies aimed at examining associations between genetic markers, urinary (urine KIM-1 and NAG) and circulating (serum creatinine) markers of kidney injury. Once firmly established, the association of a particular genetic profile and outcome could be used to risk stratify patients for the development of ARF (fig. 4). Ultimately, cytokine-modulating therapies could be employed on the basis of genotypic risk stratification with the goal to prevent kidney injury or minimize its deleterious effects on patient outcome.
References 1 2 3 4 5
6 7
8 9
Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT: Hospital-acquired renal insufficiency: A prospective study. Am J Med 1983;74:243–248. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J: Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998;104:343–348. Conference ACoCPSoCCMC: Definitions of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;13:818–822. Opal S, DePalo V: Anti-inflammatory cytokines. Chest 2000;117:1162–1172. De Waal Malefyt F, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209–1220. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A: IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815–3822. Perianayagam M, Jaber B, Guo D, King A, Pereira B, Balakrishnan V: Defective interleukin-10 synthesis by peripheral blood mononuclear cells among hemodialysis patients. Blood Purif 2002; 20:543–550. Fouqueray B, Philippe C, Herbelin A, Perez J, Ardaillou R, Baud L: Cytokine formation within rat glomeruli during experimental endotoxemia. J Am Soc Nephrol 1993;3:1783–1791. Cunningham P, Dyanov H, Park P, Wang J, Newell K, Quigg R: Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 2002;168:5817–5823.
Liangos/Balakrishnan/Pereira/Jaber
72
10
11 12
13 14
15
16 17
18 19
20
21
22 23 24
25
26 27
28
29 30
Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N, Sellevold OF, Espevik T, Sundan A: Inflammatory response after open heart surgery: Release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 2002;105:685–690. Bonventre J, Weinberg J: Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003;14:2199–2210. Zoja C, Angioletti S, Donadelli R, Zanchi C, Tomasoni S, Binda E, Imberti B, Te Loo M, Monnens L, Remuzzi G, Morigi M: Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int 2002;62: 846–856. Solez K, Morel-Maroger L, Sraer J-D: The morphology of acute tubular necrosis in man: Analysis of 57 renal biopsis and a comparison with glycerol model. Medicine 1979;58:362–376. Burne M, Daniels F, El Ghandour A, Mauiyyedi S, Colvin R, O’Donnell M, Rabb H: Identification of the CD4 T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 2001;108:1283–1290. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S, Star RA: Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 2001;60:2118–2128. Ramesh G, Reeves W: TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002;110:835–842. Burne-Taney M, Kofler J, Yokota N, Weisfeldt M, Traystman R, Rabb H: Acute renal failure after whole body ischemia is characterized by inflammation and T cell-mediated injury. Am J Physiol 2003;285:F87–F94. Kelly KJ, Williams WWJ, Colvin RB, Bonventre JV: Antibody to inter-cellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 1994;91:812–816. Gormley SM, McBride WT, Armstrong MA, Young IS, McClean E, MacGowan SW, Campalani G, McMurray TJ: Plasma and urinary cytokine homeostasis and renal dysfunction during cardiac surgery. Anesthesiology 2000;93:1210–1216;discussion 1215A. Himmelfarb J, Sezer M, Shyr Y, Freedman S, Ikizler T, Becker K, Spratt D, Group PS: A prospective analysis of pro-inflammatory and anti-inflammatory cytokines in patients with acute renal failure (abstract). J Am Soc Nephrol 2002;13:5A. Iglesias J, Marik PE, Levine JS, Investigators NIS: Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as predictive factors for ARF in patients with septic shock. Am J Kidney Dis 2003;41:62–75. Venter J, Adams M, Myers E: The sequence of the human genome. Science 2001;291:1304–1351. Guttmacher A, Collins F: Genomic medicine: Genomic medicine – A primer. N Engl J Med 2002;347:1512–1520. Haukim N, Bidwell J, Smith A, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott M, Oksenberg J, McNicholl J, Pociot F, Hardt C, D’Alfonso S: Cytokine gene polymorphism in human disease: On-line databases, supplement 2. Genes Immun 2002;3:313–330. Nussbaum R, McInnes R, Willard H (eds): Genetic variation in individuals: Mutation and polymorphism; in Thompson & Thompson Genetics in Medicine, ed 6. Philadelphia, Saunders, 2001, pp 79–94. Abraham LJ, Kroeger KM: Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: Relevance to disease. J Leukoc Biol 1999;66:562–566. Morse H, Olomolaiye O, Wood N, Keen L, Bidwell J: Induced heteroduplex genotyping of TNF-alpha, IL-1beta, IL-6 and IL-10 polymorphisms associated with transcriptional regulation. Cytokine 1999;11:789–795. Wilson AG, Symons JA, McDowell TL, McDewitt HO, Duff GW: Effects of a polymorphism in the human tumor necrosis factor- promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195–3199. Abraham L, Du D, Zahedi K, Dawkins R, Whitehead A: Haplotypic polymorphisms of the TNFB gene. Immunogenetics 1991;33:50–53. Pociot F, Molvig J, Wogensen L, Worsaae H, Dalboge H, Baek L, Nerup J: A tumour necrosis factor beta gene polymorphism in relation to monokine secretion and insulin-dependent diabetes mellitus. Scand J Immunol 1991;33:37–49.
Cytokine Gene Polymorphism in Acute Renal Failure
73
31
32
33
34
35
36
37
38
39
40 41
42
43
44 45 46
47 48 49
Messer G, Spengler U, Jung M, Honold G, Blomer K, Pape G, Riethmuller G, Weiss E: Polymorphic structure of the tumor necrosis factor (TNF) locus: An NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991;173:209–219. Heesen M, Kunz D, Bachmann-Mennenga B, Merk H, Bloemeke B: Linkage disequilibrium between tumor necrosis factor (TNF)-alpha-308 G/A promoter and TNF-beta NcoI polymorphisms: Association with TNF-alpha response of granulocytes to endotoxin stimulation. Crit Care Med 2003;31:211–214. Mira J-P, Cariou A, Grall F, Delclaux C, Losser M-R, Heshmati F, Cheval C, Monchi M, Teboul J-L, Riche F, Leleu G, Arbibe L, Mignon A, Delpech M, Dhainaut J-F: Association of TNF2, a TNF[alpha] promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 1999;282:561–568. Tang GJ, Huang SL, Yien HW, Chen WS, Chi CW, Wu CW, Lui WY, Chiu JH, Lee TY: Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 2000;28: 2733–2736. Wunderink RG, Waterer GW, Cantor RM, Quasney MW: Tumor necrosis factor gene polymorphisms and the variable presentation and outcome of community-acquired pneumonia. Chest 2002;121:87S. Majetschak M, Flohe S, Obertacke U, Schroder J, Staubach K, Nast-Kolb D, Schade FU, Stuber F: Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 1999;230: 207–214. Waterer G, ElBahlawan L, Quasney M, Zhang Q, Kessler L, Wunderink R: Heat shock protein 70–2 1267 AA homozygotes have an increased risk of septic shock in adults with communityacquired pneumonia. Crit Care Med 2003;31:1367–1372. Yende S, Quasney MW, Tolley E, Zhang Q, Wunderink RG: Association of tumor necrosis factor gene polymorphisms and prolonged mechanical ventilation after coronary artery bypass surgery. Crit Care Med 2003;31:133–140. Treszl A, Toth-Heyn P, Kocsis I, Nobilis A, Schuler A, Tulassay T, Vasarhelyi B: Interleukin genetic variants and the risk of renal failure in infants with infection. Pediatr Nephrol 2002;17: 713–717. Jaber B, Rao M, Guo D, Balakrishnan V, Perianayagam M, Freeman R, Pereira B: Cytokine promoter gene polymorphisms and mortality in acute renal failure. Cytokine 2004;25:212–219. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P: Polymorphic haplotypes of the interleukin-10 5 flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999;42:1101–1108. van der Pol WL HT, Vidarsson G, van der Linden MW, Jansen MD, Keijsers V, de Straat FG, Westerdaal NA, de Winkel JG, Westendorp RG: Relevance of Fc-gamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 2001;184:1548–1555. Gallagher P, Lowe G, Fitzgerald T, Bella A, Greene C, McElvaney N, O’Neill S: Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 2003;58: 154–156. Lowe PR, Galley HF, Abdel-Fattah A, Webster NR: Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 2003;31:34–38. Ridker P, Stampfer M: Assessment of genetic markers for coronary thrombosis: Promise and precaution. Lancet 1999;353:687–688. Newman TB, Browner WS, Hulley SB: Enhancing causal inference in observational studies; in Hulley SB, Cummings SR (eds): Designing Clinical Research. Baltimore, Williams & Wilkins, 1988, pp 98–109. Jo S, Hu X, Kobayashi H, Lizak M, Miyaji T, Koretsky A, Star R: Detection of inflammation following renal ischemia by magnetic resonance imaging. Kidney Int 2003;64:43–51. Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: Inhibition of NF-kB activity through induction of IkB synthesis. Science 1995;270:286–290. Han J, Thompson P, Beutler B: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990;172:391–394.
Liangos/Balakrishnan/Pereira/Jaber
74
50 51 52
53
54 55
56 57
58 59
60
61
62
63 64 65 66
67
Doherty GM, Jensen JC, Alexander H, Buresh CM, Norton JA: Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991;110:192–198. Parry G, Mackman N: Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. J Immunol 1997;159:5450–5456. Semmler J, Wachtel H, Endres S: The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-production by human mono-nuclear cells. Int J Immunopharmacol 1993;15:409–413. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675–1680. Moore K, de Waal M, Coffman R, O’Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;765:683–765. Pajkrt D, Camoglio L, Tiel-van Buul M, de Bruin K, Cutler D, Affrime M, Rikken G, van der Poll T, ten Cate J, van Deventer S: Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: Effect of timing of recombinant human IL-10 administration. J Immunol 1997;158:3971–3977. Bermudez LE, Wu M, Young LS: Effect of stress-related hormones on macrophage receptors and response to tumor necrosis factor. Lymphokine Res 1990;9:137–145. Brenner S, Prosch S, Schenke-Layland K, Riese U, Gausmann U, Platzer C: cAMP-induced Interleukin-10 promoter activation depends on CCAAT/enhancer-binding protein expression and monocytic differentiation. J Biol Chem 2003;278:5597–5604. Mascali J, Cvietusa P, Negri J, Borish L: Anti-inflammatory effects of theophylline: Modulation of cytokine production. Ann Allergy Asthma Immunol 1996;77:34–38. Escofier N, Boichot E, Germain N, Silva P, Martins M, Lagente V: Effects of interleukin-10 and modulators of cyclic AMP formation on endotoxin-induced inflammation in rat lung. Fundam Clin Pharmacol 1999;13:96–101. van Furth A, Seijmonsbergen E, Langermans J, van der Meide P, van Furth R: Effect of xanthine derivates and dexamethasone on Streptococcus pneumoniae-stimulated production of tumor necrosis factor alpha, interleukin-1 beta (IL-1 beta), and IL-10 by human leukocytes. Clin Diagn Lab Immunol 1995;2:689–692. Cho M, Kim W, Min S, Min D, Min J, Lee S, Park S, Cho C, Kim H: Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes. Arthritis Rheum 2002;46:42–51. Tabardel Y, Duchateau J, Schmartz D, Marecaux G, Shahla M, Barvais L, Leclerc JL, Vincent JL: Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery 1996;119:76–80. Jaber BL, Liangos O, Pereira BJ, Balakrishnan VS: Polymorphism of immunomodulatory cytokine genes: Implications in acute renal failure. Blood Purif 2004;22:101–111. Nadel S, Newport MJ, Booy R, Levin M: Variation in the tumor necrosis factor-6 promoter region may be associated with death from meningococcal disease. J Infect Dis 1996;174:878–880. Zhang D, Li J, Jiang Z, Yu B, Tang X: Association of two polymorphisms of tumor necrosis factor gene with acute severe pancreatitis. J Surg Res 2003;112:138–143. Stuber F, Petersen M, Bokelmann F, Schade U: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996;24:381–384. Keijsers V, Verweij C, Westendorp R, et al: IL-10 promotor haplotypes: Discrepancy between lack of functionality in transfection assays and skewed distribution in meningococcal disease. Genes Immun 1999;1:78–79. Bertrand L. Jaber, MD Department of Medicine, Caritas St. Elizabeth’s Medical Center 736 Cambridge Street, Boston, MA 02135 (USA) Tel. 1 617 562 7832, Fax 1 617 562 7797, E-Mail
[email protected]
Cytokine Gene Polymorphism in Acute Renal Failure
75
Ronco C, Bellomo R, Brendolan A (eds): Sepsis, Kidney and Multiple Organ Dysfunction. Contrib Nephrol. Basel, Karger, 2004, vol 144, pp 76–93
Mechanisms of Immunodysregulation in Sepsis Jean-Marc Cavaillon, Catherine Fitting, Minou Adib-Conquy UP Cytokines and Inflammation, Institut Pasteur, Paris, France
Tissue injury, blood loss, hypoxia, transfusion, bacterial translocation, microbial infection, and cell activation by microbial products occur in patients with systemic inflammatory response syndrome (SIRS) (e.g. trauma, hemorrhage, burns, surgery or sepsis). These events contribute to the inflammatory response and affect the quality of the immune status. In addition, drugs (e.g. anesthetics, opioids…) also influence immune responses (fig. 1). Depressed immune status including decreased blood cell counts, low expression of surface markers (e.g. MHC class II antigen), altered natural killer (NK) cell activity, diminished cellular cytotoxicity, reduced antigen presentation, poor proliferation in response to mitogens and depressed cytokine production, are seen in vitro, and illustrated in vivo by anergy to skin test antigens. These observations led Bone [1] to coin the concept of ‘compensatory anti-inflammatory response syndrome’ or CARS. Bone postulated that when the SIRS response predominates, the syndrome is associated with an organ dysfunction and cardiovascular compromisation leading to shock; in contrast, when CARS predominates, it is characterized by anti-inflammatory responses associated with a suppressive effect on the immune system, also known as ‘immunoparalysis’. However, this term is far too excessive and we will see that the alteration of the immune response is not a generalized phenomenon. It was initially accepted that the SIRS response occurred first and was followed in some patients by the CARS response. However, it is most probable that the two syndromes occur concomitantly [2]. Although alterations in immune responses are probably associated with an enhanced sensitivity to nosocomial infections, there is no clear demonstration that they are directly responsible for poor outcome in sepsis. Furthermore, the mechanisms behind the maintenance of the sustained suppression of the immune function remain incompletely understood.
Trauma—Hemorrhage—Burns—Surgery—Sepsis
Anesthetics Hypoxia
Blood loss Transfusion
Opioids Tissue injury Microbial agents
Bacterial translocation
Inflammatory response
Lymphocyte and monocyte populations changes
Immune status
Cell surface markers changes (e.g. HLA DR)
Anergy to skin test antigens
Immune dysregulation
Apoptosis Lymphocyte proliferation NK activity
Cytokine production
Fig. 1. Numerous events occurring during systemic inflammatory response syndrome contribute to modify the immune status as illustrated by various altered immune responsiveness that can be monitored either in vitro, ex vivo or in vivo.
Assessment of Immunodysregulation
Circulating Leukocytes and HLA-DR Expression The absolute number of circulating cells is modified during sepsis. Analysis of lymphocyte subsets reveal a decreased number of circulating NK cells, CD4⫹, and CD8⫹ lymphocytes, and an increase of B lymphocytes [3] and of regulatory T cells (CD4⫹/CD25⫹) [4]. Within monocytes, the subset of CD14low/CD16⫹ cells is increased [5]. In a mouse model of sepsis, an enhanced number of NK-T cells found in the spleen has been associated with immune suppression [6]. Abnormal antigen presentation has been observed in SIRS patients [7], and decreased HLA-DR expression on monocytes may contribute to this defect [8]. In a study by Hershman et al. [9], there was a significant decrease of
Mechanisms of Immunodysregulation in Sepsis
77
HLA-DR expression on peripheral blood monocytes of trauma patients as compared to that of healthy volunteers. In those who developed sepsis, HLA-DR expression took 3 weeks to return to normal and in the patients who did not survive, this expression never returned to normal. HLA-DR antigen expression correlated directly with the clinical status and identified a group of patients at high risk of infection and death following trauma. Low HLA-DR expression is now widely recognized as a good marker of the intensity of the immune depression and of increased risk of bacterial infection [10]. In an elegant study, Fumeaux and Pugin [11] showed that the presence of circulating IL-10 in septic plasma was partially responsible of the reduced HLA-DR expression following intracellular sequestration of the molecule. Lymphocyte Proliferation Impaired lymphocyte proliferation in SIRS patients was reported more than three decades ago [12]. The impairment was proportional to the severity of the injury. In vitro, lymphocyte proliferative response to antigens, mitogens and mixed lymphocyte reaction are all significantly decreased. Longer depression of lymphocyte responses and lower responses were observed in patients who became infected and developed sepsis [13–15]. Increased level of apoptosis is not directly associated with lowered T-cell proliferative response [16]. However, a profound apoptosis of B and T lymphocytes has been found in humans [17, 18], and it has been established that prevention of lymphocyte apoptosis improves survival in a sepsis model in mice [19]. Natural Killer Cell Activity Significantly depressed NK cell activity has been described in burn and trauma patients. In the study by Maturana et al. [20], patients with septic shock had also a markedly lower NK activity than healthy controls. Pre-incubation of peripheral blood lymphocytes with either interferon-␣ (IFN␣) or interleukin-2 (IL-2) enhanced NK cell activity in healthy controls but not in patients with sepsis indicating the difficulty to reverse the depressed immune responsiveness [21]. Neutrophil Functions Apoptosis of circulating neutrophils (PMN) is delayed in patients with SIRS or sepsis [22], and mRNA expression of Mcl-1, an anti-apoptotic member of the Bcl-2 family, is upregulated in PMN of patients with sepsis [23]. In addition, some of the activities mediated by PMN appear to be altered. This is the case of phagocytosis, bactericidal activity [24] and migration [25]. The reduced responsiveness of PMN to chemoattractant agents may reflect the action of nitric oxide [25], the decreased expression of certain chemokine receptors [26], or a deactivation occurring in the blood stream after interacting
Cavaillon/Fitting/Adib-Conquy
78
with large amounts of circulating chemokines as assessed, for example, by the huge amounts of IL-8 found associated to PMN in septic patients [27]. Delayed Hypersensitivity The in vitro evidence of immune depression is also reflected in vivo by tests of delayed type hypersensitivity. Several years ago, Christou et al. [28] skin tested surgical patients with recall antigens prior to operation. Patients who had normal skin test responses were of similar age and had equal degrees of surgical procedures performed compared with those patients who were anergic (i.e. had depressed skin test responses). Post-operatively, sepsis, mortality and death due to sepsis were significantly higher in the anergic population, reconfirming the hypothesis that skin test anergy pre-operatively is a signal of increased risk for septic complications and death in such patients. These authors [29] reported that surgical patients who were anergic to a battery of five skin test antigens had a two-fold higher rate of postoperative infection than those who reacted to only two antigens and were more than fivefold likely to die in the post-operative period. The hallmark of anergy is a lack of recruited specific T cells at the site of injection in the skin [30]. Ex vivo Cytokine Production A reduced capacity of circulating leukocytes from septic patients to produce pro-inflammatory cytokines as compared to cells from healthy controls has been regularly reported in ex vivo experiments. The very first observation on the hyporeactivity of circulating cells in septic patients was demonstrated in peripheral blood lymphocytes: Wood et al. [31] reported a decreased IL-2 production upon phytohemagglutinin (PHA) stimulation. Interferon-␥ (IFN␥) production is affected in sepsis as well as in patients with severe injury [32]. It is often suggested that the depressed response mainly affects the production of Th1 cytokines (IL-2, IFN␥) whereas production of Th2 cytokines would be upregulated. However, we demonstrated in sepsis and in SIRS patients that the production of Th2 cytokines (IL-5, IL-10) could also be altered and that the nature of the triggering agent itself influences the observation [33]. Similarly, in patients resuscitated after cardiac arrest, identified as a sepsis-like syndrome, we showed that both concanavalin A-induced IL-10 (Th2) and IFN␥ (Th1) productions were significantly decreased in ex vivo assays [34]. Similarly, ex vivo cytokine production (IL-1, IL-1ra and IL-8) by LPSactivated neutrophils from septic patients is reduced as compared to PMN of healthy controls [35–37]. Most interestingly, van der Poll’s group [38] demonstrated that injection of endotoxin in healthy human volunteers led to hyporeactive blood derived-PMN in terms of production of the chemokines IL-8,
Mechanisms of Immunodysregulation in Sepsis
79
GRO-␣ and ENA-78, when further challenged in vitro with either LPS, heatkilled Streptococcus pneumoniae or heat-killed Pseudomonas aeruginosa. The reactivity to LPS stimulation has been particularly studied in isolated monocytes and in whole-blood assays. Monocytes from septic patients have a diminished capacity to release TNF␣, IL-1␣, IL-1, IL-6, IL-10 and IL-12 [32, 39–42], whereas this is not the case for IL-1ra [40] and G-CSF [43]. In human volunteers, intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells (PBMC) when activated in vitro by LPS [44]. Most interestingly, it was shown that the reduced production of cytokines reflects a reduced number of cytokine-producing cells [45]. Many parameters of immmunoparalysis observed in SIRS patients are reminiscent of the endotoxin tolerance phenomenon, which characterizes the refractoriness of cells or whole animals to respond to a second endotoxin challenge, shortly after a first encounter. Cross-tolerance has been regularly reported in experimental models of endotoxin tolerance between LPS and other Toll-like receptors (TLR), ligands [46–48] or whole bacteria [49, 50]. Similarly, in sepsis patients and in LPS-injected human volunteers a reduced responsiveness to gram-positive bacteria and superantigens have been reported [44, 51–53]. However, this is not always the case and we showed that in SIRS patients, cells normally responded to certain stimuli [54]. Revisiting the crosstolerance with gram-positive bacteria in a mouse model of endotoxin tolerance, we showed that the phenomenon was only transient, especially in the blood compartment [55]. In addition to the nature of the stimuli, there are other observations that allow ascertaining that the cellular hyporeactivity is not a global phenomenon. For example, we showed that the release of ‘macrophage migration inhibitory factor’ (MIF) by circulating mononuclear cells was enhanced in sepsis [Maxime et al., submitted]. Furthermore, during sepsis and SIRS, cells derived from tissues are either fully responsive to ex vivo stimuli, or even primed, in contrast to cells derived from hematopoietic compartments (blood, spleen…), which are hyporeactive. This dichotomy illustrates the concept of compartmentalization, which occurs within the body during sepsis [56]. Thus, during systemic inflammation, SIRS and CARS seem to be present concomitantly [2]: SIRS predominating within the inflamed tissues, while in the blood the leukocytes show hyporeactivity.
Concept of Compartmentalization
The measurement of inflammatory mediators is in agreement with the concept of a compartmentalization of inflammation. For example, iNOS activity
Cavaillon/Fitting/Adib-Conquy
80
was found to be restricted to the nidus of infection in patients undergoing a septic shock after cellulitis [57]. TNF and IL-6 concentrations were higher in cerebrospinal fluids than in plasma of patients with meningitis [58]. After chest trauma, significantly higher levels of IL-1 and IL-8 were found in bronchoalveolar lavage fluids than in plasma, whereas anti-inflammatory mediators (sTNFRI and II, IL-1ra) were present both locally and systematically [59]. Measurement of pro-inflammatory cytokines and anti-inflammatory mediators in pleural fluids also suggested the occurrence of both systemic and compartmentalized response in septic as well as in non-septic patients [60]. Finally, the compartmentalized cytokine production was elegantly demonstrated by Dehoux et al. [61] who showed higher levels of inflammatory cytokines in broncho-alveolar lavage (BAL) fluids recovered from involved lung of patients with unilateral pneumonia as compared to the contralateral, non-involved lung. In this study, the authors showed that the productions of IL-1, IL-6, and TNF by alveolar macrophages activated with LPS were reduced as compared to the responses obtained with cells recovered from healthy controls. However, in contrast to this report, which deals with a local infectious process, and in contrast to the hyporeactivity of the circulating leukocytes, it has often been shown that cells derived from the inflamed tissues are activated and primed and fully responsive to ex vivo stimulation. In acute respiratory distress syndrome (ARDS) patients, alveolar macrophages displayed an enhanced capacity of producing IL-1 after ex vivo stimulation with LPS alone or together with IFN␥ [62]. Interestingly, in human volunteers, Smith et al. [63] reported that intravenous endotoxin primed alveolar macrophages for an enhanced in vitro LPSinduced production of IL-1, TNF and PGE2. We analyzed the reactivity of alveolar macrophages derived from baboons that had undergone unilateral lung irradiation. In the days following irradiation, not only the spontaneous production of IL-8 and TNF was enhanced, but those induced by LPS, Staphylococcus and Streptococcus were increased as compared to the response obtained with the alveolar macrophages recovered before irradiation [2]. The study of peritoneal macrophages obtained from continuous ambulatory peritoneal dialysis patients revealed that LPS-activated cells released significantly more IL-1 during peritonitis as compared with the infection-free period [64]. In women with endometriosis, spontaneous and LPS-induced production of TNF␣, IL-6, IL-8, IL-10, IL-12 and nitric oxide (NO) by peritoneal macrophages was higher than in controls [65, 66]. In patients with inflammatory bowel disease, adherent lamina propria mononuclear cells activated with pokeweed mitogen or with a combination of LPS and IFN␥ displayed an upregulated production of TNF␣, IL-1␣, IL-1 and IL-6 [67]. The activation of intracellular signaling pathways has also been studied. Schwartz et al. [68] observed an increased activation of NF-B in alveolar
Mechanisms of Immunodysregulation in Sepsis
81
macrophages from patients with ARDS. Moine et al. [69] subsequently showed decreased cytoplasmic levels of p50, p65 and c-Rel in alveolar macrophages from patients with ARDS, consistent with an enhanced migration of liberated NF-B dimers from the cytoplasm to the nucleus. In murine models of hemorrhage or of endotoxinemia, activation of NF-B, CREB, MEK-1/2 and Erk2 were found in alveolar neutrophils but not in blood neutrophils [70, 71]. It is worth noting that cells derived from inflammatory foci may be far less sensitive to anti-inflammatory mediators. This was elegantly demonstrated by Pang et al. [72] who showed, in chronic bronchial sepsis patients, that the production of IL-8 by PMN derived from sputum was not significantly reduced by the addition of increasing amounts of IL-10 in contrast to the inhibitory effect of IL-10 on circulating PMN. Similarly, we showed in cystic fibrosis patients that sputum-derived PMN that produce high levels of IL-8 were poorly downregulated by dexamethasone in contrast to circulating PMN [73].
Mechanisms of Hyporesponsiveness of Monocytes
Desensitizing Agents in Plasma The presence of deactivating or immunosuppressive agents within the blood stream may contribute to the hyporeactivity of circulating leukocytes. In the late 70’, it was reported that sera of burn patients were able to suppress the proliferative response of normal cells [74]. Prins et al. [75] showed that sera from septic patients had the capacity to downregulate the TNF production by activated monocytes from healthy donors. The fact that ‘septic plasma’ behave as an immunosuppressive milieu [76] is illustrated in human volunteers by the capacity of endotoxin to induce plasma inhibitors [77]. Most interestingly, in septic patients this suppressive effect was significantly reduced after passage of plasma through a resin and after incubation with anti-IL-10 antibodies [78]. IL-10 was identified as a major functional deactivator of monocytes in human septic shock plasma [79]. TGF was also shown in animal models of hemorrhagic shock and of sepsis to be the causative agent of the depressed splenocyte responsiveness [80]. Monocytes from immunocompromised trauma patients seem to be a source of TGF [81], and TGF released by apoptotic T cells contributes to this immunosuppressive milieu [82]. In addition, there is accumulating evidence for a strong interaction between components of the nervous and the immune systems. Numerous neuromediators have been shown to behave as immunosuppressors. Catecholamines, found to be at higher concentrations in stressful situations [83], suppress the activity of immunocompetent cells, inhibit TNF production and favor IL-10 release. Alpha-melanocyte-stimulating hormone also contributes to immunosuppression by inducing IL-10 production
Cavaillon/Fitting/Adib-Conquy
82
by human monocytes [84]. In addition, vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide directly inhibit endotoxin induced pro-inflammatory cytokine secretion [85]. SIRS is also associated with an activation of the hypothalamus-pituitary-adrenal axis which leads to the release of glucocorticoids, well known for their potent ability to limit cytokine production [86]. Prostaglandins are produced during sepsis and can also contribute to the down regulation of cytokine production [87]. Finally, the levels of circulating heat shock proteins (HSP) are elevated in SIRS and sepsis patients [88]. Since it has been shown that over-expression of HSP can inhibit LPS induced production of cytokines [89], one can postulate that HSP may play a role in desensitizing circulating cells. Endotoxin-Neutralizing Molecules in Plasma As mentioned previously, the reduced capacity of monocytes to produce inflammatory cytokines has been particularly established using LPS as a triggering agent. Since numerous recent studies analyzed the hyporeactivity phenomenon with whole blood samples, it is possible that endotoxin-neutralizing molecules interfered in these studies. Indeed, we showed that the hyporeactivity to LPS was both, an intrinsic property of circulating monocytes, as well as the reflection of a specific neutralizing activity within the plasma of SIRS patients [90]. It has been reported that plasma of septic patients content large amounts of LPS-binding protein (LBP) which can either inhibit the LPS molecules [91], or transfer LPS to lipoproteins [92] known for their inhibitory activity towards LPS [93]. Furthermore, sera from septic patients contain great amounts of soluble CD14 which also favors the shuttle of LPS towards lipoproteins [94]. More recently, enhanced levels of ubiquitin, an 8.6-kD protein involved in intracellular function, have been found in serum of sepsis and trauma patients and shown to specifically inhibit TNF induction by LPS [95]. Toll-Like Receptor Expression Toll-like receptors (TLR) are a family of receptors that recognize components of bacteria, virus, parasites and fungi and induce a pro-inflammatory response by several cell types. So far, 10 human TLRs differing in their specificity for microbial components have been cloned, which respond to various components, including LPS from Gram-negative bacteria, lipopeptides of Gram-positive cell walls, bacterial DNA, and flagella. TLR4 was identified as the receptor for LPS and requires the presence of an extracellular accessory protein called MD-2. CD14 physically associates with LPS complexed with LPS binding protein (LBP) and transfers the endotoxin to the TLR4 and MD-2 dimer. Each component of this complex is required for efficient LPS-induced signaling.
Mechanisms of Immunodysregulation in Sepsis
83
Recent studies reported a downregulation of surface expression of TLR4 in endotoxin-tolerant macrophages [96, 97]. Therefore, it was of interest to investigate the expression of this molecule on the surface of monocytes from SIRS patients. A decreased expression of TLR4 but not TLR2, on CD14-positive cells was found in trauma patients compared with healthy subjects [54]. However, this lower expression of TLR4 was not sufficient to explain the decreased capacity of the cells to respond to some stimuli. Indeed, while LPS-induced TNF was decreased, this was not the case of LPS-induced IL-1ra and IL-10. This later observation suggests that the defect may occur at the level of the signaling pathways within the cell leading to TNF production, rather than at the initiation of the signaling cascade on the cell surface. In contrast to our observation, an enhanced expression of TLR4 was found on monocytes of SIRS patients [98], and at the present time we don’t have any explanations for these divergent findings. Nuclear Factor-kB Nuclear factor-B (NF-B) is critical for maximal expression of many cytokines involved in the pathogenesis of inflammation. Activation and regulation of NF-B are tightly controlled by a group of inhibitory proteins (IB), which maintain NF-B in the cytoplasm of effector cells. Blackwell et al. [99] investigated the role of NF-B in the mechanism of endotoxin tolerance in a rat alveolar macrophage cell line, which was made endotoxin-tolerant. This treatment induced a state of tolerance such that subsequent exposure to high-dose LPS resulted in decreased production of cytokines as compared to LPSsensitive cells. This decreased cytokine production was associated with an impaired activation of NF-B and a depletion of both p65 and p50 forms. This study suggested that endotoxin tolerance may be mediated by limiting the amount of NF-B available for activation and thus, inhibiting transcription of NF-B-dependent genes. On the other hand, Ziegler-Heitbrock et al. [100] demonstrated that endotoxin tolerance in monocyte cell line was associated with an increase of the inactive p50 homodimer of NF-B and a decrease of the p50p65 active heterodimer. Accordingly, we studied NF-B expression and dimer characteristics in mononuclear cells of patients with severe sepsis or major trauma and of healthy controls [101, 102]. The expression of p65p50 heterodimer was significantly reduced for all patients as compared to controls. The p50p50 homodimer was reduced in the survivors of sepsis. In addition, subsequent in vitro stimulation of PBMC with LPS did not induced further NF-B nuclear translocation: the survivors of sepsis showed low expression of both p65p50 and p50p50, while non-survivors of sepsis showed a predominance of the inactive homodimer and a low p65p50/p50p50 ratio when compared to controls. In the later group of patients there was a reverse correlation between plasma IL-10 levels and the p65p50/p50p50 ratio after in vitro LPS stimulation
Cavaillon/Fitting/Adib-Conquy
84
(r ⫽ ⫺0.8, p ⫽ 0.04). The reduced expression of nuclear NF-B was not due to its inhibition by IB␣, since very low expression of IB␣, and low levels of p65 and p50 were found in the cytoplasm of PBMC from sepsis patients when compared to controls. These results demonstrate that upon LPS activation, PBMC of SIRS patients show patterns of NF-B expression that resemble those reported during LPS tolerance: global downregulation of NF-B in survivors of sepsis, presence of large amounts of the inactive homodimer in the non-survivors of sepsis [101]. In trauma patients, we observed a long-term reduction of both p65/p50 heterodimers and p50/p50 homodimers and a reduced p65p50/p50p50 ratio after LPS stimulation in vitro [102]. Other mechanisms of NF-B regulation have been reported in a rat model of sepsis for which the reduced capacity of PMN to produce TNF was associated with an increased generation of IB␣ caused by the intrinsic generation of C5a [103]. Downregulation of TLR-Associated Signaling Pathways There are still very few studies, which have addressed in humans the link between immunodepression seen in circulating cells in SIRS patients and alteration of some signaling pathways. In the past few years, numerous intracellular molecules that negatively regulate LPS-activated signaling pathways have been discovered (table 1). This is the case of Toll-interacting protein (Tollip), an adaptor protein found to associate with the cytoplasmic TIR domain of IL-1R, TLR2 and TLR4 and to potently suppress the activity of IL-1 receptor associated kinase (IRAK) after TLR activation [104]. A splice variant of MyD88, termed MyD88s, induced upon LPS activation has been described. This molecule is defective in its ability to induce IRAK phosphorylation and behaves as dominant-negative inhibitor [105]. Single immunoglobulin IL-1R-related molecule (SIGIRR) and ST2, members of the TLR/IL-1R superfamily, are negative modulators of the signaling induced by IL-1 or TLR ligands in different types of cells [106a, 106b]. RanGTPase plays a major role in nuclear trafficking and reduces NF-B accumulation in the nucleus. As a consequence it acts as a dominant-negative regulator of LPS-induced TNF [107]. IRAK-M prevents the dissociation of IRAK and IRAK-4 from MyD88 and the formation of IRAK-TRAF6 complexes, and is a negative regulator of TLR signaling. Interestingly, endotoxin tolerance is significantly reduced in IRAK-M-deficient mice [108]. It has been recently reported that monocytes from septic patients when stimulated with LPS ex vivo, express IRAK-M mRNA more rapidly than cells from healthy donors [109]. Similarly to IRAK-M⫺/⫺ mice, endotoxin tolerance cannot be observed in mice deficient for suppressor of cytokine signaling-1 (SOCS-1) [110]. In contrast to IRAK-M and SOCS-1 that function during the second or continuous exposure to stimulation, phosphatidylinositol 3-kinase (pi3K) can behave as an early inhibitor of TLR signaling [111]. Learn et al. [112] reported in septic patients that the repressed
Mechanisms of Immunodysregulation in Sepsis
85
Table 1. Negative regulators of LPS-induced TNF production Mediators
Mechanisms
Found in mouse models (M) or in human (H) SIRS
p50/p50 NF-B homodimer IRAK-M
prevents action of bioactive p65/p50 heterodimer prevents dissociation of IRAK and IRAK-4 from MyD88 and formation of IRAKTRAF6 complexes early negative signal, favors IL-1Ra production dominant-negative inhibitor of MyD88 associates with the cytoplasmic TIR domain interacts with IL-1R, TLR4, 5 and 9 and TRAF6 sequestration of adaptators MyD88 and TIRAF/Mal reduces NF-B accumulation in the nucleus inactivation of STAT-1 and NF-B induced by IL-10 induced by IL-10 induced by IL-10 induced by IL-10
H, M
Pi3K MyD88s Tollip SIGIRR ST2 RanGTPase SOCS-1 SOCS-3 Bcl-3 Stat-3 HO-1
H, M H n.d. n.d. n.d. n.d. n.d. M M n.d. M H
HO-1 ⫽ Heme oxygenase-1; IRAK ⫽ IL-1 receptor-associated kinase; NF-B ⫽ nuclear factor-B; pi3K ⫽ phosphatidylinositol 3-kinase; SIGIRR ⫽ single immunoglobulin IL-1Rrelated molecule; SOCS ⫽ suppressor of cytokine signaling; STAT-1 ⫽ signal transducer and activator of transcription; Tollip ⫽ Toll-interacting protein; TRAF-6 ⫽ TNF receptorassociated factor-6. n.d. ⫽ Not determined (see text for references).
production of IL-1 and the selective elevation of secreted form of IL-1Ra in response to LPS was linked to a probably altered IRAK signaling pathway and a maintained efficient pi3K dependent signaling pathway. In addition to negative regulators directly induced upon activation by TLR ligands, other molecules induced by IL-10 can be involved such as heme oxygenase-1 [113], Bcl-3 [114], Stat-3 [115], or SOCS-3 [116]. Indeed, in an experimental model of sepsis, an upregulation of SOCS-3 was noticed in macrophages and neutrophils present in spleen, lung and peritoneal cavity [117].
Cavaillon/Fitting/Adib-Conquy
86
Reversal of Monocytes Hyporeactivity IFN␥ and GM-CSF can restore the responsiveness of monocytes from SIRS and sepsis patients [118–120]. These observations are reminiscent of the well-known capacity of these cytokines to reverse endotoxin tolerance [121, 122]. Whether an in vivo treatment by these cytokines could have beneficial effects remains to be fully established. Indeed, it is still unclear whether this immune alteration is responsible of poor outcome or only a reflect of a physiological adaptation. In this context, it is worth to mention the fact that extracorporeal immunotherapy with IL-2 lowered mortality of surgical infection [123]. Alteration or Physiological Adaptation?
Sepsis and non-infectious SIRS are paradoxically associated with an exacerbated production of cytokines, as assessed by their presence in biological fluids, and a diminished ability of circulating cells to produce cytokine upon in vitro activation. This may represent a protective response against an overwhelming dysregulation of the pro-inflammatory process, but on the other hand it may alter the immune status (‘endogenous immunosuppression’) leading to an increased risk of subsequent nosocomial infections [56]. However, cellular hyporeactivity is not a global phenomenon and some signaling pathways are unaltered and allow the cells to respond normally to certain stimuli. Furthermore, during sepsis and SIRS, cells derived from tissues or inflammatory foci are either fully responsive to ex vivo stimuli or even primed, in contrast to cells derived from hematopoietic compartments (blood) that are hyporeactive. The first analysis of intracellular signaling pathways within leukocytes of sepsis patients revealed that some alterations are associated with cellular hyporeactivity. Thus, the immunodysregulation reported in sepsis and SIRS patients, often illustrated by a diminished capacity of leukocytes to respond to LPS, is not a generalized phenomenon and SIRS is associated with a compartmentalized responsiveness, which involves either anergic or primed cells. References 1 2
3 4
Bone RC, Grodzin CJ, Balk RA: Sepsis: A new hypothesis for pathogenesis of the disease process. Chest 1997;121:235–243. Cavaillon J-M, Adib-Conquy M, Cloëz-Tayarani I, Fitting C: Immunodepression in sepsis and SIRS assessed by ex vivo cytokine production is not a generalized phenomenon: A review. J Endotoxin Res 2001;7:85–93. Holub M, Kluckova Z, Beneda B, et al: Changes in lymphocyte subpopulations and CD3⫹/DR⫹ expression in sepsis. Clin Microbiol Infect 2000;6:657–660. Monneret G, Debard AL, Venet F, et al: Marked elevation of human circulating CD4⫹CD25⫹ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med 2003;31:2068–2071.
Mechanisms of Immunodysregulation in Sepsis
87
5
6 7 8 9 10
11 12 13 14 15
16 17 18 19 20 21
22 23 24 25 26 27 28 29 30
Fingerle G, Pforte A, Passlick B, Blumenstein M, Strobel M, Ziegler-Heitbrock HWL: The novel subset of CD14⫹/CD16⫹ blood monocytes is expanded in sepsis patients. Blood 1993;82: 3170–3176. Rhee R, Carlton S, Lomas J, et al: Inhibition of CD1d activation suppresses septic mortality: A role for NK-T cells in septic immune dysfunction. J Surg Res 2003;115:74–81. Polk HJ, George CD, Wellhausen S, et al: A systematic study of host defense processes in badly injured patients. Ann Surg 1986;204:282–299. Livingston D, Appel S, Wellhausen S, Polk H: Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg 1988;123:1309–1312. Hershman MJ, Cheadle WG, Wellhausen SR, Davidon P, Polk HC: Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patients. Br J Surg 1990;77:204–207. van den Berk JMM, Oldenburger RHJ, van den Berg AP, et al: Low HLA DR expression on monocytes as a prognostic marker for bacterial sespsis after liver transplantation. Transplantation 1997; 63:1846–1848. Fumeaux T, Pugin J: Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 2002;166:1475–1482. Salo M, Merikanto J, Eskola J, Nieminen S, Aho AJ: Impaired lymphocyte transformation after accidental trauma. Acta Chir Scand 1970;145:367–372. Baker C, Miller C, Trunkey D: Predicting fatal sepsis in burn patients. J Trauma 1979;19:641–648. Keane R, Birmingham W, Shatney C, Winchurch R, Munster A: Prediction of sepsis in the multitraumatic patients by assays of lymphocyte responsiveness. Surg Gynecol Obstet 1983;156:163–167. Levy EM, Alharbi SA, Grindlinger G, Black PH: Changes in mitogen responsiveness lymphocytes subsets after traumatic injury: Relation to development of sepsis. Clin Immunol Immunopathol 1984;32:224–233. Pellegrini J, De A, Kodys K, Puyana J, Furse R, Miller-Graziano C: Relationships between T lymphocyte apoptosis and anergy following trauma. J Surg Res 2000;88:200–206. Hotchkiss RS, Tinsley KW, Swanson PE, et al: Sepsis-induced apoptosis causes progressive profound depletion of B and CD4⫹ T lymphocytes in humans. J Immunol 2001;166:6952–6963. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003;348: 138–150. Hotchkiss RS, Tinsley KW, Swanson PE, et al: Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 1999;96:14541–14546. Maturana P, Puente J, Miranda D, Sepulveda C, Wolf ME, Mosnaim AD: Natural killer cell activity in patients with septic shock. J Crit Care 1991;6:42–45. Puente J, Carvajal T, Parra S, et al: In vitro studies of natural killer cell activity in septic shock patients: Response to a challenge with alpha-interferon and interleukin-2. Int J Clin Pharmacol Ther Toxicol 1993;31:271–275. Jimenez M, Watson R, Parodo J, et al: Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch Surg 1997;132:1263–1269. Harter L, Mica L, Stocker R, Trentz O, Keel M: Mcl-1 correlates with reduced apoptosis in neutrophils from patients with sepsis. J Am Coll Surg 2003;197:964–973. van Dijk W, Verbrugh H, van der Tol M, et al: Interactions of phagocytic and bacterial cells in patients with bacteremia caused by gram-negative rods. J Infect Dis 1980;141:441–449. Benjamim C, Ferreira S, Cunha F: Role of nitric oxide in the failure of neutrophil migration in sepsis. J Infect Dis 2000;182:214–223. Cummings CJ, Martin TR, Frevert CW, et al: Expression and function of the chemokine receptor CXCR1 and CXCR2 in sepsis. J Immunol 1999;162:2341–2346. Marie C, Fitting C, Cheval C, et al: Presence of high levels of leukocyte-associated interleukin-8 upon cell activation and in patients with sepsis syndrome. Infect Immun 1997;65:865–871. Christou NV: Host defense mechanism in surgical patients: A correlation study of the delayed hypersensitivity skin test response, granulocyte function and sepsis. Can J Surg 1985;28:39–49. Christou NV, Meakins JL, MacLean LD: The predictive role of delayed hypersensitivity in preoperative patients. Surg Gynecol Obstet 1981;152:297–301. Christou N, Meakins J, Gordon J, et al: The delayed hypersensitivity response and host resistance in surgical patients: 20 years later. Ann Surg 1995;222:534–546.
Cavaillon/Fitting/Adib-Conquy
88
31 32 33 34 35
36
37
38
39 40
41 42 43 44 45
46
47
48
49 50 51
52
Wood J, Rodrick M, O’Mahony J, et al: Inadequate interleukin 2 production: A fundamental immunological deficiency in patients with major burns. Ann Surg 1984;200:311–320. Ertel W, Keel M, Neidhardt R, et al: Inhibition of the defense system stimulating interleukin-12 interferon-␥ pathway during critical illness. Blood 1997;89:1612–1620. Muret J, Marie C, Fitting C, Payen D, Cavaillon J-M: Ex vivo T-lymphocyte derived cytokine production in SIRS patients is influenced by experimental procedures. Shock 2000;13:169–174. Adrie C, Adib-Conquy M, Laurent I, et al: Successful cardiopulmonary resuscitation after cardiac arrest as a ‘sepsis like’ syndrome. Circulation 2002;106:562–568. McCall CE, Grosso-Wilmoth LM, LaRue K, Guzman RN, Cousart SL: Tolerance to endotoxininduced expression of the interleukin-1ß gene in blood neutrophils of humans with the sepsis syndrome. J Clin Invest 1993;91:853–861. Marie C, Muret J, Fitting C, Losser M-R, Payen D, Cavaillon J-M: Reduced ex vivo interleukin-8 production by neutrophils in septic and non-septic systemic inflammatory response syndrome. Blood 1998;91:3439–3446. Marie C, Muret J, Fitting C, Payen D, Cavaillon J-M: IL-1 receptor antagonist production during infectious and noninfectious systemic inflammatory response syndrome. Crit Care Med 2000; 28:2277–2283. Schultz MJ, Olszyna DP, de Jonge E, Verbon A, van Deventer SJH, van der Poll T: Reduced ex vivo chemokine production by polymorphonuclear cells after in vivo exposure of normal humans to endotoxin. J Infect Dis 2000;182:1264–1267. Muñoz C, Misset B, Fitting C, Bleriot JP, Carlet J, Cavaillon J-M: Dissociation between plasma and monocyte-associated cytokines during sepsis. Eur J Immunol 1991;21:2177–2184. Van Deuren M, Van Der Ven-Jongekrijg H, Demacker PNM, et al: Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis 1994;169:157–161. Marchant A, Alegre M, Hakim A, et al: Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol 1995;15:265–272. Randow F, Syrbe U, Meisel C, et al: Mechanism of endotoxin desensitization: Involvement of interleukin-10 and transforming growth factor-. J Exp Med 1995;181:1887–1892. Weiss M, Fisher G, Barth E, et al: Dissociation of LPS-induced monocytic ex vivo production of granulocyte colony stimulating factor and TNF␣ in patients with septic shock. Cytokine 2000;13:51–54. Granowitz EV, Porat R, Mier JW, et al: Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol 1993;151:1637–1645. Spolarics Z, Siddiqi M, Siegel J, et al: Depressed interleukin-12-producing activity by monocytes correlates with adverse clinical course and a shift toward Th2-type lymphocyte pattern in severely injured male trauma patients. Crit Care Med 2003;31:1722–1729. Kreutz M, Ackerman U, Hauschildt S, et al: A comparative analysis of cytokine production and tolerance induction by bacterial lipopetides, lipopolysaccharides and Staphylococcus aureus in human monocytes. Immunology 1997;92:396–401. Crabtree TD, Jin L, Raymond DP, et al: Preexposure of murine macrophages to CpG oligonucleotide results in a biphasic tumor necrosis factor alpha response to subsequent lipopolysaccharide challenge. Infect Immun 2001;69:2123–2129. Lehner MD, Morath S, Michelsen KS, Schumann RR, Hartung T: Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different toll-like receptors independent of paracrine mediators. J Immunol 2001;166:5161–5167. Cavaillon JM, Pitton C, Fitting C: Endotoxin tolerance is not a LPS-specific phenomenon: Partial mimicry with IL-1, IL-10 and TGF. J Endotoxin Res 1994;1:21–29. Nose M, Uzawa A, Nomura M, et al: Control of endotoxin shock by the dried preparation of low virulent Streptococcus pyogenes OK-432. Cell Immunol 1998;188:97–104. Cavaillon J-M, Muñoz C, Marty C, et al: Cytokine production by monocytes from patients with sepsis syndrome and by endotoxin-tolerant monocytes; in Levin J, Alving CR, Munford RS, Stütz PL (eds): Bacterial Endotoxin: Recognition and Effector Mechanisms. Amsterdam, Elsevier, 1993. Astiz ME, Saha DC, Brooks K, Carpati CM, Rackow EC: Comparison of the induction of endotoxin tolerance in endotoxemia and peritonitis by monophosphoryl lipid A and lipopolysaccharide. Circulatory Shock 1993;39:194–198.
Mechanisms of Immunodysregulation in Sepsis
89
53 54
55 56 57 58 59
60
61 62 63
64
65 66
67
68 69 70
71
72 73 74 75
Wilhelm W, Grundmann U, Rensing H, et al: Monocyte deactivation in severe human sepsis or following cardiopulmonary bypass. Shock 2002;17:354–360. Adib-Conquy M, Moine P, Asehnoune K, et al: Toll-like receptor (TLR) 2-, TLR4- and TLR9mediated TNF and IL-10 production are not similarly affected during systemic inflammation. Am J Resp Crit Care Med 2003;168:158–164. Fitting C, Dhawan S, Cavaillon JM: Compartmentalisation of endotoxin tolerance. J Infect Dis 2004;189:1295–1303. Munford RS, Pugin J: Normal response to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001;163:316–321. Annane D, Sanquer S, Sébille V, et al: Compartmentalised inducible nitric-oxide synthase activity in septic shock. Lancet 2000;355:1143–1148. Waage A, Halstensen A, Espevik T, Brandzaeg P: Compartmentalization of TNF and IL-6 in meningitis and septic shock. Mediators Inflam 1993;2:23–25. Keel M, Ecknauer E, Stocker R, et al: Different pattern of local and systemic release of proinflammatory and anti-inflammatory mediators in severely injured patients with chest trauma. J Trauma 1996;40:907–914. Marie C, Losser MR, Fitting C, Kermarrec N, Payen D, Cavaillon J-M. Cytokines and soluble cytokines receptors in pleural effusions from septic and nonseptic patients. Am J Respir Crit Care Med 1997;156:1515–1522. Dehoux MS, Boutten A, Ostinelli J, et al: Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994;150:710–716. Jacobs RF, Tabor DR, Burks AW, Campbell GD: Elevated interleukin-1 release by human alveolar macrophages during adult respiratory distress syndrome. Am Rev Respir Dis 1989;140:1686–1692. Smith PD, Suffredini AF, Allen JB, Wahl LM, Parrillo JE, Wahl SM: Endotoxin administration to humans primes alveolar macrophages for increased production of inflammatory mediators. J Clin Immunol 1994;14:141–148. Fieren MWJA, Van Den Bemd GJ, Bonta IL: Endotoxin-stimulated peritoneal macrophages obtained from continuous ambulatory peritoneal dialysis patients show an increased capacity to release interleukin-1 in vitro during infectious peritonitis. Eur J Clin Invest 1990;20:453–457. Rana N, Braun DP, House R, Gebel H, Rotman C, Dmowski WP: Basal and stimulated secretion of cytokines by peritoneal macrophages in women with endometriosis. Fertil Steril 1996;65:925–930. Wu MY, Ho HN, Chen SU, Chao KH, Chen CD, Yang YS: Increase in the production of IL-6, IL-10 and IL-12 by LPS stimulated peritoneal macrophages from women with endometriosis. Am J Reprod Immunol 1999;41:106–111. Rugtveit J, Nilsen EM, Bakka A, Carlsen H, Brandtzaeg P, Scott H: Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 1997;112:1493–1505. Schwartz MD, Moore E, Moore FA, et al: Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med 1996;24:1285–1292. Moine P, McIntyre R, Schwartz MD, et al: NF-B regulatory mechanisms in alveolar macrophages from patients with acute respiratory distress syndrome. Shock 2000;13:85–91. Shenkar R, Abraham E: Mechanisms of lung neutrophil activation after hemorrhage or endotoxemia: Roles of reactive oxygen intermediates, NF-B and cyclic AMP response element binding protein. J Immunol 1999;163:954–962. Abraham E, Arcaroli J, Shenkar R: Activation of extracellular signal-regulated kinases, NF-B, and cyclic adenosine 5⬘-monophosphate response element binding protein in lung neutrophils occurs by differing mechanisms after hemorrhage or endotoxemia. J Immunol 2001;166:522–530. Pang G, Ortega M, Zighang R, Reeves G, Clancy R: Autocrine modulation of IL-8 production by sputum neutrophils in chronic bronchial sepsis. Am J Respir Crit Care Med 1997;155:726–731. Corvol H, Fitting C, Chadelat K, et al: Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. Am J Physiol 2003;284:L997–L1003. Constantian M: Association of sepsis with an immunosuppressive polypeptide in the serum of burn patients. Ann Surg 1978;188:209–215. Prins JM, Kuijper EJ, Mevissen ML, Speelman P, van Deventer SJ: Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: Influence
Cavaillon/Fitting/Adib-Conquy
90
76 77
78 79
80
81
82 83 84 85
86 87 88
89
90 91
92
93
94
95
of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun 1995;63: 2236–2242. Cavaillon J-M: ‘Septic Plasma’: An immunosuppressive milieu. Am J Respir Crit Care Med 2002; 166:1417–1418. Spinas G, Bloesch D, Kaufmann M, Keller U, Dayer JM: Induction of plasma inhibitors of interleukin 1 and TNF-alpha activity by endotoxin administration to normal humans. Am J Physiol 1990;259:R993–R997. Ronco C, Brendolan A, Lonnemann G, et al: A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002;30:1250–1255. Brandtzaeg P, Osnes L, Øvstebø R, Joø GB, Westwik AB, Kierulf P: Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: Identification of interleukin-10 as a major functional deactivator of human monocytes. J Exp Med 1996;184: 51–60. Ayala A, Knotts JB, Ertel W, Perrin MM, Morrison MH, Chaudry IH: Role of interleukin-6 and transforming growth factor-beta in the induction of depressed splenocyte responses following sepsis. Arch Surg 1993;128:89–94. Miller-Graziano CL, Szabo G, Griffey K, Mehta B, Kodys K, Catalano D: Role of elevated monocyte transforming growth factor production in post-trauma immunosuppression. J Clin Immunol 1991;11:95–102. Chen W, Frank M, Jin W, Wahl S: TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001;14:715–725. Jones SB, Westfall MV, Sayeed MM: Plasma catecholamines during E. coli bacteremia in conscious rats. Am J Physiol 1988;254:R470–R477. Luger TA, Kalden DH, Scholzen TE, Brzoska T: ␣-melanocyte-stimulating hormone as a mediator of tolerance induction. Pathobiology 1999;67:318–321. Delgado M, Pozo D, Martinez C, et al: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF␣ production by macrophages: In vitro and in vivo studies. J Immunol 1999;162:2358–2367. Annane D, Cavaillon JM: Corticosteroids in sepsis: From bench to bedside? Shock 2003;20: 197–207. Choudhry MA, Ahmad S, Ahmed Z, Sayeed MM: Prostaglandin E2 down-regulation of T cell IL-2 production is independent of IL-10 during Gram negative sepsis. Immunol Lett 1999;67:125–130. Njemini R, Lambert M, Demanet C, Mets T: Elevated serum heat-shock protein 70 levels in patients with acute infection: Use of an optimized enzyme-linked immunosorbent assay. Scand J Immunol 2003;58:664–669. Ding X, Fernandez-Prada C, Bhattacharjee A, Hoover D: Over-expression of hsp-70 inhibits bacterial lipopolysaccharide-induced production of cytokines in human monocyte-derived macrophages. Cytokine 2001;16:210–219. Cavaillon JM, Adrie C, Fitting C, Adib-Conquy M: Endotoxin tolerance: Is there a clinical relevance? J Endotoxin Res 2003;9:101–107. Zweigner J, Gramm HJ, Singer OC, Wegscheider K, Schumann RR: High concentration of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 2001;98:3800–3808. Vreugdenhil ACE, Snoeck AMP, van’t Veer C, Greve JWM, Buurman WA: LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. J Clin Invest 2001;107:225–234. Cavaillon JM, Fitting C, Haeffner-Cavaillon N, Kirsch SJ, Warren HS: Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect Immun 1990;58:2375–2382. Kitchens RL, Thompson PA, Viriyakosol S, O’Keefe GE, Munford RS: Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001;108:485–493. Majetschak M, Krehmeier U, Bardenheuer M, et al: Extracellular ubiquitin inhibits the TNF-alpha response to endotoxin in peripheral blood mononuclear cells and regulates endotoxin hyporesponsiveness in critical illness. Blood 2003;101:1882–1890.
Mechanisms of Immunodysregulation in Sepsis
91
96 Nomura F, Akashi S, Sakao Y, et al: Endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface Toll-like receptor 4 expression. J Immunol 2000;164: 3476–3479. 97 Medvedev AE, Kopydlowski KM, Vogel SN: Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: Dysregulation of cytokine, chemokine, and Toll-like receptor 2 and 4 gene expression. J Immunol 2000;164:5564–5574. 98 Calvano J, Agnese D, Um J, et al: Modulation of the lipopolysaccharide receptor complex (CD14, TLR4, MD-2) and toll-like receptor 2 in systemic inflammatory response syndrome-positive patients with and without infection: Relationship to tolerance. Shock 2003;20:415–419. 99 Blackwell TS, Blackwell TR, Christman JW: Induction of endotoxin tolerance depletes nuclear factor-B and suppresses its activation in rat alveolar macrophages. J Leuk Biol 1997;62:885–891. 100 Ziegler-Heitbrock HWL, Wedel A, Schraut W, et al: Tolerance to lipopolysaccharide involves mobilization of nuclear factor-B with predominance of p50 homodimers. J Biol Chem 1994;269: 17001–17004. 101 Adib-Conquy M, Adrie C, Moine P, et al: NF-B expression in mononuclear cells of septic patients resembles that observed in LPS-tolerance. Am J Respir Crit Care Med 2000;162:1877–1883. 102 Adib-Conquy M, Asehnoune K, Moine P, Cavaillon J-M: Longterm impaired expression of nuclear factor-B and IB␣ in peripheral blood mononuclear cells of patients with major trauma. J Leuk Biol 2001;70:30–38. 103 Riedemann N, Guo R, Bernacki K, et al: Regulation by C5a of neutrophil activation during sepsis. Immunity 2003;19:193–120. 104 Zhang G, Ghosh S: Negative regulation of toll-like receptor-mediated signaling by Tollip. J Biol Chem 2002;277:7059–7065. 105 Janssens S, Burns K, Tschopp J, Beyaert R. Regulation of interleukin-1- and lipopolysaccharideinduced NF-kappaB activation by alternative splicing of MyD88. Curr Biol 2002;12:467–471. 106a Wald D, Qin J, Zhao Z, et al: SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2003;4:920–927. 106b Brint EK, Xu D, Liu H, et al: ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004;publ online. 107 Yuan Q, Zhao F, Chung S, et al: Dominant negative down-regulation of endotoxin-induced tumor necrosis factor alpha production by Lps(d)/Ran. Proc Natl Acad Sci USA 2000;97:2852–2857. 108 Kobayashi K, Hernandez LD, Galan JE, Janeway CAJ, Medzhitov R, Flavell RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002;110:191–202. 109 Escoll P, del Fresno C, Garcia L, et al: Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients. Biochem Biophys Res Commun 2003;311:465–472. 110 Nakagawa R, Naka T, Tsutsui H, et al: SOCS-1 participates in negative regulation of LPS responses. Immunity 2002;17:677–687. 111 Fukao T, Koyasu S: PI3K and negative regulation of TLR signaling. Trends Immunol 2003;24: 358–363. 112 Learn CA, Boger MS, Li L, McCall CE: The phosphatidylinositol 3 kinase pathway selectively controls sIL-1ra not interleukin-1 production in the septic leukocytes. J Biol Chem 2001;276: 20234–20239. 113 Lee T, Chau L: Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 2002;8:240–246. 114 Kuwata H, Watanabe Y, Miyoshi H, et al: IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF-alpha production in macrophages. Blood 2003;102:4123–4129. 115 O’Farrell A-M, Liu Y, Moore KW, Mui ALF: IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: Evidence for Stat3-dependent and-independent pathways. EMBO J 1998;17:1006–1018. 116 Berlato C, Cassatella MA, Kinjyo I, Gatto L, Yoshimura A, Bazzoni F: Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharideinduced macrophage activation. J Immunol 2002;168:6404–6411. 117 Grutkoski P, Chen Y, Chung C, Ayala A: Sepsis-induced SOCS-3 expression is immunologically restricted to phagocytes. J Leukoc Biol 2003;74:916–922.
Cavaillon/Fitting/Adib-Conquy
92
118 Döcke WD, Randow F, Syrbe U, et al: Monocyte deactivation in septic patients: Restoration by IFN␥ treatment. Nat Med 1997;3:678–681. 119 Flohé S, Lendemans S, Selbach C, et al: Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma. Crit Care Med 2003; 31:2462–2469. 120 Williams M, Withington S, Newland A, Kelsey S. Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo. J Infect Dis 1998;178:1421–1433. 121 Randow F, Döcke WD, Bundschuh DS, Hartung T, Wendel A, Volk HD: In vitro prevention and reversal of lipopolysaccharide desensitization by IFN␥, IL-12 and GM-CSF. J Immunol 1997;158: 2911–2918. 122 Adib-Conquy M, Cavaillon J-M: IFN␥ and GM-CSF prevent endotoxin tolerance in human monocytes by promoting IRAK expression and its association to MyD88, and not by modulating TLR4 expression. J Biol Chem 2002;277:27927–27934. 123 Pal’tsev A, Ovechkin A, Zakharova N, et al: Cytokines in the treatment of a generalized surgical infection. Anesteziol Reanimatol 2000;2:27–30.
Jean-Marc Cavaillon UP Cytokines and Inflammation Institut Pasteur, 28, rue Dr Roux, FR–75015 Paris (France) Tel. ⫹33 1 45 68 82 38, Fax ⫹33 1 40 61 35 92, E-Mail
[email protected]
Mechanisms of Immunodysregulation in Sepsis
93
Fluid, Electrolyte and Acid Base Ronco C, Bellomo R, Brendolan A (eds): Sepsis, Kidney and Multiple Organ Dysfunction. Contrib Nephrol. Basel, Karger, 2004, vol 144, pp 94–104
Goals of Resuscitation from Circulatory Shock Michael R. Pinsky Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pa., USA
Cardiovascular insufficiency commonly occurs in critically ill patients and may be the reason for intensive care unit (ICU) admission or a complication of treatment or disease during ICU stay. If cardiovascular insufficiency is associated with inadequate O2 delivery to the tissues, then the patient is said to be in shock. The management of shock-like states depends on both the etiology of the condition and attaining certain cardiovascular targets of blood flow, O2 delivery and perfusion pressure. Thus, the physician caring for such individuals needs to have a rational approach to both the diagnosis of shock and its resuscitative therapy.
Shock States
Shock is a circulatory a state characterized by inadequate delivery of nutrients and O2 delivery to meet the metabolic requirements of the tissues. Shock etiologies have been traditionally divided into four broad categories based on pathophysiologic mechanisms [1]: hypovolemic, cardiogenic, distributive, and obstructive. Although resuscitation of patients in shock may restore adequate global O2 transport, it may not restore blood flow to damaged vascular beds due to the associated alterations in autoregulation and microvascular blood flow. Clearly, any given patient may demonstrate qualities that blur the separation of shock into these specific states. Still, the most common quality of a shock-like state is hypovolemia, as characterized by hypovolemic shock. In hypovolemic shock, the vascular volume is near or below the stressed volume, resulting in a profound decrease in venous return. Independent of any changes in vasomotor tone or cardiac pump function, a loss of 30–40% of the circulating volume will lead to marked hypotension and organ hypoperfusion [2]. Although not clearly
documented in humans, in animal models of hemorrhagic shock, a greater than a 40% loss of intravascular volume can result in irreversible shock and death if not treated effectively with fluid resuscitation in less than two hours [3]. The normal physiologic response to a hypovolemic stress is to increase sympathetic output that increases vascular tone and thus reduces unstressed volume. The resultant effect is to increase upstream pressure in the venous reservoirs increasing venous return. The associated increased sympathetic tone increases heart rate, contractility and cortisol secretion. Furthermore, the associated release of aldosterone from the adrenal cortex increases sodium and water reabsorption in the kidney. Although these endocrinological responses are effective in restoring intravascular volume in the long run, over the immediate resuscitative interval they only serve to prevent sodium excretion. Cardiogenic shock reflects any process wherein inadequate ventricular pump function induces hypoperfusion. Cardiac arrhythmia, ischemia, infarction, valvular dysfunction, or myocardial failure are all capable of inducing cardiogenic shock. Myocardial failure may also be secondary to systemic metabolic processes such as hypoxia, acidemia, hypothyroidism or hyperthyroidism. Only a small percentage of subjects with cardiogenic shock will demonstrate increased cardiac output in response to isolated inotropic during administration. Thus, patients demonstrating cardiogenic shock need to have their etiology quickly and accurately identified if appropriate etiology-specific therapy is to be given. Distributive shock represents a state in which the body looses its ability to autoregulate blood flow. Loss of vascular integrity often occurs in response to sepsis (malignant intravascular inflammation), adrenal cortical insufficiency, hypocalcemia and with the infusion of vasodilator drugs. Presently, physician’s interest in distributive shock focuses on systemic inflammatory states, such as severe sepsis, burns, pancreatitis and trauma. In these conditions, cytokine activation and release into the systemic circulation commonly occurs and induces a generalized inflammatory response characterized by up-regulation of vascular endothelial inducible nitric oxide synthase (iNOS), release of arachidonic acid metabolites and primary vascular smooth muscle dysfunction [4–6]. Moreover, localized production of nitric oxide, O2 radicals, prostaglandins, platelet aggregating factor, and up-regulation of CD11b/CD18 receptors on leukocytes lead to loss of capillary integrity, adherence of circulating leukocytes to the vascular endothelium, and localized disruption of the microcirculation [4, 6, 8–10]. Importantly, one needs not evoke infection to see this systemic response. Severe trauma also displays a similar sustained inflammatory mediator activation state. Non-cardiogenic obstructive shock includes all causes of diminished cardiac output secondary to compression on the vascular system or obstruction to blood flow other than from valvular disease, such as tension pneumothorax, pericardial tamponade, constrictive pericarditis, pulmonary embolism, and acute pulmonary
Goals of Resuscitation
95
hypertension with acute cor pulmonale. Pulmonary embolism and acute pulmonary hypertension deserve special mention, since both cause shock by inducing right heart failure and diminished left ventricular end diastolic volume. An acute rise in pulmonary artery pressure from massive pulmonary emboli or hypercarbic respiratory failure leads to dilation of the right ventricle. This in turn displaces the intraventricular septum toward the left ventricle, and by the process of ventricular interdependence, decreases left ventricular diastolic compliance. The resulting decrease in preload leads to diminished cardiac output. Thus, treating such patients with fluid resuscitation will induce only more right ventricular dilation and worsen the obstructive state.
Goals of Therapy
The individual who is in shock may exhibit a wide range of clinical signs (associated with increased sympathetic tone). There is no universal set of variables that may be assessed to determine the presence or absence of shock. The determination of shock is often made clinically from the history and physical examination. Patients often present with tachypnea and dyspnea as early signs of cardiovascular deterioration. They may appear pale, diaphoretic, with cold, clammy skin, or may appear warm, erythematous, and dry. The blood pressure may be normal, elevated, or low, and the heart rate may be tachycardic, bradycardic, and rarely normal. Urine output is often diminished, and mentation impaired. On laboratory evaluation, a metabolic acidosis may be present with elevation of serum lactate, excesses chloride loading or be unexplained [11, 12]. Except in acute hypovolemic shock the metabolic acidosis is in excess to that explained by anaerobic metabolism (lactic acidosis) alone. However, this is neither sensitive nor specific for the presence of shock [13]. The arterial blood gas analysis may reveal a respiratory alkalosis, metabolic acidosis or a combination of the two. Since the signs of circulatory shock can be non-specific, it follows that the end-points of therapy may also be difficult to define. Resuscitation of shock can be divided into primary and secondary periods. The primary period is the time from initial evaluation through the first round of resuscitation. The goals during this period are cardio-pulmonary-cerebral resuscitation [14]. Basic and advanced life support principles are utilized with the initial goal being attainment of an adequate coronary and cerebral perfusion pressure and perfusion of the tissues with oxygenated blood. This encompasses establishment of an adequate airway and, if necessary, mechanical ventilation, restoration of productive cardiac rhythm and forward blood flow, and attainment of a mean arterial blood pressure ⬎60 mm Hg [15]. Without reaching this immediate goal, all other resuscitative goals are of questionable value and thus
Pinsky
96
should not be considered alone. Once mean arterial blood pressure is adequate to maintain cerebral and myocardial perfusion, then the secondary period of resuscitation begins. The goals of this period are: (1) establishment of an adequate organ perfusion pressure for all organs; (2) establishment of adequate organ blood flow, and (3) establishment of adequate O2 transport to the metabolically active tissues. The first two goals are reached by utilizing volume expansion and vasoactive agents, often using data acquired by invasive hemodynamic monitoring via a pulmonary artery (PA) catheter. Although the utility of the PA catheter in treating patients in shock has been questioned [16], data derived from the PA catheter is often critical in establishing the correct etiological diagnosis. Improving O2 content, cardiac output and vascular responsiveness accomplish the third goal in acute resuscitation. Delays in resuscitation of the previously healthy subject now in shock may render them not responsive to aggressive therapy later on, in an analogy to the irreversible shock model described by Wiggers in the 1920s. In support of this hypothesis is the recent large single center clinical trial of early goal-directed therapy for the management of severe sepsis. This study documented a marked improved outcome when subjects were aggressively treated for circulatory shock in the Emergency Department during the initial 6 h of hospitalization rather than waiting for them to be transferred to the ICU for better monitoring [17]. That study focused on rapidly achieving not only an adequate mean arterial pressure, central venous pressure and urine output, but also an adequate degree of tissue perfusion, as assessed by superior vena caval SO2 (SsvcO2). This study is in stark contract to the negative results of numerous large studies that aimed to improve survival for subjects once transferred into the ICU using similar resuscitation end-points [18–21]. These negative studies do not mean that resuscitation is ineffective to support life in the patient in shock. They merely demonstrate that there is no specific level of TO2 or mixed venous O2 saturation that one must attain to insure a good outcome [16, 22]. Clearly, what are needed are real time measures of tissue wellness and metabolic function, such as gastric tonometry [23], or functional measures of cardiovascular responsiveness [24]. Unfortunately, such non-invasive metabolic monitoring devices have yet to be validated as superior to non-specific measures presently available [25]. Potentially, the lack of documented benefit of these many noninvasive measures reflects inadequate study design.
Hemoglobin and the Optimal Hematocrit
Assuming that one has established an adequate mean arterial pressure, then one needs to insure that O2 transport (TO2) out of the heart to the body is adequate
Goals of Resuscitation
97
to meet the metabolic demands. Traditionally, resuscitation guidelines have mirrored the determinants of TO2. TO2 is equal to the product of cardiac output and arterial O2 content (CaO2). CaO2 in turn is equal to the amount of O2 adsorbed onto hemoglobin and dissolved in the plasma. Since 1,200 times more O2 is carried on hemoglobin than dissolved in the plasma one usually ignores the plasma component of TO2. The ideal hemoglobin concentration is unknown, but based on experience with Jehovah’s Witnesses, it seems the lowest limit tolerable below which even otherwise healthy people suffer cardiovascular collapse is 2–5 g/dl [26–29]. Many patients have done well during and after surgery despite very low hemoglobin and hematocrit levels as long as they can maintain adequate tissue perfusion and cardiac output. This infers that the body is able to augment cardiac output to sustain TO2. All else being equal, there seems to be little evidence to resuscitate a stable patient with a hematocrit ⱖ20% with red blood cells [30]. Rather, packed red blood cells (PRBCs) should be transfused to specifically correct evidence of tissue ischemia or hypoxia or to reverse a high outputinduced myocardial ischemia or failure state. Animal data suggest the maximum systemic extraction ratio for O2 is about 70%, with each organ having its own O2 requirements [31]. If O2 transport fails to meet this minimum, then O2 consumption will be dependent on organ blood flow [12, 31, 32]. Although we do not know the optimal hemoglobin concentration, aiming for adequate organ perfusion and O2 delivery with PRBC transfusions is reasonable up to a hemoglobin concentration of about 7 gm/dl [33, 34]. Above this, any additional benefit in O2 delivery is offset by increases in blood viscosity. Moreover, stored blood is depleted of 2,3-diphosphoglycerate, causing it to be very oxygen-avid, further limiting O2 utilization [35].
Fluid Resuscitation
Patients presenting with most forms of shock, excluding acute left ventricular failure with cardiogenic pulmonary edema, are initially responsive to intravascular volume replacement. Initial resuscitation, therefore should include intravascular volume replacement as part of a diagnostic and treatment strategy. For example, failure to show any significant increase in mean arterial pressure after rapid bolus infusion of crystalloid despite an increase in right atrial pressure usually signifies the need for vasoactive drug support. An adequate fluid challenge is defined as one in which either end-organ blood pressure or cardiac output increases (volume responsive); or in which either heart rate decreases or left ventricular filling pressure or central venous pressure increases without changes in systemic blood flow measurements (volume resistant).
Pinsky
98
The choice of crystalloid or colloid solutions to treat a patient in shock is based more on religion than on science. Crystalloids are solutions that contain sodium as their major osmotically active particle [36]. Lactated Ringer’s and normal saline (0.9% NaCl) are examples of frequently used isotonic crystalloids. However, normal saline is still slightly hypertonic and carries a profoundly elevated chloride content relative to intravascular fluid. Hyperchloremic metabolic acidosis is a common occurrence in the ICU and is usually due to saline resuscitation. It is unclear, however, if the hyperchloremic metabolic acidosis induced by normal saline adversely affects outcome. Colloids are fluids with large molecular weight substances that do not readily pass across capillary walls [36]. Examples include albumin solutions, dextran, and hetastarch. Hetastarch gelatins are carried in a normal saline vehicle, thus they share the chloride load problems with normal saline. However, since one often gives less colloid than crystalloid, this concern is less important. Newer gelatins include put hetastarch in a lactated Ringer’s-like vehicle, thus minimizing the chloride loading. Recent interest in excess mortality in subjects given albumin has arisen. However, a large double blind multicenter trail of crystalloid versus albumin is presently underway in Australia to address this and other issues. Thus, conclusions about the risks and benefits of albumin infusions will need to wait until this trial is concluded. Infused albumin has a plasma half-life of approximately sixteen hours, but its effect lasts for approximately twenty-four hours. 25% albumin expands the vascular volume by translocation of interstitial fluid, such that for each 100 ml of 25% albumin given, the vascular volume will increase by 450 ml. Other albumin containing solutions have a near-physiologic colloid osmotic pressure, and therefore expand the vascular volume by 1 ml for each ml given. Dextran is a synthetic colloid that is rarely used because of its associated side effects [37, 38]. Hetastarch is also a synthetic colloid solution. It comes as a 6% solution in normal saline (Hesban) or lactated Ringers (Hextend) and functions similarly to 5% albumin solutions. It has a very long plasma half-life (17 days) and unlike dextran, is non-immunogenic [39]. Potential problems with hetastarch infusions arise when massive resuscitation is given (⬎1,500 ml) wherein one may see an elevation of serum amylase, osmotic diuresis, and increase bleeding tendency [39]. Colloids have several potential benefits, such as greater sustained intravascular volume presence and less edema formation, while being much more expensive. Despite all the potential benefits of using colloid as part of resuscitation, there is no proven benefit in outcome. A meta-analysis of eight studies in sepsis showed an overall 5.7% relative decrease in mortality in patients resuscitated with crystalloids alone, and a 12.3% difference in favor of crystalloid in trauma patients. A 7.8% difference was found in favor of colloid use in medical
Goals of Resuscitation
99
patients [40]. Due to the relatively few studies included in this analysis, it is difficult to make any conclusions regarding benefit in survival by use of colloid versus crystalloid.
Vasopressors
Since the goal of the primary resuscitation period is to obtain an adequate cerebral and coronary perfusion pressure, if this cannot be done with volume therapy alone, or if the blood pressure is profoundly depressed, then use of a vasoactive agent is required. These agents may also be necessary during the secondary resuscitation period to maintain adequate organ perfusion pressure and cardiac output in the setting of inflammatory mediator-induced pathological vasodilation. Selective use of agents may augment blood pressure and cardiac output to achieve the desired goals, but which agent is used often does not matter as long as the desired goals are achieved. Vasopressors induce their response by stimulating the ␣-adrenergic receptors on vascular smooth muscle cells. -Adrenergic receptor stimulation augments contractility and induces vasodilation and tachycardia. Several vasopressor agents are available with varying degrees of ␣-, - and vasopressin-2 receptor activity. Phenylephrine is a pure ␣-agonist and isoproterenol is a pure -agonist [41, 42]. All other vasoactive agents have varying degrees of effect on both ␣ and  types of receptors. The most potent vasoactive agent is epinephrine, since this will stimulate all adrenergic receptors. Dopamine is often used in states of shock to preserve renal function; however, no study has demonstrated a proven protective effect of dopamine on renal function [43, 44] and a recent large multicenter trail powered to show no effect documented or no effect of low dose dopamine on the development of renal failure in postoperative surgical ICU patients [45]. In septic shock, dopamine has not been shown superior to other agents such as dobutamine and norepinephrine in obtaining target values for O2 delivery and O2 consumption [46]. Furthermore, dopamine increased splanchnic O2 requirements over that of norepinephrine [47]. Finally, other agents such as dopexamine may produce similar hemodynamic profiles and renal preservation in patients with reduced cardiac index following coronary artery bypass surgery [48]. Furthermore, in a retrospective study of similarly matched subjects given norepinephrine versus all other vasopressor, Martin et al. [49] demonstrated that those subjects treated with norepinephrine had a markedly reduced mortality. Sepsis is associated with a reduction in vasopressin-2 receptor activity, making vascular smooth muscle cells less responsive to ␣-adrenergic stimulation. Infusions of low does vasopressin may reverse this desensitization. However,
Pinsky
100
higher does of vasopressin induce profound splanchnic vasoconstriction. Thus, it is not clear that vasopressin infusions will improve outcome in distributive shock states. A large multicenter clinical trial of vasopressin is on going. We shall need to await the results of this trial before making any conclusions about the use of vasopressin in shock.
What Are the Targets for Cardiovascular Resuscitation?
Based on the clinical trials of early goal-directed therapy, vasopressorinduced ischemia and inflammation and unclear benefits from hemoglobinbased resuscitation the following approach seems reasonable. First, in the hypotensive patient restoration of a mean arterial pressure to ⬎60 mm Hg in a previously normotensive subject by the rapid infusion of volume and, if needed, vasopressor, is indicated to prevent and/or reverse cerebral and coronary ischemia. Second, rapid diagnosis of the etiology of shock should be undertaken. Except in the setting of obstructive or cardiogenic shock, volume resuscitation is the mainstay of initial therapy. The choice of fluid is optional, but lactated Ringer’s solution seems like a reasonable choice if blood products are not going to be infused simultaneously. The choice of vasopressor agent is still not defined, but norepinephrine is gaining increased usage because of its therapeutic profile. In the setting of cardiogenic or obstructive shock, although inotropic agents may transiently increase cardiac output, every effort needs to be done to make the diagnosis and treat the primary problem because few of the etiologies that induce either of these two types of shock respond to inotropic drug infusion alone. The infusion of packed red blood cells to treat patients with concomitant anemia and circulatory shock is problematic. In the setting of reduced cardiac reserve, red blood cells may be life saving, whereas in the otherwise healthy patient, there is little data to defend transfusing to a hematocrit above 25%. Clearly, the attempt in a resuscitated ICU patient to sustain TO2 at some defined elevated level is not justified.
Conclusion
Resuscitation from circulatory and respiratory failure represent mainstays of emergency and critical care management. Importantly, no amount of resuscitative effort will be successful in promoting patient survival if the primary reason for the shock state is not identified and treated, independent of resuscitation. Having said that, aggressive resuscitation to normal functional levels of blood flow and organ perfusion pressure during the first 6 h following the
Goals of Resuscitation
101
development of shock improves outcome both in patients with trauma or sepsis. However, clinical studies have demonstrated that restoration of total blood flow to supranormal levels in subjects with established shock that has been present for over 6 h does not improve survival. Still, some defined clinical targets are essential in these patients as well to prevent further organ injury due to ischemia and its associated inflammatory response. Thus, the rapid restoration of normal hemodynamics by conventional means, including fluid resuscitation and surgical repair, results in a better long-term outcome than inadequate or delayed resuscitative efforts. Clear initial targets for resuscitation are a mean arterial pressure ⬎65 mm Hg, and a cardiac output and O2 transport to the body adequate enough to prevent tissue hypoperfusion. The level of cardiac output needed to achieve this goal is probably different among subjects and within subjects over time. Indirect signposts of adequate perfusion, such as venous O2 saturation, mentation, urine output and local measures of tissue blood flow are useful in monitoring this response.
Acknowledgement This work was supported in part by the federal government (GM61992–03, NHLBI K-24 HL67181–01A2, and NRSA 2-T32 HL07820–06).
References 1 2
3 4 5 6 7
8 9 10 11
Hinshaw LB, Cox BG: The Fundamental Mechanisms of Shock, Plenum Press, New York, 1972. Calcagni DE, Bircher NG, Pretto E: Resuscitation: Blood, blood component, and fluid therapy; in Grande CM, et al (eds): Textbook of Trauma Anesthesia and Critical Care. St. Louis, Mosby-Year Book, 1993, p 400. Rush BF: Irreversibility in post-transfusion phase of hemorrhagic shock. Adv Exp Med Biol 1971; 23:215–221. Calandra T, Glauser MP: Cytokines and septic shock. Diagn Microbiol Infect Dis 1990;13: 377–381. Mason JW, et al: Plasma kallikrein and Hageman factor in gram-negative bacteremia. Ann Intern Med 1970;73:545–551. Pinsky MR, Vincent JL, et al: Serum cytokine levels in human septic shock: Relation to multiplesystem organ failure and mortality. Chest 1993;103:565–575. Rosenbloom AJ, Pinsky MR, et al: Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS: Correlation with serum interleukin-6 levels and organ dysfunction. JAMA 1995;274:58–65. Salin ML, McCord JM: Free radicals and inflammation: Protection of phagocytosing leukocytes by superoxide dismutase. J Clin Invest 1975;56:1319–1323. Bernard GR, et al: Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Am Rev Resp Dis 1991;144:1095–1101. Snyder SH, Bredt DS: Biologic roles of nitric oxide. Scient Am 1992;266:68–77. Cilley RE, et al: Low oxygen delivery produced by anemia, hypoxia, and low cardiac output. J Surg Res 1991;51:425–433.
Pinsky
102
12 13 14 15 16
17
18 19 20
21
22 23 24 25 26 27 28 29 30
31 32 33 34 35
Cain SM: Oxygen delivery and uptake in dogs during anemic and hypoxic hypoxia. J Appl Physiol 1977;42:228–234. Cohen RD, Woods F: Lactic acidosis revisited. Diabetes 1983;32:181–191. Safar P: Cerebral resuscitation after cardiac arrest: Research initiatives and future directions. Ann Emerg Med 1993;22:324–349. Fazekas JF, Kleh J, Parrish AE: The influence of shock on cerebral hemodynamics and metabolism. Am J Med Sci 1955;229:41–45. Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, Doig CJ, Laporta DP, Viner S, Passerini L, Devitt H, Kirby A, Jacka M, and Canadian Critical Care Clinical Trials Group: A Randomized, Controlled Trial of the Use of Pulmonary-Artery Catheters in High-Risk Surgical Patients. N Engl J Med 2003;348:5–14. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich E: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345: 1368–1377. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hindo CJ, Watson D: Evaluation of systemic oxygen delivery in the treatment of the critically ill. N Engl J Med 1994;330:1717–1722. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, Fumagalli R: A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995;333:1025–1032. McKinley BA, Kozar RA, Cocanour CS, Valdiva A, Sailors RM, Ware DN, Moore FA: Normal versus supranormal oxygen delivery goals in shock resuscitation: The response is the same. J Trauma 2002;53:825–832. Velmahos GC, Demetriades D, Shoemaker WC, Chan LS, Tatevossian R, Wo CCJ, Vassiliu P, Cornwell III EE, Murray JA, Roth B, Belzberg H, Asensio JA, Berne TV: Endpoints of resuscitation of critically injured patients: Normal or supranormal? A prospective randomized trial. Ann Surg 2000;232:409–418. Miller MJ, Cook W, Mithoefer J: Limitations of the use of mixed venous pO2 as an indicator of tissue hypoxia. Clin Res 1979;27:401A. Gutierrez G, Palizas F, Doglio G, et al: Gastric intramucosal pH as a therapeutic index of tissue oxygenation in critically ill patients. Lancet 1992;339:195–199. Pinsky MR: Functional hemodynamic monitoring: Asking the right question. Intensive Care Med 2002;28:386–388. Pinsky MR: Beyond global oxygen supply-demand relations: In search of measures of dysoxia. Intens Care Med 1994;20:1–3. Olugbenga A, et al: Management of severe anemia without transfusion in a pediatric Jehovah’s Witness patient. Crit Care Med 1994;22:524–528. Parker RI: Aggressive non-blood product support of Jehovah’s Witnesses. Crit Care Med 1994; 22:381–382. Koenig HM, et al: Use of recombinant human erythropoietin in a Jehovah’s Witness. J Clin Anesth 1993;5:244–247. Viele MK, Weiskopf RB: What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah’s Witnesses. Transfusion 1994;34:396–401. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetsir E: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409–417. Schlichtig R, et al: Tolerance of unusually low mixed venous oxygen saturation: Adaptations in the chronic low cardiac output syndrome. Am J Med 1986;80:813–818. Schwartz S, et al: Sequential hemodynamic and oxygen transport responses in hypovolemia, and hypoxia. Am J Physiol 1981;241:H864–H871. Welch HG, et al: Prudent strategies for elective red blood cell transfusion. Ann Intern Med 1992;116:393–402. Carson JL, et al: Severity of anemia and operative mortality and morbidity. Lancet 1988;i: 727–729. Weisel RD, et al: Adverse effects of transfusion therapy during abdominal aortic aneurysmectomy. Surgery 1978;83:682–690.
Goals of Resuscitation
103
36
37 38 39 40 41 42 43 44 45
46 47 48 49
Rainey TG, Read CA: Pharmacology of colloids and crystalloids; in Chernow B (ed): The Pharmacologic Approach to the Critically Ill Patient, ed 3. Baltimore, Williams & Wilkins, 1994, pp 272–290. Imm A, Carlson RW: Fluid resuscitation in circulatory shock. Crit Care Clins 1993;9:313–333. Thoren L: Dextran as a plasma volume substitute. Prog Clin Biol Res 1978;19:265–282. Waxman K, et al: Blood and plasma substitutes: Plasma expansion and oxygen transport properties. World J Med 1985;143:202–206. Velanovich V: Crystalloid versus colloid fluid resuscitation: A meta-analysis of mortality. Surgery 1989;105:65–71. Bisonni RS, et al: Colloids versus crystalloids in fluid resuscita